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ABSTRACT

Effects of Duration of Proton Pump Inhibitor (PPI)
Therapy on Markers of Bone Health in
Men and Post-Menopausal Women

Zarina M. Pabin
Department of Nutrition, Dietetics, and Food Science
Master of Science

This observational study compared bone health biomarkers, bone mineral density (BMD),
dietary habits, and physical activity levels of men (n=31) and non-estrogen supplementing postmenopausal women (n=23) divided according to duration of proton pump inhibitor (PPI)
therapy;more than 5 years (n=16), less than 5 years (n=15), and no PPI therapy (n=23). The
shortest duration of PPI therapy was 2 months and the longest duration of PPI therapy was 25
years with a mean duration of 7.5 years. No significant differences were found between
measures of spine BMD, urinary deoxypyridinoline (bone resorption), urinary calcium and
magnesium, serum osteocalcin (bone formation), serum parathyroid hormone, serum magnesium,
serum 25 hydroxyvitamin D3, dietary and supplement intake, or physical activity levels.
However, mean hip BMD was higher in females than in males in participants who took PPI
therapy for any duration. In the no PPI therapy group, hip BMD was not significantly different
between genders. These results suggest that there may be no measurable or clinically significant
negative effects of long term PPI therapy on bone health. However, men may be at higher risk of
hip fracture when taking long-term PPI therapy than women.
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CHAPTER 1
INTRODUCTION

STATEMENT OF THE PROBLEM

Gastroesophageal reflux disease (GERD), more commonly known as heartburn, refers to
symptoms and damage to the lining of the esophagus due to reflux of acidic gastric contents most
often due to inappropriate relaxation of the lower esophageal sphincter (1,2). It has been
estimated that the worldwide prevalence of GERD has doubled in the past thirty years with
population based studies indicating up to 25% of adults experiencing heartburn at least once
monthly and 5% of adults experiencing heartburn daily (1,2). Both men and women appear to be
equally affected by GERD with some studies showing a higher prevalence in women than men
(3,4).
Alongside lifestyle modifications to manage GERD, most patients require the use of
medications to control symptoms (5). The most commonly prescribed medications are
histamine-2 (H2) blockers [Tagamet® (cimetidine), Zantac® (ranitidine), Pepcid® (famotidine),
Axid®(nizatidine)] and proton pump inhibitors (PPI) [Prevacid® (lansoprazole), Prilosec®
(omeprazole), Protonix® (pantoprazole), Aciphex® (rabeprazole), Nexium® (esomeprazole)].
The goal of these medications is to reduce symptoms of GERD through decreasing hydrochloric
acid production in the stomach (5). In 2002, the sales of PPI's reached more than $10 billion,
second only to the sales of statins and in 2004, Nexium® became the third highest selling
prescription drug in the United States (6,7).
Three of four recently published large case-control studies have reported an independent
correlation between long-term PPI use and risk of hip or spine fracture, with one study showing
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PPI's only associated with a limited increase in fracture risk (8-11). The mechanism of this
association is proposed as being chronically decreased calcium absorption because of acid
suppression and consequential hyperparathyroidism, such that individuals who are meeting the
recommendations for dietary calcium intake may not be absorbing enough calcium to maintain
bone mass (12). A recently published literature review has indicated that calcium carbonate (the
most common form of supplemental calcium), appears to be more difficult to absorb in an
environment with an elevated pH than other supplemental forms (13). Current recommendations
suggest calcium citrate as the ideal calcium supplement, due to its increased solubility, for people
with achlorhydria or those taking either H2 blockers or PPI’s (14).
The prevalence, incidence, and cost of osteoporosis and associated fractures are
increasing, particularly in women. Alongside the graying of the general population and the
widespread use of PPI therapy in the aging population, determining the impact of long-term PPI
therapy on bone health is a worthy research cause. Research in this area is likely to support the
emerging practice of prescribing PPI therapy in the minimum effective dose to avoid long-term
complications of GERD while not compromising bone health (2,5).

Purpose
The purpose of this project was to determine if there was a significant difference between
the spine and hip bone mineral density (BMD), calcium status, magnesium status, or markers of
bone metabolism of men and post-menopausal women who have taken long-term proton pump
inhibitor (PPI) therapy for more than 5 years and the same parameters of men and postmenopausal women who have taken PPI therapy for less than 5 years or who have never taken
PPI therapy.
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Objectives and Hypotheses
Objective 1: To compare the spine and hip BMD of men and post-menopausal women who have
taken PPI therapy for more than five years to the spine and hip BMD of men and postmenopausal women who have taken PPI therapy for less than five years or have never taken PPI
therapy.
Null hypothesis: There is no difference between the spine or hip BMD of men and
post-menopausal women who have taken PPI therapy for more than 5 years and the
spine or hip BMD of men and post-menopausal women who have taken PPI therapy for
less than 5 years or have never taken PPI therapy.
Alternative hypothesis: There is a difference between the spine or hip BMD of men and
post-menopausal women who have taken PPI therapy for more than 5 years and the spine
or hip BMD of men and post-menopausal women who have taken PPI therapy for less
than 5 years or have never taken PPI therapy. PPI users have lower bone mass than nonPPI users.
Objective 2: To compare the biomarkers of calcium status, magnesium status, and bone
metabolism of men and post-menopausal women who have taken PPI therapy for more than five
years to the biomarkers of calcium status, magnesium status, and bone metabolism of men and
post-menopausal women who have taken PPI therapy for less than five years or never taken PPI
therapy.
Null hypothesis: There is no difference between the biomarkers of calcium status,
magnesium status, or bone metabolism of men and post-menopausal women who have
taken PPI therapy for more than five years and the biomarkers of calcium status,
magnesium status, and bone metabolism of men and post-menopausal women who have
taken PPI therapy for less than five years or never taken PPI therapy.
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Alternative hypothesis: There is a difference between the biomarkers of calcium status,
magnesium status, or bone metabolism of men and post-menopausal women who have
taken PPI therapy for more than five years and the biomarkers of calcium status,
magnesium status, and bone metabolism of men and post-menopausal women who have
taken PPI therapy for less than five years or never taken PPI therapy. PPI users
biomarker levels favor bone resorption over bone formation while non-PPI users favor
neither bone resorption nor bone formation.
Objective 3: To compare the physical activity levels and dietary intakes of energy, carbohydrate,
protein, fat, calcium, magnesium, and vitamin D of men and post-menopausal women who have
taken PPI therapy for more than five years to the dietary intakes of energy, carbohydrate, protein,
fat, calcium, magnesium, and vitamin D of men and post-menopausal women who have taken
PPI therapy for less than five years or never taken PPI therapy.
Null hypothesis: There is no difference between the physical activity levels or dietary
intakes of energy, carbohydrate, protein, fat, calcium, magnesium, or vitamin D of men
and post-menopausal women who have taken PPI therapy for more than 5 years and the
physical activity levels or dietary intakes of energy, carbohydrate, protein, fat, calcium,
magnesium, or vitamin D of men and post-menopausal women who have taken PPI
therapy for less than five years or never taken PPI therapy.
Alternative hypothesis: There is a difference between physical activity levels or the
dietary intakes of energy, carbohydrate, protein, fat, calcium, magnesium, or vitamin D of
men and post-menopausal women who have taken PPI therapy for more than 5 years and
the physical activity levels or the dietary intakes of energy, carbohydrate, protein, fat,
calcium, magnesium, or vitamin D of men and post-menopausal women who have taken
PPI therapy for less than five years or never taken PPI therapy.
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Limitations
This study is purely observational. No statements of causal inferences can be made about
participants in our study or the general population. Any limitations in methods are discussed in
Chapter 3 – Materials and Methods.
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DEFINITION OF TERMS
Bone mineral content (BMC): the mineral (calcium, phosphorus, magnesium) content within
an area of bone expressed in grams.
Bone mineral density (BMD): a measure of fracture risk calculated from the BMC (g) and the
area of the bone (cm2) to yield an areal measure of BMD (g/cm2). Can be expressed as a
volumetric BMD in g/cm3.
Hormone replacement therapy (HRT): pharmacologic therapy used to prevent or treat
osteoporosis with the intention of mimicking the effects of estrogen or modifying the process of
bone remodeling to reduce bone loss.
Interleukin-1, 6, 11: peptides, released by activated monocytes and lymphocytes, that assist in
the coordination of bone remodeling.
Menarche: the first menstrual period, usually occurring at puberty.
Menopause: the cessation of menses.
Menses: the first portion of the uterine cycle, the portion in which the endometrial lining sloughs
away.
Monocyte colony-stimulating factor (M-CSF): a peptide that stimulates the production of
monocytes.
Osteocalcin (Bone Gla Protein): a non-collagenous protein produced by osteoblasts commonly
used as a measure of bone formation.
Osteoprotegerin (OPG): a receptor found on the surface of osteoblasts involved in the
regulation of bone remodeling.
Peak bone mass: the maximal bone mass attained during childhood, adolescence, and young
adulthood.
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Primary amenorrhea: the absence of menstruation by the age of 16 in a girl who has secondary
sex characteristics.
Receptor for activation of nuclear factor kappa B (RANK): a receptor found on the surface
of osteoclasts that participates in the regulation of bone remodeling through binding of RANKL
and OPG.
Receptor for activation of nuclear factor kappa B ligand (RANK-L): a receptor found on the
surface of osteoblasts involved in the regulation of bone remodeling.
Secondary amenorrhea: the absence of the menstrual period for greater than 3 months after
menarche.
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CHAPTER 2
LITERATURE REVIEW

Osteoporosis
Osteoporosis is a disease characterized by low bone mass and deterioration of bone
structure that causes bone fragility and increased risk of fracture (15). The terms primary, agerelated, or post-menopausal osteoporosis (used interchangeably) refer to the cumulative bone
loss that occurs with aging (15). Primary osteoporosis is the most common type of osteoporosis
and is a considerable public health concern (15). Secondary osteoporosis refers to osteoporosis
produced as a byproduct of another disease or condition and is less common (15). According to
the National Health and Nutrition Examination Survey (NHANES III, 1988-1994), 56%
(approximately 30.3 million) of women 50 years or older in the United States have low bone
mass (formerly referred to as osteopenia) and 16% of these (approximately 4.8 million) have
osteoporosis (16-18). While osteoporosis is not currently as considerable a public health concern
for men as for women, according to the same survey, 18% (approximately 7.3 million) of men 50
years or older in the United States have low bone mass with 2% (approximately 150,000) having
osteoporosis (16,17). By the year 2020, the number of women and men over the age of 50 with
osteoporosis is expected to reach 10.5 million and 3.3 million, respectively, as a result of the
expected growth and aging of the overall population (15).
General diet and lifestyle guidelines for the prevention and treatment of osteoporosis
include obtaining adequate intakes of dietary calcium, phosphorus, and vitamin D, performing
regular weight-bearing exercise, and avoiding tobacco products and alcohol abuse (19).
Adherence to these behavioral guidelines is especially important between birth and young
adulthood to ensure attainment of peak bone mass. Following the attainment of peak bone mass
and with subsequent aging, bone mass slowly declines in both men and women at a rate of 1-
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1.5% per year (15). Women, however, also experience an estrogen deficiency attributed rapid
bone loss of ~2% annually beginning 2-3 years prior to the last menses and ending 3-5 years
after menopause (20). Rate of bone loss then returns to the slow steady rate of 1-1.5% per year
experienced prior to menopause (15,20). Men do not experience the same drastic effects on bone
due to the hormonal changes of menopause, however, men reach the same fracture risk level as
women but at an older age (21).
Irrespective of known strategies to prevent and treat osteoporosis, osteoporosis causes 1.5
million fractures in the United States alone, with the largest portion being vertebral (700,000),
followed by hip (300,000), wrist (250,000), and fractures at other sites (300,000) (22). The
health implications for those diagnosed with an osteoporotic fracture vary based on the site and
severity of the fracture and include severe pain, decreased functional capacity, and increased risk
of mortality within 1 year following the fracture (15,17). While most fractures occur in women,
the consequences of fracture are more severe in men with some research showing men having
almost twice the mortality from hip fractures as women (21,23).

Costs
In 2002, estimated direct medical costs to the United States healthcare system for
treatment of osteoporotic fractures, largely borne by society through Medicare, ranged from
$12.2-$17.9 billion (15). These costs routinely include medications and in-patient and long-term
nursing home care stays related to orthopedic surgery. Costs are expected to exceed $60 billion
by the year 2030 due to increased incidence of osteoporosis (22).

Pharmacologic Treatment of Osteoporosis
Current drug treatments used to supplement dietary and lifestyle modifications in the
prevention and treatment of osteoporosis in post-menopausal women include hormone
9

replacement therapy (HRT) (Prempro®) which mimics the protective effects of endogenous
estrogen on bone, raloxifene (Evista®) which modifies the sensitivity of estrogen receptors on
bone, bisphosphonates (Fosamax®, Boniva®, Actonel®) which act by inhibiting the activity of
osteoclasts (bone resorption), and calcitonin, and teriparatide [a form of parathyroid hormone
(PTH)], which both stimulate bone formation (19,20,23,24). All of these agents are effective at
improving bone mineral density in post-menopausal women at clinically significant sites with no
apparent adverse side effects aside from upper gastrointestinal disorders from bisphosphonate
use (20). These upper gastrointestinal irritations sometimes results in concurrent prescribing of
PPI's alongside bisphosphonates. The long-term safety of many of these bone building
medications has not yet been fully researched and some recent population studies have
associated the use of HRT with increased risk of heart attack and stroke (20,25). Also, although
effective at increasing bone mineral density and decreasing fracture risk in both men and women,
non-compliance to oral bisphosphonate therapy is common (23,26).

Treatment of Fracture
Treatment for an osteoporotic fracture begins by stabilizing and repairing the fracture
(27). Hip and wrist fractures are commonly repaired through hip replacement surgery or surgical
repositioning and casting, respectively (15). For surgical treatment of vertebral fractures, two
techniques used to repair vertebral fractures are vertebroplasty and kyphoplasty (15). Both
techniques involve injecting bone cement into the body of the vertebrae in an attempt to
reestablish structure and reduce pain (27). Both techniques also carry risk of the cement leaking
into the blood stream and causing significant complications, including, but not limited, to
pulmonary emboli (27). Aside from complications resulting from surgical repair of an
osteoporotic fracture, additional resources are required following surgery to minimize pain,
improve function and mobility, reduce fracture risk, motivate the patient to continue
medication/exercise interventions, address psychosocial consequences of fracture, and monitor

10

bone health (27). Non-surgical treatment of fractures aimed at reducing the incidence of
additional fractures and preserving current bone mass, include bracing, pharmacological pain
control, and functional rehabilitation programs including fall prevention training and spinal
biomechanics education (23,28).

Bone Structure
Bones provide mobility, support, leverage, and protection for the body as well as serving
as a reservoir for calcium and phosphorus and participating in acid-base balance (15,29,30).
Nearly 70% of the weight of a bone is composed of strong but brittle hydroxyapetite crystals
[Ca10(PO4)6(OH)2] which collectively are capable of withstanding large compressive forces but
poorly tolerate bending, torsion, or other sudden impacts (30). The remaining ~30% of the
weight of the bone is composed of flexible collagen fibers collectively capable of withstanding
bending, torsion, and tensile forces (30). The microarchitectural arrangement of the bone matrix
of strong hydroxyapetite crystals surrounding flexible collagen fibers gives bone its dynamic
biomechanical properties, allowing the bearing of chronic compressive loads required by body
weight with resiliency to high tensile forces typical of movement, both without structural failure
(30).
There are two types of adult bone; 1) cortical or compact bone, found in the diaphyseal
walls of long bones and on the surface of cuboid and flat bones and 2) trabecular or cancellous
bone, found in the epiphyseal and metaphyseal ends of long bones and on the interior of cuboid
and flat bones contain the same basic materials but are arranged in distinctly different ways
(31,32). Cortical bone matrix contains numerous small, tightly packed cylindrical units called
osteons, each composed of multiple concentric rings of bone matrix called lamellae (32). The
hollow center of each osteon is called a Haversian canal and houses the blood and nerve supply
(32). The spaces between the lamellae are called lacunae and these spaces house mature bone
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cells called osteocytes (32). Tiny channels called canaliculi connect the Haversian canals to the
lacunae, allowing nerve communication and exchange of materials between osteocytes and the
blood (30). Cortical bone provides strength to withstand typical longitudinal compressive forces
due to gravity (15).
Conversely, the matrix of trabecular bone is organized into a lattice-like structure with
lacunae containing osteocytes nestled within the struts of the structure. The large spaces
separating individual trabeculae allow for exchange of materials between the lacunae and the
blood (32). The principal function of trabecular bone is to act in a spring-like fashion to disperse
mechanical loads thus allowing adaptation to dynamic or unusual loads in addition to
compressive loads without structural damage (33). Trabecular bone is also the major site of agerelated changes to bone mass due to increased surface area available for resorption (19,29,33).
This decreases the thickness and number of trabeculae, significantly compromising the structural
integrity of bone and leading to increased risk of fracture (33).

Bone Modeling/Remodeling
Normal growth and maintenance of bone is achieved through the coordinated actions of
the two primary bone cell types; osteoblasts (bone formation) and osteoclasts (bone resorption)
(34). Osteoblasts and osteoclasts form organized units called basic multicellular units (BMUs)
or bone remodeling units (BRUs) that participate in the processes of bone modeling and
remodeling (15,34). Modeling refers to bone formation and resorption in different sites within
the same bone, such as occurs during growth (15). Remodeling refers to the process of bone
formation and resorption at the same site within a bone and is the dominant process following the
attainment of peak bone mass after age 25-30 years with complete replacement of the skeleton
occurring approximately every 10 years (15).
The four major bone cell types include osteoblasts, osteocytes, lining cells, and
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osteoclasts. Osteoblasts form bone by secretion of collagen matrix (31). Osteocytes, mature
osteoblasts buried within the matrix, are the most numerous cell in bone and function to maintain
the bone matrix via their long branches which connect them to other osteocytes as well as bone
lining cells (30,35). Lining cells, are flat cells derived from osteoblasts that cover the periosteum
and rapidly release calcium from the bone in response to low blood calcium, protect bone from
bone dissolving chemicals in the blood, and contain receptors for hormones and other factors that
control bone turnover (36). Osteoclasts, derived from monocytes, secrete acids and enzymes that
dissolve bone matrix as part of routine bone turnover (30,35,37).
While some remodeling may be targeted to repair specific microdamaged sites, a large
portion of remodeling likely occurs randomly (29). The process of remodeling consists of four
distinct phases termed activation, resorption, reversal, and formation (29). Activation refers to
recruitment of osteoclastic precursors from circulation that permeate the bone lining cell layer
and merge together forming preosteoclasts (29). Next, the preosteoclasts form a ―bone-resorbing
compartment‖ by binding to the bone matrix on the surface of trabeculae and on the endosteal
and intracortical surfaces of cortical bone (15,29,38). The resorption phase begins with pumping
of protons into the ―bone-resorbing compartment‖ by specific proton pumps within the osteoclast
membrane, lowering the pH to ~4.0 (29). Theoretically, proton pump inhibitor (PPI) therapy
may be beneficial to bone health by decreasing bone resorption through inhibiting the action of
these proton pumps, the vacuolar type H+-ATPases, responsible for maintaining the acidic
environment on the ruffled border of the osteoclasts (8). While some research supports this
theory, closer examination is needed to demonstrate its validity (39-43). Next, numerous
enzymes that are most active at a low pH are secreted from osteoclast lysosomes that digest the
bone matrix within the ―bone-resorbing compartment‖ (29). Following osteoclast apoptosis, the
reversal phase begins with recruitment of preosteoblasts into the resorption cavity (29). The
signaling mechanism by which this occurs is not clear although various theories have emerged
including the secretion of chemoattractant growth factors by osteoclasts that attract osteoblastic
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precursors and strain-regulated activation of osteoblasts (29). The formation phase involves the
synthesis and mineralization of collagen matrix by osteoblasts (29). Eventually, as bone
formation continues, osteoblasts become buried within the matrix as osteocytes (29).
Under normal conditions, remodeling results in maintenance of the adult skeleton by
replacing damaged and old bone tissue with new tissue through the coupling of bone resorption
and bone formation (44). Both androgens and estrogens have been shown to positively influence
bone remodeling by increasing the lifespan of osteoblasts and decreasing the lifespan of
osteoclasts (45). Loss of androgens or estrogens increases the rate of bone resorption without an
appropriate compensatory increase in bone formation, resulting in net bone loss (45). In estrogen
deficiency, deeper resorption sites on the surface of trabeculae and on the endosteal and
intracortical surfaces of cortical bone occur without equivalent bone formation to refill the site of
resorption leading most notably to a reduction in trabecular number and thickness, compromising
bone structure and strength (15,29,38). While this bone loss can be postponed through the use of
hormone replacement therapy (HRT), results from the Women's Health Initiative study have
warned of potential adverse health effects of long-term HRT leading many women to opt out of
hormonal treatment (25). Normal healthy men do not experience a comparable rapid loss of
androgens, however, bone loss still occurs at a steady rate, putting them at risk of fractures later
in life (21).

Factors Affecting Bone Mineral Density (BMD)
Peak bone mass
Skeletal mass increases longitudinally from birth to adulthood with a particularly rapid
rate of growth during adolescence (29). The precise ages of the attainment of peak bone mass at
various body sites have yet to be determined but popular scientific opinion generally supports
peak bone mass being reached by age 30 (29). Decline in bone mass begins as early as age 30
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and continues as age advances with an increased rate experienced by women at menopause (29).
Thus, maximizing peak bone mass during growth and young adulthood through known
osteogenic strategies including adequate intakes of calcium, phosphorus, and vitamin D, and
participation in regular physical activity is essential to withstand the gradual loss of bone that
occurs with aging.
Suboptimal attainment of peak bone mass may be associated with a premature increase in
bone fragility and increased risk for fractures later in life (29). Young female athletes are at an
especially high risk of failure to attain peak bone mass due to the prevalence of both primary and
secondary amenorrhea in this population (46). Androgen deficiency during adolescence can also
lead to poor attainment of peak bone mass in males (45). During puberty, men develop longer
and larger bones, and adult men typically have greater bone mineral density than women (45).

Hormones
While estrogens and androgens exert marked beneficial effects on bone remodeling,
superseding this influence are multiple other hormonal mechanisms including those of systemic
hormones such as PTH, calcitonin, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3 - calcitriol), and
local factors such as Receptor for Activation of Nuclear factor Kappa B Ligand (RANKL), and
various monocyte derivatives including interleukins (IL), colony stimulating factors (CSF), and
prostaglandins (PG) (29,36).

Parathyroid Hormone. Especially important is the release of PTH from the parathyroid glands in
response to low blood calcium (47). PTH release results in increased blood calcium by
increasing calcium reabsorption in the kidney, increasing bone resorption, and indirectly
increasing absorption of dietary calcium in the intestine through increased production of
1,25(OH)2D3 (47). PTH increases bone resorption by binding to osteoblast membrane receptors
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and causing a decrease in the expression of osteoprotegerin (OPG) on the surface of the
osteoblast, an increase in expression of RANKL on the surface of the osteoblast, and increased
production of IL-6 (a potent stimulator of bone resorption) by the osteoblast (47). Binding of
RANKL, found anchored to the surface of osteoblasts or in a free form, to its receptor, RANK,
on the surface of osteoclastic precursors causes an increase in differentiation of osteoclasts which
increases mobilization of calcium from bone (37,47). Without the influence of PTH, binding of
OPG from osteoblasts to RANK on osteoclast precursors inhibits the differentiation of
osteoclasts and inhibits bone resorption (47).

Calcitonin. Released from the C-cells of the thyroid gland in response to high blood calcium,
calcitonin, favors bone mineralization through inhibition of osteoclasts (36,47). Thyroid
hormones, however, favor bone resorption through stimulation of osteoclasts. Thus defects in
parathyroid and/or thyroid metabolism can significantly alter the process of bone remodeling.

Vitamin D. Aside from its role in increasing intestinal absorption of calcium, 1,25(OH)2D3 also
promotes differentiation of osteoblast and osteoclast precursors through favoring expression of
RANKL on the surface of osteoblasts (as opposed to OPG) (37). This process is also proposed
to be mediated through increased production of IL-6, similar to the effects of PTH (36,37).
However, recent studies showing inhibition of bone resorption by administration of
1,25(OH)2D3 to OPG knockout mice (simulating the increased bone resorption occurring during
osteoporosis), challenge this long-standing theory (48). In these studies, 1,25(OH)2D3 appears
to inhibit bone resorption through effects on osteoclast differentiation via interference with the
RANKL/RANK pathway (48). 1,25(OH)2D3 has also been shown to increase the production of
monocyte-CSF (M-CSF) which is the only cytokine aside from RANKL that is required for the
differentiation of osteoclasts from their monocyte lineage (36,37). Therefore, 1,25(OH)2D3 may
have variable effects on bone remodeling dependent on the presence or absence of excess
16

osteoclastic activity (48). Regardless, the presence of vitamin D receptors (VDR) on the surface
of osteoblasts, leads many to assume a role of vitamin D beyond increasing calcium absorption
(49). Also being explored more recently are the roles of numerous genetic VDR variations
which have been found to be associated with differences in fracture risk due to phenotypic
effects on adult height, bone size, and BMD (50-52).
Currently, serum 25(OH)2D3 concentrations are measured to assess the adequacy of
dietary vitamin D (53). Serum levels of 25(OH)2D3 below 27.5 nmol/L are considered to
indicate vitamin D deficiency (54). Serum levels of 25(OH)2D3 decline with age even with
dietary supplementation (55). Vitamin D deficiency is associated with increased incidence of
hip fractures, most likely due to impaired calcium absorption and other effects at the cellular
level as mentioned above (55).

Local Factors. Many local factors also influence bone remodeling by manipulation of the
expression of RANKL and OPG. IL-11 and prostaglandin E2 (PGE2) increase the expression of
RANKL on the surface of osteoblasts, thus increasing the number of active osteoclasts and
promoting bone resorption (37). IL-1 can also stimulate osteoclastogenesis directly or indirectly
through increasing IL-6, M-CSF and IL-11 (37). Both tumor necrosis factor alpha (TNF-α) and
transforming growth factor beta (TGF- initiate osteoclast formation independently of the
RANKL pathway, likely through increased production of IL-6 by osteoblasts (37).

Other Hormones. Growth hormone/IGF-1 (Insulin-like growth factor) and cortisol also affect
bone remodeling; growth hormone/IGF-1 favoring bone formation through enhancing osteoblast
function and cortisol, favoring bone resorption, by promoting osteoblast apoptosis, increasing
osteoclast activity, and decreasing intestinal calcium absorption (36,37). In addition to IGF-1,
bone morphogenic proteins (BMP) released from osteoblasts stimulate further synthesis of
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osteoblasts as do various fibroblast growth factors (FGF) (37). Glucocorticoids can also inhibit
the synthesis of IL-1, IL-6, and prostaglandins, all of which enhance bone resorption (37). In
fact, glucocorticoid induced osteoporosis (GIO) is the most common form of medication induced
secondary osteoporosis (15). While not typically categorized as a hormone, vitamin A can
directly oppose the action of vitamin D via stimulation of osteoclastogenesis via the shared
retinoic acid receptor (RXR) nuclear binding site (36).

Estrogens. The influence of estrogens on attainment of peak bone mass and maintenance of bone
mass is substantial. Men develop longer and larger bones in adolescence than women likely due
to the absence of the stimulating effect of estrogen on epiphyseal closure and its inhibitory effect
on periosteal apposition (45). While detailed mechanisms are not complete, estrogen receptors
have been found to be present on osteoblasts, osteocytes, lining cells, osteoblastic precursor
cells, osteoclastic precursor cells, and multiple other cells and factors associated with bone
metabolism (37). Estrogen, specifically the 17β-estradiol form, exerts an overall protective
effect on bone via multiple potential mechanisms. Estrogen inhibits the synthesis of osteoclastic
precursors [through decreasing monocyte colony-stimulating factor (M-CSF), increasing the
ratio of OPG to RANKL on the surface of osteoblasts, and decreasing the expression of the IL-1
receptors on osteoclasts and osteoclastic precursors], inhibits the synthesis of osteoclasts (by
decreasing IL-6 concentrations), induces osteoclast apoptosis, and may also enhance osteoblast
survival (20,36,37,47). Estrogen also influences extraskeletal processes related to calcium
homeostasis such as intestinal calcium absorption, serum concentrations of 1,25(OH)2D3, renal
calcium reabsorption, and the secretion of PTH (37).
Mounting in vivo research suggests multiple other protective functions of estrogen on
bone including promoting the proliferation and viability of osteoblasts through control of
osteoblast apoptosis, promoting the production and mineralization of bone matrix through
regulation of the expression of proteins such as alkaline phosphatase, osteocalcin, and type I
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collagen, promoting growth factor/cytokine expression and responsiveness which are required
for the normal coupling of osteoclastic action with osteoblastic action, regulating factors
affecting bone resorption including a possible suppression of PTH action in addition to
decreasing IL-6 (as mentioned above), and enhancing osteoblast receptor expression and signal
transduction, promoting bone formation (37). Interestingly, several in vivo studies also suggest
that estrogens may regulate the process of mechanosensory stimulation or that mechanical strain
and estrogen action share common signaling pathways (37).
The protective effects of estrogen on bone are also evidenced by human studies that show
substantial increases in BMD when exercise programs are combined with HRT or from HRT
alone and the successful use of HRT to treat osteoporosis (24,56,57). In addition, detrimental
effects on bone have been observed following discontinuance of HRT in post-menopausal
women, reporting BMD declines between 2.3% and 6.2% in the first year (58). Tremollieres et
al (59) reported a transient acceleration of bone loss at the spine in women discontinuing HRT
similar to that experienced in untreated women in the first 2 years following menopause.

Androgens. Research supports the independent benefit of androgens on bone health in both men
and women with effects of deficiency more pronounced in men (37). It has been estimated that
30-50 percent of elderly men are deficient in sex steroids due to an increase in sex hormone
binding globulin (SHBG) which binds both androgens and estrogens rendering them inactive
(15). Case control studies also report a higher than normal prevalence of hypogonadism in men
with spine or hip fracture (45). Further demonstrating the influence of androgens on bone health
in females, animal research has shown osteopenia in intact female rats with blockage of
androgen receptors (37).
Androgen deficiency induces bone loss in men similar to that found in women with
estrogen deficiency, especially at trabecular bone sites (45). Androgens exert their effects on
bone via androgen receptors or indirectly via estrogen receptors following conversion to
19

estrogens (45). Androgen receptors have been found in osteoblasts, osteocytes, and in
mononuclear cells and endothelial cells of blood vessels within bone marrow (60). Like
estrogens, androgens have been shown to promote bone maintenance through decreasing
osteoblast and osteocyte apoptosis, increasing TGF- and IGF-1 (factors involved with bone
formation), and decreasing IL-6 production (a factor involved with bone resorption)(37,45).
Whether androgens increase OPG (a factor involved in bone formation) as estrogens has yet to
be determined (45). The most dramatic impact of androgens in males is their effect during
growth on bone size, particularly increasing cortical thickness, via their stimulatory effect on
periosteal apposition (37). The effects of androgens during other life stages has not been as well
studied as that of estrogens (37).

Dietary Calcium Intake
It is essential that abundant calcium be available for hormonal control of bone remodeling
to occur normally. Since plasma calcium is tightly controlled, adequate dietary calcium intake is
necessary to minimize bone resorption stimulated by low plasma calcium. While the
recommended AI (adequate intake) of calcium for men and women aged 51-70 years is 1200
mg/day, evidence from NHANES (1971-2000) suggests that while dietary calcium intake from
food sources in this age group has increased over the last 3 decades, intakes by women are
currently only ~50% of these recommendations and intakes by men are only ~65% (61,62).
Although calcium supplementation (including calcium containing antacids, multivitamins, and
calcium alone) is prevalent in older men and women, most epidemiologic surveys include
questions about the mere presence of current or past dietary supplementation, providing little
data as to the consistency of the intake of dietary supplements (63,64). Therefore, supplemental
calcium may only contribute minimally if at all to total dietary calcium intake in this population
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unless strict adherence is observed, such as occurs during research. Further, the estimated
dietary intake of calcium is so low that supplemental calcium, even if taken on a regular basis,
may not bring total intake up to the AI.

Dietary Vitamin D Intake
Under the stimulation of PTH, vitamin D acts to maintain normal plasma calcium levels
by increasing calcium absorption from dietary sources, which becomes increasingly important as
age advances (65). The current AI for vitamin D for men and women aged 51-70 years is 400
IU/day (10 µg) (61). According to NHANES 1999-2000, the intake of vitamin D from both food
and supplemental sources in persons aged 51 and over is ~95% of the recommended value (66).
However, this intake data does vary by race and circulating vitamin D can also be compromised
by the absence of adequate sun exposure (66). Also, recent controversy regarding the need to
increase vitamin D recommendations to 1000 IU/day (25 µg) to maintain circulating vitamin D
at levels associated with health benefits may render these intakes inadequate in the coming years.
The effects of variations in VDR's also supports the theory that individual requirements for
vitamin D may vary (50-52).

Dietary Phosphorus Intake
Dietary phosphorus deficiency occurs very rarely due to the abundance of phosphorus
containing foods in the diet with half of the needed intake coming from all types of animal
products (65). Efficient intestinal absorption and renal conservation of phosphorus also protect
very well against deficiency (65). Hypophosphatemia and phosphorus deficiency are rarely seen
among healthy non-hospitalized people (67). However, depletion of phosphorus can occur from
megadoses of aluminum hydroxide containing antacids, which bind dietary phosphorus in the
gut, preventing its absorption (65).
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Dietary Magnesium Intake
While magnesium has not been shown to have as definitive a role in bone health as other
nutrients, most of the magnesium in the human body is found in bones alongside calcium and
phosphorus (15). Adequate dietary magnesium appears to enhance bone quality through
improving bone density (15). A dietary deficiency of magnesium can lead to hypocalcemia
through interference with PTH secretion (54). Under normal circumstances, magnesium acts
similarly to calcium in inhibiting PTH secretion and conversely, its absence, increases PTH
which stimulates bone resorption (68). Magnesium deficiency is also associated with reduced
synthesis of 1,25(OH)2D3 in humans (68). Studies done in rats with intakes ranging from no
magnesium to levels set to reflect the dietary deficiency of Americans, have shown bone loss,
decrease in osteoblasts, and increases in osteoclasts as well as low levels of PTH and
1,25(OH)2D3, decreased levels of OPG, and increased levels of RANKL, all factors favoring
bone resorption (68).
Both men and women in the United States consume less than the recommended level of
magnesium with median intakes of 220 mg/day for women and 320 mg/day for men with
recommended intakes being 320 mg/day for women, and 420 mg/day for men (54). Numerous
epidemiological studies conducted with subjects of all ages, mostly cross sectional, have linked
dietary magnesium deficiency with osteoporosis (68,69). However, few studies have examined
the magnesium status of people with osteoporosis and the results of these studies are not
consistent (70-75). Also, epidemiological studies are somewhat limited as they identify
population trends and are often difficult to apply to individuals.
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Physical activity
Intermittent mechanical stresses on bone provided by physical activity in childhood and
adolescence are essential for the proper development of bone structure and optimization of peak
bone mass (31). Based on epidemiological evidence correlating physical activity with overall
better health, both public and private health organizations recommend that moderate physical
activity continue throughout the life cycle. Weight bearing exercise is proposed to provide the
greatest site-specific osteogenic effects according to Wolff's law of biomechanics stating that
bone tissue will adapt its structure to the mechanical demands placed upon it (34). Although less
commonly than appendicular sites such as the wrist and hip, this principle has been suggested to
apply equally to the lumbar spine (76). Marked decreases in bone density during periods of
immobility or in zero gravity situations such as space travel also support Wolff's law (77).
Common aerobic activities such as walking, running, jumping, and aerobics are well known to
place an osteogenic load at the hips in post-menopausal women, but their effects on lumbar spine
BMD are inconsistent (78,79). Also, any exercise that strengthens postural muscles and/or
increases flexibility can improve balance and thus lower the risk of falls which can lead to
fractures (80).
While multiple socioeconomic and psychological factors influence individual physical
activity level, general functional ability and overall physical activity levels tend to decrease over
time. A reduced physical activity level supports decline in bone mass and density due to the
absence of mechanical loads or strains to stimulate bone formation. With most evidence
suggesting that low physical activity levels persist among older adults in the United States,
identification of exercises that can modify measurable health outcomes such as bone density may
provide motivation for increases in physical activity in these high risk populations (81,82).
Sometimes overlooked among the most potent factors in the pathogenesis of osteoporotic
fracture including low bone density and poor bone quality, is the propensity to fall which can be
remedied by regular balance training (19,83). Strengthening of the core muscles of the lower
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back and abdomen to prevent falls has been suggested as an important step in fracture prevention
in older adults (83). While little research exists showing a definitive reduction in the occurrence
of fracture due to balance training, the enhanced sense of control and increases in postural
balance are likely protective against falls (84-86).

Interestingly, recent animal research

provides evidence that exercise may be able to effectively reduce fracture risk by inducing
favorable changes in bone geometry without dramatic effects on bone mass (80).

Smoking and Alcohol Consumption
Both tobacco smoking and alcohol consumption are associated with increased risk for
fracture at all sites in both men and postmenopausal women (15,87-90). Smoking has been
shown to be detrimental to bone health in a variety of ways including direct toxic effects on bone
cells, impairing calcium absorption, and interfering with the normal metabolism of vitamin D
and other hormones important for bone health including estrogen (15). Current smoking places a
person at higher risk of bone fracture than does former smoking (15). One recent study found
that women who smoked were more likely to have a particular gene mutation that negatively
affects bone health (87).
Alcohol abuse has well established negative effects on bone health (15). Alcohol inhibits
bone remodeling through interfering with the effect of vitamin D and may also increase calcium
and magnesium loss (15). While some studies suggest moderate alcohol intake increases bone
density (particularly in women), it does not seem to lower overall fracture risk (15). Excessive
alcohol consumption increases the risk of fracture most likely due to the increased risk of falling
(15).
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Genetics
Multiple hereditary factors greatly influence peak bone mass and quality of bone structure
which collectively form the largest determinants of the timing of fracture risk (29,33). In fact, it
has been indicated that between 50-90% of peak bone density is attributable to genetic factors
(15). Additionally, women with a family history of osteoporosis in first degree relatives tend to
have lower bone density than women with no family history of osteoporosis (20). Both low
body weight/size and weight loss have also been associated with reductions in overall BMD in
post-menopausal women due to the reduced loads (15,31).

Gender and Race
Asian and white women in the United States have been found to be at higher risk for
osteoporosis due to lower BMD than other racial or ethnic groups (15). While men experience
the same gradual decline in bone mass as women, they do not experience the accelerated bone
loss accompanying menopause and generally attain higher peak bone mass due to longer and
larger bones (45). This higher bone mass has been argued to be an artifact of the areal bone
mineral density measure given by dual x-ray absorptiometry (DXA) and may not translate to a
higher bone strength (45).

25

Measuring BMD
Currently, the gold standard for assessment of BMD is dual x-ray absorptiometry (DXA).
DXA detects bone mineral content (BMC), expressed in grams (g), and the area of the bone,
expressed in square centimeters (cm2) by measuring the attenuation of x-rays passed through
various body sites (91,92). A two-dimensional BMD value, expressed in (g/cm2) is calculated
based on these measures (92). Since DXA cannot detect the depth of the bone being measured,
the BMD value obtained represents an ―areal‖ density in units of g/cm2 rather than a true
volumetric density in units of g/cm3 (91). A BMD score is interpreted by either the number of
standard deviations from the mean of age-matched controls (Z-score), or the number of standard
deviations from the young normal mean (T-score) (93). The World Health Organization (WHO)
reference standards for diagnosis of osteoporosis and low bone mass for women are T-scores of 2.5 or less and between -1.0 and -2.5, respectively, and are derived from the NHANES III femur
bone density data for 20-29 year old white, females (18,93). A T-score -2.5 or less with an
accompanying fracture is classified as severe osteoporosis (92). For assessing the BMD of postmenopausal women, the preferred method is the T-score (18). The validity of applying these
standards to men is questionable, however, it is the commonly used method of diagnosing
osteoporosis in men (23).

Osteocalcin (Bone Gla protein)
Osteocalcin is a vitamin K dependent, noncollagenous protein secreted almost
exclusively by osteoblasts that is incorporated into normal bone matrix (53,94). Approximately
thirty percent of the total osteocalcin produced by osteoblasts is released into the blood where it
is measured as an indicator of bone turnover (53). Serum osteocalcin is the most commonly
marker of bone formation during pharmacological treatment of patients with osteoporosis but its
release during bone resorption has not been ruled out (53,94).
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Pyridinium Crosslinks
Deoxypyridinoline (DPX) is a crosslinked protein found in type 1 collagen that makes up
nearly 90% of the bone matrix providing tensile strength to the bone (53). DPX is released into
the bloodstream and excreted in the urine in response to bone resorption (53). By measuring at
least one measure of bone formation, osteocalcin, and at least one measure of bone resorption,
DPX, it is possible to draw strong conclusions about overall bone turnover (95).

Gastroesophageal Reflux Disease (GERD)
Gastroesophageal reflux disease (GERD), more commonly known as heartburn, refers to
symptoms and damage to the lining of the esophagus due to reflux of acidic gastric contents into
the esophagus most often due to inappropriate relaxation of the lower esophageal sphincter
(LES) (1,2). It has been estimated that the worldwide prevalence of GERD has doubled in the
past thirty years, with population-based studies indicating up to 25% of adults experiencing
heartburn at least once per month and 5% of adults experiencing heartburn daily (1,2). Both men
and women appear to be equally affected by GERD with some studies showing a higher
prevalence in women than men (3,4,96).
Alongside lifestyle modifications to manage GERD, most patients require the use of
medications to control symptoms (5). The most commonly prescribed medications are
histamine-2 (H2) blockers [Tagamet® (cimetidine), Zantac® (ranitidine), Pepcid® (famotidine),
Axid®(nizatidine)] and proton pump inhibitors (PPI) [Prevacid® (lansoprazole), Prilosec®
(omeprazole), Protonix® (pantoprazole), Aciphex® (rabeprazole), Nexium® (esomeprazole)].
The goal of these medications is to reduce symptoms of GERD through decreasing hydrochloric
acid production in the stomach (5). In 2002, the sales of PPI's reached more than $10 billion,
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second only to the sales of statins and in 2004, Nexium® became the third highest selling
prescription drug in the United States (6,7).
In 2002, the annual direct cost for diagnosing and managing GERD in the United States
was estimated at $9.3 billion, more than any other digestive disease (97). Long-term effects of
uncontrolled GERD include esophageal strictures and/or ulcers, Barrett's esophagus (benign
changes in esophageal mucosal cells), and esophageal adenocarcinoma (2).

Risk Factors for GERD
Risk factors associated with GERD include being overweight or obese, consumption of
alcohol, smoking, family history of upper gastrointestinal symptoms, diet, and lifestyle (3).
While often recommended as a reasonable treatment for GERD as well as other health benefits, it
remains unclear whether weight loss in people who are overweight or obese will decrease
symptoms of GERD (3,99). The relationship between obesity and GERD may be due to the
increased incidence of hiatal hernia in this population and to other mechanical and physiological
factors predisposing obese people to GERD (99). Alcohol and cigarette smoking both increase
the risk of GERD through exacerbation of already existing problems with LES pressure (3).
Tobacco smoking may increase the frequency of GERD events through the stimulatory effects of
nicotine (3). Alcohol has been shown to reduce the strength of peristalsis waves in the
esophagus, impair the clearance of acid contents from the stomach, and reduce saliva output in
normal subjects, all which would increase the likelihood of GERD events in persons with GERD
(3).
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Treatment of GERD
Lifestyle modifications are the first line of treatment for GERD. The American College
of Gastroenterology recommends elevating the head of the bed (HOB), decreased fat, chocolate,
alcohol, peppermint, and coffee intake, smoking cessation, and avoiding laying down for 3 hours
following a meal (100). While there is physiologic evidence suggesting that these modifications
will improve symptoms of GERD and some have been associated with improvements in GERD
in case-control studies, most patients require further treatment with H2 receptor antagonists
(H2RA) or proton pump inhibitors (PPI) (100-102). H2RA are generally used for initial therapy
or temporary management of GERD, while the majority of PPI use is for long-term management
of GERD that remains uncontrolled with H2RA therapy (5).

Gastric Acid Production and Secretion
Parietal cells produce and secrete hydrochloric acid (HCl) into the stomach. This process
is tightly regulated by neural, hormonal, paracrine, and intracellular pathways to adjust the pH of
the stomach to the needs of the body to maintain normal digestive and absorptive properties (98).
Lower than normal acid production can interfere with the absorption of iron, calcium, and
vitamin B12, and is associated with gastrointestinal infections, bacterial overgrowth, and gastric
cancer (98). Excess acid production can cause ulcerations of the esophagus, stomach, and
proximal small intestine (98).
Secretion of gastric acid begins with the sight, taste, smell, or thought of food stimulating
mucous cells, chief cells, parietal cells, and G cells to produce mucous, digestive enzymes, HCl,
and gastrin respectively (30). Gastrin released into the bloodstream stimulates acid secretion
primarily by stimulating enterochromaffin-like (ECL) cells to release histamine as well as direct
stimulation of parietal cells (98). Histamine binds to histamine H2 receptors on surrounding
parietal cells that are coupled to generation of cAMP and the resulting acid secretion (98).
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Acetylcholine also directly stimulates parietal cells and plays a role in suppression of
somatostatin, the primary inhibitor of ECL and parietal cells (98). Other inhibitors include
cholecystokinin (CCK), atrial natriuretic peptide (ANP), both of which exert their effects through
increasing somatostatin, and nitric oxide (98).
Increased concentrations of calcium or cAMP inside the parietal cell triggers the
translocation of the inactive H+K+ -ATPase proton pump from cytoplasmic tubulovesicles to the
apical plasma membrane where it is activated and becomes subject to the action of PPI's (98). A
proton is pumped out of the parietal cells into the canaliculis in exchange for a potassium ion
(98). An apical chloride channel pumps the needed chloride ion out to combine with the
hydrogen ions to produce HCl (98). An apical potassium channel provides the means for
maintaining a potassium gradient to drive the H+K+ -ATPase (98).

H2 Receptor Antagonists
H2RA's block the receptors for histamine that stimulate gastric acid production (12).
However, as described above, there are more potent stimulators of gastric acid secretion making
H2RA therapy less effective than PPI therapy which suppresses the final step in gastric secretion
at the level of the H+K+ -ATPase pump (12). Of the few studies that have examined chronic
H2RA therapy and BMD, the results are inconsistent and suggest that taking the less potent
H2RA's may be detrimental to bone health but requires a longer duration of therapy than the
more potent PPI's to show decreases in BMD or increases in fracture (10,103,104).

Proton Pump Inhibitors
PPI's inhibit gastric acid secretion by targeting the H+K+ ATPase pump of the parietal
cell (105). PPI's are weak bases that accumulate in compartments with a pH less than 4 (105).
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These include the resorption lacunae of osteoclasts and the canaliculis of a stimulated parietal
cell (105). In these spaces, PPI's are converted to tetracyclic sulfenamides which form stable
disulfide bonds with cysteines on the surface of the H+K+ ATPase pump and reduce its activity
(98,105). The potential anti-resorptive effect of these drugs at the level of the osteoclast was
discussed previously.
Most PPI's are only available by prescription, with the exception of Prilosec (omeprazole)
which became available over the counter in 2002 as Prilosec OTC (12). Typical doses of PPI's
range from 10-40 mg daily. Despite emerging evidence about the possible detrimental effect of
PPI's on BMD, no warnings about chronic use are contained in the patient educational
information available on the website for the American College of Gastroenterology.

Surgery
Surgical management of GERD is performed in only 10-20% of all GERD patients and is
only resorted to when there is failure or patient refusal pharmacological therapy (5,106). Antireflux surgery to decrease the size of the opening between the stomach and esophagus
(laparoscopic Nissen fundoplication) and other similar procedures are successful at relieving the
major symptoms of GERD but can also bring on new and persistent symptoms that require other
pharmacologic treatment (5,106). Also, due to transitional nature of the area of the esophagus,
there is a typical need for repeat surgery within 5 years (106).

Helicobacter Pylori
Helicobacter pylori (H. pylori) is a bacteria that infects the gastric mucosa and causes
prolonged and often chronic gastroduodenal inflammation that can alter both the structure and
function of the stomach and proximal duodenum leading to gastric or duodenal cancer, ulcers,
and atrophic gastritis (107). Atrophic gastritis can lead to malabsorption of iron, and other
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divalent cations such as calcium, and magnesium, as well as vitamin B12 via decreased acid and
intrinsic factor secretion (107).
Depending on where the infection is located within the stomach, the acid secretion can be
either suppressed or elevated. Most patients with H. pylori infection present with general
inflammation of the stomach and show suppressed acid secretion due to atrophy of the parietal
cells, antibodies to H. pylori and products secreted by H. pylori that directly interfere with the
H+,K+ -ATPase pumps, and other products secreted by H. pylori that indirectly inhibit acid
secretion by affecting gene expression of anti-secretory cytokines and other proteins (98).
Patients with an infection located in the antrum or lower region of the stomach show elevated
levels of acid secretion due to hypergastrinemia. These patients are at highest risk of developing
duodenal ulcers or gastroesophageal reflux disease (98).
While infections of H. pylori are much less common in the United States than in the last
50 years, treatment is aimed at reducing gastric acidity since H. pylori thrives in an acidic
environment (107). The most common treatments include prolonged PPI therapy in combination
with antibiotics (107). Due to the seriousness of the cancerous conditions that are likely if H.
pylori is left untreated, patients with H. pylori are likely to be compliant to long term PPI
therapy.

Hypochlorhydria and Achlorhydria
The most common cause of achlorhydria in the older population is progressive atrophic
gastritis which can occurs as a result of H. pylori infection, autoimmune conditions such as
pernicious anemia, or more commonly non-autoimmune or environmental factors (108). While
hypochlorhydria and achlorhydria are typical in the older population and have been theorized to
significantly impact nutrient absorption by affecting both the basal and maximal acid outputs, the
only vitamin with clinically significant malabsorption is vitamin B12 due to the impaired

32

secretion of intrinsic factor by the atrophied gastric cells (55,109).
Hypochlorhydria has been shown to result in weaker bones in animal studies attributed to
different rates of calcium absorption (110). Mixed results have been obtained on the effects of
hypochlorhydria on calcium absorption in humans with most studies showing some level of
decrease in calcium absorption with acid suppression therapy (111-115). One study showed no
difference in calcium absorption from insoluble calcium carbonate or soluble calcium citrate
with intragastric pH of 7 or 3 (116). These studies, however, were performed on a short term
basis only and may not accurately reflect changes in calcium absorption from prolonged PPI
therapy.
Most studies support that calcium carbonate is the most difficult form of calcium to
absorb but is the most commonly available form of supplemental calcium. The general
recommendation for a healthy population with normal gastric acid secretion is to take calcium
supplements with food to improve percent absorption (110). This recommendation stems from
the theory that since calcium salts need high amounts of acid for dissolution, and acid output is
highest postprandially, that with meals is the best time to maximize absorption. Some authors
suggest that in hypochlorhydric patients, this higher acid output may not occur and the acid that
is present is simply used to digest the other food and does not increase dissolution of calcium
salts (109). These authors suggest maximizing calcium absorption in these patients by
supplementing small doses of the most soluble calcium salt available in combination with
vitamin D given several times per day on an empty stomach with water or acid juice or perhaps
as effervescent tablets (109). However, increasing doses of medicines or supplements has been
associated with a decrease in compliance.
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Calcium Absorption
Calcium in foods and dietary supplements is present as part of fairly insoluble salts.
Ionized calcium (Ca+2) must be released from these salts to be absorbed. The acidic pH within
the stomach is responsible for solubilizing the ionized calcium within about 1 hour of ingestion.
However, calcium and divalent cations, once solubilized from their dietary sources, tend to form
complexes with other minerals or molecules within the more alkaline pH of the small intestine
(54,117). The formation of these complexes and competition with other divalent cations for
absorption leads to a relatively low percent absorption of calcium. Percent absorption of calcium
is at or below 25% for most adults and is highest (as much as 60%) in periods of rapid growth
such as infancy and the second and third trimesters of pregnancy (61). Both the percent calcium
absorption as well as the compensatory increase in calcium absorption when faced with low
calcium intake tend to decrease with age (55). It has also been estimated that calcium absorption
declines by as much as 0.2% per year following age 40 with an additional 2.2% loss
accompanying menopause in women (61,118). This decline in calcium absorption with age is
directly related to the decrease in circulating 1,25(OH)2D3 and a subsequent decline in intestinal
vitamin D receptors (118,119). Circulating 1,25(OH)2D3 levels decrease with age due to a
decline in kidney function, decreased synthesis of vitamin D in the skin related to lower sun
exposure, and a general decline in intestinal absorption of vitamin D (55,118).
Calcium is absorbed into the blood by active transport (transcellular pathway) and passive
diffusion (paracellular pathway) (54,61). The predominant mechanism of absorption by active
transport is regulated primarily by the circulating level of 1,25(OH)2D3 and occurs mainly in the
duodenum and proximal jejunum (54). This mechanism is predominant during times of low or
moderate calcium intake (61). Most calcium absorption occurs in the ileum due to the relatively
longer period of time calcium is present in this part of the intestine (54).
The mechanism by which 1,25(OH)2D3 acts to increase calcium absorption begins with
low blood calcium triggering the production of PTH which then stimulates the action of the renal
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enzyme 25-hydroxyvitamin D 1 alpha-hydroxylase which results in production of the active
1,25(OH)2D3 from the inactive 25-dihydroxyvitamin D3 synthesized in the skin (54). This
1,25(OH)2D3 acts to increase calcium absorption by binding to vitamin D receptors (VDR) in
the cytoplasm of the enterocyte and translocating to the nucleus to increase the gene expression
of the brush-border calcium channel TRPV6, the cytosolic mobile calcium buffer calbindin D,
and the basolateral membrane Ca+2 ATPase exporter pump (54,67). TRPV6 allows for
increased influx of calcium from the lumen of the intestines (54). Calbindin D facilitates
absorbed calcium for export into the blood by acting as a chaperone protein to increase substrate
availability to the Ca+2 ATPase exporter pump on the basolateral membrane (54).
The paracellular mechanism of passive diffusion that predominates with high calcium
intakes allows the movement of calcium between mucosal cells depending on the concentration
gradient between the luminal side of the enterocyte and the serosal side of the enterocyte and is
not regulated by hormones (54,61). Some evidence suggests that another absorption process
involving the transport of calcium through the enterocyte via endosomal and lysosomal vesicles
and exit from the cell via exocytosis may exist (54). However, little is known about the
contribution of this process to overall calcium absorption or how it is regulated (54).

Magnesium Absorption
As with calcium, magnesium absorption occurs through two different pathways, a
saturable active transcellular pathway and a nonsaturable paracellular passive transport pathway
(54). The paracellular mechanism accounts for approximately 90% of intestinal magnesium
absorption with the remaining absorption theorized to be through a magnesium-specific transport
protein/channel that is not yet well defined (67). In healthy individuals, magnesium is absorbed
along the entire gastrointestinal tract with an absorption percentage of 30% to 50% and
absorption is inversely proportional to intake (54).
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Unlike calcium absorption, the role of hormones in the regulation of magnesium
absorption at the intestine is less clear and the regulation of magnesium homeostasis is largely
dependent on the filtration and reabsorption of magnesium in the kidney tubules (54,67).
Calcium and magnesium have similar absorption patterns with magnesium's active transport
process seeming to be saturable at much lower concentrations than that of calcium. This is why
the passive pathway is so much more dominant in magnesium absorption than it is in calcium
absorption. While the mechanism remains unknown, vitamin D appears to enhance magnesium
absorption (54).
Since magnesium exists in food in its elemental form, gastric acid is not required for
solubilization as it is with calcium. While the absorption of magnesium salts from dietary
supplements may be affected by decreased gastric acid secretion, supplements do not currently
contribute significantly to the dietary intake of magnesium in the United States.

Important Considerations for Future Studies
While the primary reason for taking PPI's is to prevent symptoms of GERD, PPI's are
also taken to prevent inflammation and ulcers associated with the use of nonsteroidal antiinflammatory drugs (NSAIDS). This introduces another population who may be affected by
chronic PPI therapy and could be studied without the confounding factors relating to the
underlying condition of GERD (8). More attention should also be focused on examining the
validity of the protective effect of PPI therapy on bone health through decreasing bone resorption
by inhibiting the acidifying action of osteoclasts. While this mechanism may be unlikely, as
proton pump inhibitors likely only affect cells within the stomach, it merits further investigation.
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Limitations of Previous Research
To our knowledge, only one other study has been published examining BMD in patients
taking long term PPI therapy (120) and no studies have been published examining biochemical
markers of bone turnover in patients on long term PPI therapy. Yu et al (120) concluded that
long term PPI therapy in combination with low calcium intake was associated with a modest
increase in hip fracture. Previous research associating PPI use with higher risk of bone fracture
is limited to retrospective studies examining medical records (8-11).

Summary
This purpose of this study was to determine the effect of long term PPI therapy on BMD
and related bone biomarkers in men and post-menopausal women not on HRT who represent the
population most affected by osteoporosis. The study was designed to more closely examine the
biochemical effects of PPI therapy on biomarkers of bone health following the results of
population studies showing an independent correlation between BMD, fracture risk, and duration
of PPI therapy.
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CHAPTER 3

MATERIALS AND METHODS

Research Design
This observational study compared bone health markers in men and post-menopausal
women who had been taking PPI therapy for more than 5 years, less than 5 years, or never taken
PPI therapy.

Subjects
Twenty-five women and 31 men (n=56) were recruited by posting fliers on BYU campus,
in waiting areas at local medical offices, and by mailing fliers to BYU Alumni. Women
qualified for the study if they were at least five years post-menopausal and had not been on HRT
for at least five years. Additional exclusion criteria for both men and women included known
osteoporosis, history of osteoporosis medications, current smoking, current excessive alcohol
intake, large bone fracture within the last 10 years, and/or presence of diseases or use of
medications that affect bone metabolism. Two female participants dropped out after the blood
draw. Data from 54 participants (23 female, 31 male) were used in the final analysis. Of the 31
males in our study, 25 were PPI users and 6 were not. Of the females in our study, 6 were PPI
users and 17 were not. Total PPI users = 31, total non-PPI users = 23. Participants were further
divided into three groups based on duration of PPI therapy, no PPI therapy, PPI therapy of
greater than or equal to 5 years, and PPI therapy of greater than 5 years (See Table 1). Of the
non-PPI users 6 were males and 17 were females. In the greater than or equal to 5 years PPI
therapy group, 12 were males and 3 were females. In the greater than 5 years PPI therapy group,
13 were male and 3 were female.
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Table 1: Characteristics of groups divided according to gender and duration of PPI therapy
Duration of PPI Therapy
None

< 5 years

> 5 years

Male

6

12

13

Female

17

3

3

Total

23

15

16

62 years

63.4 years

63.2 years

Gender

Mean Age

Food Frequency Questionnaire
The online version of the Diet History Questionnaire (DHQ) version 2007 was used to
assess dietary habits and Diet Calc (1.4.3) was used to analyze the dietary intake data.
Participants were allowed to perform this test either in paper and pencil format or the web-based
format either away from the laboratory or within the laboratory depending on their preference.
Supplemental questions were added to determine physical activity level. Food frequency
questionnaires (FFQ) are widely used in population based research and the strength of these tools
increases with the number of respondents. FFQ’s are useful in identifying trends in dietary
intake, however, their use in smaller studies is limited by the number of respondents and relies
heavily on accurate recollection of study participants. Long-term dietary intake of bone health
related nutrients is more relevant to our study than short-term dietary intake so the FFQ was
chosen as the tool for assessing dietary intake.
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Physical Activity Level
Current and past levels of aerobic activity and resistance training were assessed using a
questionnaire created by our research team. Participants were designated as ―active‖ for current
aerobic activity if they self-reported a minimum of 30 minutes per day at least 3 days per week
of aerobic activity over the last 6 months. Participants were designated as ―active‖ for current
resistance training if they self-reported a minimum of 2 days per week of resistance training over
the last 6 months. Participants were designated as ―active‖ for past aerobic activity if they selfreported a consistent participation in aerobic activities for a minimum of 30 minutes per day at
least 3 days per week over the last 20 years. Participants were designated as ―active‖ for past
resistance training if they self-reported a consistent participation in resistance training a
minimum of 2 days per week over the last 20 years. Physical activity levels was designated as
―inactive‖ for current aerobic activity, current resistance training, past aerobic activity, or past
resistance training if participant self-reported any activity level less than described above.

Anthropometric Data
Height
Height was measured to the nearest 0.5 inch using a professional grade stadiometer,
Model PE-WM-60-76-BRG2 (Perspective Enterprises, Portage, MI). Subjects were measured
standing with head, shoulder blades, buttocks, gastrocnemius muscles, and calcaneus bones
touching the wall and weight distributed evenly between both feet. Participants were measured
without shoes.

40

Weight
Weight was measured to the nearest 0.25 pound (lb) using an electronic scale (Tanita
310). Subjects were weighed wearing their underwear and one layer of clothing with no shoes.

Waist-to-hip Ratio
Waist-to-hip ratio was measured to the nearest 0.25 inch using a tension controlled tape
measure. All measures were performed by the same researcher.

Body Composition and Bone Density
Body composition and bone density were assessed using DXA (Lunar, GE Prodigy).
Body composition was measured using a total body scan. Bone density was measured at the
lumbar spine (L1-L4) and the hips. Technician coefficient of variation for lumbar spine BMD
and hip BMD was established using recommended protocol at 0.5%(92).

Blood and Urine Samples
Serum samples were spun down and frozen to -20 degrees Farenheit immediately
following the blood draw by BYU Student Health Center laboratory staff and transported and
frozen to -80 degrees farenheit within one week of collection by a member of our research staff.
Urinary samples were processed according to standard protocol and frozen within one week of
collection to -80 degrees farenheit. Urine sample jugs were inverted three times and samples for
freezing were obtained from the middle of the specimen.
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Osteocalcin and Deoxypyridinoline (DPX)
Serum osteocalcin and urinary DPX were measured using LabCorp standard protocol.
Since osteocalcin levels peak at night and are lowest in the morning, serum samples were drawn
between 8 and 11 AM for consistency. Urinary DPX samples were collected from the first
morning voids, also between the hours of 8-11 AM.

Other Laboratory Values
Serum parathyroid hormone, serum magnesium, serum 25(OH)2D3, serum osteocalcin,
24-hour urinary calcium, 24 hour urinary magnesium, and urinary DPX to creatinine ratio were
all measured using LabCorp standard protocol using the samples described above.

Statistical Analysis
Statistical comparisons were done using ANOVA to compare the three groups of less
than 5 years PPI therapy, more than 5 years PPI therapy, and no PPI therapy to each other on
measures of hip and spine BMC, hip and spine BMD, serum parathyroid hormone, serum
magnesium, serum 25(OH)2D3, serum osteocalcin, 24-hour urinary calcium, 24 hour urinary
magnesium, and serum DPX to urinary creatinine ratio. The decision to divide the groups at 5
years was made to be consistent with other research examining the effects of long-term PPI
therapy. Since the groups contained both genders, differences between genders were
investigated by utilizing an interaction between gender and duration to see if there was any
difference in how the genders responded to the duration of PPI therapy.
Stepwise regression was performed on all covariates affecting any outcome variables to
determine if any were significant. This was done to rule out the effects of any of the covariates
on the outcome variables. Covariates considered were age, waist:hip ratio; use of thyroid
medication; use of a multivitamin; BMI; output from body composition analysis including tissue,
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fat, lean, and fat-free mass; body weight; current or past aerobic or resistance exercise; total
dietary intake (including supplements) of phosphorus, sodium, potassium, vitamin A, vitamin C,
calcium, magnesium, vitamin D, and caffeine; and presence of osteoporosis or osteopenia at hip
or spine.
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CHAPTER 4
RESULTS
Lean and fat free mass were both significant at a p-value of <0.0001 for covariates
affecting BMD which was expected. Diagnosis of osteoporosis or osteopenia was significant for
urinary calcium and DPX:creatinine ratio which was also expected. No other covariates were
found to be significant. ANOVA results showed no significant differences between groups of
varying durations of PPI therapy on hip or spine BMD or any other bone health biomarkers
(Table 2). Because our groups were imbalanced in numbers of men and women (Table 1), we
investigated differences in gender through investigating the interaction between gender and
duration to determine if the effect of duration of PPI therapy was affected by gender. The effect
of the interaction between gender and duration was significant at a p-value of 0.04 for hip BMD,
implying that the duration of PPI therapy affected the men and women in our study differently.
Hip BMD was higher in females than males at both duration levels of PPI therapy but was not
significantly different between groups who took no PPI therapy (Graph 1 and Table 3).
Furthermore, the T-score associated with the mean BMD of males at both durations of PPI
therapy was categorized as osteopenia while the same of females was classified as normal. Mean
age of all participants was 63 years.
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Table 2: Outcome variables with means and standard errors
Gender
Group

Duration of PPI Therapy

Male

Female

None

< 5 years

> 5 years

n = 31

n = 23

n = 23

n = 15

n = 16

0.940 (0.02)

1.026 (0.04)

0.979 (0.03)

0.973 (0.03)

0.997 (0.03)

1.203 (0.03)

1.196 (0.04)

1.136 (0.03)

1.253 (0.04)

1.209 (0.04)

28.38 (2.55)

23.60 (2.25)

29.21 (2.92)

24.87 (2.63)

11.00 (1.93)

10.48 (1.47)

10.02 (1.80)

11.24 (1.88)

25.55 (2.79)

24.61 (2.32)

29.65 (2.80)

25.46 (2.65)

163.87 (28.72)

204.10 (26.06)

151.54 (34.28)

172.43 (30.87)

41.39 (6.69)

49.28 (4.32)

39.30 (5.18)

41.13 (5.05)

2.06 (0.04)

2.07 (0.03)

2.03 (0.04)

2.09 (0.04)

78.26 (10.31)

115.40 (9.50)

82.10 (11.91)

79.72 (10.92)

Hip BMD
Mean (g/cm2)
Spine BMD
Mean (g/cm2)
Serum Osteocalcin
Normal Range = 9.4 – 47.4 ng/ml
Mean (ng/ml)

23.40 (1.87)

Urinary DPX:Creatinine Ratio
Normal Range = 2.3 – 7.4 nmol DPX : mmol Creatinine
Mean

10.16 (1.55)

Serum 25 dihydroxyvitamin D3
Normal range = 32 – 100 ng/ml
Mean (ng/ml)

27.59 (2.11)

24 Hour Urinary Calcium
Normal Range = 100 – 300 mg/24 hours
Mean (mg/24
hours)

188.18 (23.93)

Serum Parathyroid Hormone
Normal Range = 15 – 65 pg/ml
Mean (pg/ml)

45.09 (5.07)

Serum Magnesium
Normal Range = 1.6 – 2.6 mg/dl
Mean (mg/dl)

2.07 (0.03)

24 Hour Urinary Magnesium
Normal Range = 12-293 mg/24hours
Mean (mg/24
hours)

106.55 (7.77)

45

Table 3: Mean hip BMD, standard errors, and T-score classifications of males and females
according to duration of PPI therapy
Duration of PPI Therapy
Gender

None

< 5 years

> 5 years

Males (g/cm2)

0.993 (0.040)

0.885 (0.038)

0.940 (0.031)

T-score Classification

Normal

Osteopenia

Osteopenia

Females (g/cm2)

0.965 (0.036)

1.060 (0.060)

1.054 (0.064)

T-score Classification

Normal

Normal

Normal
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Graph 1: Hip BMD by gender and varying durations of PPI therapy
1.1

Bone mineral density (grams/squared centimeter)
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DISCUSSION
According to our results, the effects of gender and duration of PPI therapy on hip bone
mineral density were dependent on one another without being statistically significant when
considered independently. This suggests that men and women may respond differently to longterm PPI therapy; however, not in the way one would expect. In general, females have a lower
bone mass than males at any age. However, in our study, women had a higher bone mineral
density at the hip than men when on PPI therapy for a longer duration. Furthermore, the T-score
associated with the mean BMD of males at both durations of PPI therapy was categorized as
osteopenia while the same of females was classified as normal. Osteopenia is a known
independent risk factor for osteoporotic fracture in both genders (15). These results suggest that
men are more likely to increase their fracture risk by taking PPI therapy for long durations than
women.
By measuring at least one measure of bone formation, osteocalcin, and at least one
measure of bone resorption, DPX, it is possible to draw strong conclusions about overall bone
turnover (95). While no participants had an osteocalcin outside of normal, all participants had an
above normal DPX:Creatinine ratio suggesting a higher level of bone resorption with a normal
amount of bone formation. These results are consistent with the mechanism resulting in agerelated osteoporosis of increased bone resorption without an appropriate increase in bone
formation.
By measuring PTH, vitamin D, serum calcium, urinary calcium, serum magnesium, and
urinary magnesium simultaneously, we obtained a fairly complete biochemical picture of overall
calcium and magnesium balance. While some participant values were outside the normal range,
especially for vitamin D, no significant differences were found between groups relating to
calcium or magnesium balance.
Given these results, the reasons for the previously demonstrated associations between
long-term PPI therapy and increased risk of bone fracture (8-11) may be related to another
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independent or otherwise unrelated cause. Regardless of any calcium or other nutrient
supplementation, our BMD results indicate that even in the face of sub-par calcium (<1200
mg/day) and vitamin D (<400 IU/day) intake, long-term PPI therapy did not have obvious
adverse effects on bone health. Our results do suggest that male PPI users may be at a higher
risk of fracture when compared with female PPI users due to a premature decline in bone mass,
the cause of which has yet to be determined.
To significantly affect bone status, calcium and vitamin D nutriture would need to be
decreased for a long period of time. In this study, we did not examine long-term calcium or
vitamin D status. Long durations of PPI therapy can impair absorption of calcium supplements,
which are increasingly being used to help meet the elevated calcium requirements of people over
age 50. Physicians should consider the solubility of the various forms of supplemental calcium
when recommending calcium supplementation to long-term PPI users. While we did not collect
details about calcium supplementation such as dosage, frequency, or type, it is interesting to note
that more male PPI users were supplementing calcium than female PPI users. With lower bone
mass in the male PPI users, perhaps the calcium supplements were not being absorbed as well
and true calcium intake was lower than the food frequency questionnaire would have been able
to identify. Future research should focus on tracking changes in BMD in calcium supplemented
and non-calcium supplemented PPI users to determine if the effectiveness of the calcium
supplementation is impaired due to the acid suppression.
One recently published study directly compared BMD and risk of fracture at the spine
and hip and use of PPI's and H2RA's in men and women already enrolled in two larger studies
related to osteoporosis and bone fracture. They discovered than men taking either class of
medications had lower cross-sectional bone mass. Also, they found an increased risk of
nonspine fracture in women, but only in men who were not taking calcium supplements(120).
These results spark more research questions in the area of possibly increased calcium needs and
the role of calcium supplementation in long term PPI users.

49

Conclusion
The results of this study support the theory of a protective effect of PPI's on bone health,
although the mechanism may not be directly related to the PPI's. Long-term PPI therapy did not
appear to inhibit calcium absorption enough to bring about any detrimental changes in bone
mineral density in the men and post-menopausal women in our study. However, male PPI users
were at a higher risk of fracture at the hip than female PPI users.
While the number of participants in each group was imbalanced and significantly
decreases the power of our findings, future studies in this area should focus on assessing total
calcium intake from all sources and help to determine if there is a higher need for calcium for
long-term PPI users to avoid any medication induced bone losses.
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DEPARTMENT OF NUTRITION, DIETETICS, AND FOOD SCIENCE
MASTER OF SCIENCE THESIS PROSPECTUS
Zarina Pabin, RD
PO BOX 7010
Provo, UT 84604
November 16, 2007
Proposed Title
Effects of Long-Term Proton Pump Inhibitor Therapy on Bone Mineral Density and Biomarkers
of Calcium, Magnesium, Iron, Zinc and Vitamin B12 Status in Post-Menopausal Women*
*Note: For my thesis project I will not be measuring all the listed biomarkers due to funding
constraints. I plan to measure bone mineral density and at least the markers for calcium.
Statement of the Problem
GERD refers to symptoms and damage to the lining of the esophagus that occur due to
reflux of acidic gastric contents into the esophagus (1). It has been estimated that the worldwide
prevalence of GERD has doubled in the past thirty years with approximately 25% of people
reporting having heartburn at least once per month (1,2). In 2002, the annual direct cost for
managing GERD in the United States was estimated to exceed $9 billion dollars (2). Long-term
effects of uncontrolled GERD include esophageal strictures and/or ulcers, Barrett's esophagus
(benign changes in esophageal mucosal cells), and esophageal adenocarcinoma (2).
The most commonly prescribed medications for the management of GERD are histamine-2
(H2) blockers (Tagamet®, Zantac®, Pepcid®, Axid®) and PPI's (Prevacid®, Prilosec®,
Protonix®, Aciphex®, Nexium®). The goal of these medications is to reduce symptoms of
GERD through decreasing hydrochloric acid production in the stomach (3). H2 blockers are
generally used for initial therapy or temporary management of GERD, while the majority of PPI
use is for long-term management of GERD that remains uncontrolled with H2 blockers (3). In
2002, the sales of PPI's reached more than $10 billion, second only to the sales of statins and in
2004, Nexium® became the third highest selling drug in the United States (4,5).
It is widely accepted that optimal absorption of minerals, particularly the divalent cations
calcium, magnesium, iron, and zinc, requires the acidic environment of the stomach to release
the mineral from food and/or supplements and convert it to its ionized form (6,7). It is also
proposed that the absorption mechanisms requiring ionization become more predominant during
times of suboptimal intake (6,8) which is typical of calcium and magnesium intakes in postmenopausal women (9-11). Vitamin B12 also requires gastric acid for optimal absorption and
current literature supports the practice of routinely testing patients who are taking long term PPI
therapy for vitamin B12 deficiency (12,13).
Justification of the Problem
Post-menopausal women are already at particularly high risk for osteoporosis and
subsequent fractures due to the accelerated bone loss experienced at menopause (14). In 2006, a
large case-control study conducted with over 192,000 subjects over the age of 50, found an
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association between long-term PPI therapy and increased risk of hip fracture after controlling for
an extensive list of confounding factors including BMI, smoking history, alcoholism, diseases
affecting bone metabolism, and prior history of fracture (15). Most previous research into the
effects of PPI's on mineral absorption has examined patients on PPI therapy for relatively short
periods of time (the longest lasting 4 years) with mixed results (8,16-25). Coupled with the
increased use and longer durations of PPI therapy seen in the last decade, current literature
suggests further research into the long-term effects of these medications on mineral status (13).
Methods/Procedures
Participants
We plan to recruit 100 women who are at least five years post-menopausal of whom 50
have taken long term PPI therapy either continuously or intermittently for at least ten years and
50 have never been on PPI therapy. Exclusion criteria for all participants includes use of
hormone replacement therapy (HRT) in the last five years, history of osteoporosis medication
use, and/or presence of diseases or use of medications that affect bone metabolism. We will
begin recruiting via fliers on BYU campus and extend written letters of invitation to local
medical offices asking permission for fliers to be displayed in their waiting areas as needed to
achieve recruiting goals. A website will be utilized to assist with recruitment, screening, and
answer frequently asked questions. Our study will also be registered with clinicaltrials.gov.
Written consent will be obtained from all qualifying participants prior to any procedures being
performed.
Blood Draw
A licensed phlebotomist at the BYU Student Health Center (SHC) will perform blood
draws of 26 ml (~3 Tablespoons) per participant. Samples will be analyzed for biomarkers of
bone formation, bone resorption, parathyroid hormone, vitamin D, magnesium, iron, zinc, and
vitamin B12 status. A written report of results will be available to participants upon request.
Urine Collection
Participants will be asked to collect 2 consecutive 24-hour urine collections for laboratory
analysis of markers of calcium and magnesium status. All necessary materials and instructions
will be provided to the participants by researchers or research assistants directly involved in the
project. Specimens will be returned to the BYU Student Health Center and analyzed in the
NDFS department.
Diet Survey
To estimate the adequacy of participant intake of calcium, magnesium, iron, zinc, and
vitamin B12, an electronic version of the National Institutes of Health Diet History Questionnaire
(DHQ) will be administered to each participant. The estimated time to complete the survey is
40-60 minutes. Participants will be mailed a report of the results of the survey and given the
opportunity to review it with a Registered Dietitian.
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Dual X-Ray Absorptiometry (DXA) Scan
DXA scans will be performed on each participant assessing bone mineral content (BMC)
and bone mineral density (BMD) at the hip and spine and body composition by one of two
qualified technicians. A written report of results will be immediately available to participants.
Data Analysis
T-tests will be performed on single measures of BMC, BMD, and all biomarkers using
SAS software Version 9.1.
Delimitations of the Problem
Our study is purely observational and no causal relationships can be inferred from the results to
our study participants or to the general population.
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Have you been taking any of these medications for
10 years or more?
Prevacid®

Prilosec®

Protonix®

Aciphex®

Nexium®

(Lansoprazole)

(Omeprazole)

(Pantoprazole)

(Rabeprazole)

(Esomeprazole)

Researchers in the Nutrition, Dietetics, and Food Science Department at BYU need
female volunteers who:
• Are at least 5 years post-menopausal
• Do not have osteoporosis
• Have not taken hormone replacement therapy for at least 5 years
• Either have been taking proton pump inhibitors for 10 years or more
-ORHave never taken proton pump inhibitors

Study participation includes FREE:

Bone density testing (using low dose x-rays)

Dietary analysis with a Registered Dietitian

Body composition testing (percent body fat)

Blood and urine analysis for markers of bone health
(blood draw and urine collection required)
* All study related testing will require a maximum of 4 hours of your time spread over 3 visits
Interested? Please visit www.byuppiproject.com or call 877.4.BYU.PPI (877.429.8774)
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Research Participant Screening Questions
1. Name: ________________________________________
2. Phone number: ___________________
3. What is your age?

_______________

4. What is your gender?

_______________

5. Are you currently or have you taken hormone replacement therapy or estrogens [e.g., Prempro®
(conjugated/medroxyprogesterone)],in the past 5 years?
YES
NO
6. Have you ever taken or are you currently taking any osteoporosis medications? [e.g.,
Fosamax® (alendronate), Boniva® (ibandronate), Actonel® (risedronate), Evista® (raloxifene)]
YES
NO
If so, please list the months and years of treatment ____________________
7. Have you experienced a bone fracture in the last 10 years?

YES

NO

8. Do you currently smoke?

YES

NO

9. Have you ever smoked?

YES

NO

If so, please list the months and years of smoking _____________________
10. Do you consume more than 1 alcoholic drink per day?

YES

NO

(Each of the following count as one drink: 12 fluid ounces of regular beer, 5 fluid ounces of
wine, or 1.5 fluid ounces of 80-proof distilled spirits)
Please list all medications, including dietary supplements you currently take at least once per
week including dosage and frequency.
Supplement

Dose

Frequency
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Consent to be a Research Participant
Introduction
This research study is being conducted in the Nutrition, Dietetics, and Food Science (NDFS) Department
at Brigham Young University (BYU) to determine the effect of ten years or more of proton pump
inhibitor (PPI) therapy used to treat gastroesophageal reflux disease (GERD), on bone mineral density
(BMD), and biomarkers of calcium, magnesium, iron, zinc, and vitamin B12. The researchers conducting
this study are Robert Davidson, PhD, Assistant Professor in the NDFS Department at BYU, Kay B Franz,
Professor in the NDFS Department at BYU, and Zarina Pabin, RD, a graduate student in the NDFS
Department at BYU.
Procedures
You will be asked to complete the following procedures during your participation in the study.
1. Blood draw (26 mL or approximately 3 Tablespoons) performed by a licensed phlebotomist at the
BYU Student Health Center used to measure biomarkers of calcium, magnesium, iron, zinc, and
vitamin B12.
2. Two consecutive 24-hour urine collections, instructions and specimen return will take
approximately 30-45 minutes.
3. Bone mineral content (BMC), bone mineral density (BMD), body composition, and weight using
dual x-ray absorptiometry (DXA), height using a stadiometer, waist and hip circumference using
a tape measure, and completion of a food frequency questionnaire, visit will take approximately
90-120 minutes.
DXA is a painless procedure that estimates bone density and body composition [fat mass, and lean mass
(organ and muscle)] by measuring the attenuation of two low-dose x-ray beams as they pass through the
body. The total radiation dose expected from the duration of the study is 19.1 mrem [compared to a
mammogram (45 mrem), dental x-ray (6 mrem) or a round trip transcontinental flight (6 mrem)]. The
average radiation dose from natural background sources in the environment is estimated to be about 300
mrem/year. With the exception of pregnant women, there are no known risks associated with a DXA
scan.
Lab analysis will be performed at the BYU Student Health Center and all other procedures will take place
in the NDFS Department at BYU.
*It is asked that you complete eachof the following no later than May 15, 2007.
1. Go to BYU Student Health Center between the hours of 8 AM-11 AM, Monday-Friday to
participate in the blood draw and to receive your urine collection materials.
2. Return urine collection to BYU Student Health Center between the hours of 8 AM-5 PM,
Monday-Friday.
3. Make an appointment to receive your DXA scan and complete your food frequency questionnaire
in the Nutrition, Dietetics, and Food Science Department by logging on to the following website:
www.byuppiproject.com using your participant identification number and password.
Page 1 of 3 _____ initials
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Risks/Discomforts
There are minimal risks associated with participation in this study. You may experience physical
discomfort during the blood draw. The x-ray dose associated with the DXA scan you will receive has
been outlined in the procedures above and will not affect your ability to receive radiation in the near
future from other diagnostic tools.
Compensation and Benefits
Participants will not receive any monetary compensation for participation in this study and there is no
financial cost to you as a participant. The potential benefits of participation in this study include dietary
analysis, nutrition counseling with a Registered Dietitian, and useful information about your bone
density, body composition, and nutritional status. Also, through your participation, researchers will learn
more about the effects of long-term proton pump inhibitor therapy on nutritional status. This information
may help healthcare professionals in optimizing the health of patients who require long-term proton
pump inhibitor therapy for management of GERD.
Confidentiality
Confidentiality will be maintained throughout the project and no individual identifying information will
be disclosed. Participants will be assigned an arbitrary identification number for purposes of data
collection and all study-related documents will be kept in a locked file cabinet and only available to
researchers directly involved in the project. DXA information will be stored securely in password
protected files on computers in the Nutrition Assessment Lab (S288) in the NDFS Department at BYU
according to participant identification number. It is the intention of the investigators to report and publish
the mean values and other statistical reports of all participants. Your personal information and the results
of your tests will not be distributed without your written permission.
Participation
Exclusion criteria for all participants includes use of hormone replacement therapy (HRT) in the last five
years, history of osteoporosis medication use, and/or presence of diseases or use of medications that
affect bone metabolism. Participation in this research study is voluntary. You have the right to withdraw
from this study at anytime. If you choose to withdraw from the study, you have a right to receive reports
of procedures completed up to the point of withdrawal (body composition, bone density).
Questions about the Research
If you have questions regarding this research study, you may contact Zarina Pabin, RD at
877-4-BYU-PPI (877-429-8774), zarina@byuppiproject.com, or Robert Davidson, PhD at 801-422-1432,
robert_davidson@byu.edu, S-243 ESC Brigham Young University - Provo, UT.
If you have questions regarding your rights as a participant in a research project, you may contact Dr.
Renea Beckstrand, Chair of the Institutional Review Board (IRB), 422 SWKT, 801.422.3873,
renea_beckstrand@byu.edu.

Page 2 of 3 _____ initials
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I, _______________________________________________, have read, understood, and received a copy
of the above consent form; the study and procedures have been explained to me and my questions have
been answered to my satisfaction. I understand the inherent risks involved and I understand that I may
withdraw at anytime without penalty. I desire of my own free will to participate in this study.
____________________________________________________
Participant Signature

__________________
Date

Page 3 of 3 _____ initials
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BYU PPI Project Visit Instructions
Visit #1 – Blood Draw, receive urine collection materials:
You do not need to make an appointment for this visit, but it does need to be completed between the
hours of 8 AM - 11 AM, M-F.
Where: BYU Student Health Center (Northeast corner of 900 E and University Parkway in Provo)
When: M-F, 8 AM - 11 AM
(The BYU Student Health Center is closed on Tuesdays from 10:45 AM – 12:15 PM for university
forums and devotionals)
Duration: 10-30 minutes
Instructions: Enter through the main entrance of the BYU Student Health Center and tell a receptionist
you are there for a blood draw for the “Acid Reflux Study.” Proceed to the lab as instructed. Sign
green consent form and return it to the lab technician. You may keep the white copy for yourself.
Receive blood draw. Receive urine collection materials. Complete 2 consecutive 24-hour urine
collections following the instruction sheet included with the collection bottles and collect a sample of
your first morning void (urination) of another day in the small blue topped cup provided, see table
below for guidelines. Remember to keep your collections refrigerated.
Day 1
● Receive blood
draw
● Pick up urine
collection
materials from
BYU Student
Health Center

Collection Day 1

Collection Day 2

Collection Day 3

● Collect first void into
small blue topped cup
● Collect all consecutive
voids for the rest of the
day in the first large urine
collection bottle (this will
be your first 24-hour
urine collection)
● Remember to
refrigerate

(Include first void on Day
2 in first 24 hour urine
collection)
● Begin new collection
with second void and
collect all consecutive
voids for the rest of the
day in the second large
urine collection bottle
(this will be your second
24-hour urine collection)
● Remember to
refrigerate

(Include first void on Day 3
in second 24 hour urine
collection)
● Remember to
refrigerate
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Visit #2 – Return completed urine collections:
You do not need to make an appointment for this visit. You may visit the BYU Student Health
Center anytime M-F between the hours of 8 AM - 5 PM.
Where: BYU Student Health Center
When: M-F, 8 AM - 5 PM
(The BYU Student Health Center is closed on Tuesdays from 10:45 AM – 12:15 PM for university
forums and devotionals)
Duration: 10-15 minutes
Instructions: Return filled urine collection containers (3) to the BYU Student Health Center within 24
hours of completed collection.

Visit #3 – Food frequency questionnaire, height, weight, waist-hip ratio, DXA scan:
You will need to make an appointment for this visit. Please schedule your appointment at
www.byuppiproject.com or call 1.877.4.BYU.PPI (1.877.429.8774).
Where: Nutrition, Dietetics, and Food Science Department at BYU – Eyring Science Center (ESC),
Room S288
When: Schedule your appointment online using your participant ID (located at the top right of your
consent form) and your last name, at www.byuppiproject.com or call 1.877.4.BYU.PPI
(1.877.429.8774) to schedule over the phone.
Duration: 90-120 minutes*
Instructions: See included parking maps to locate visitor parking lots available for parking. Also see
included maps to the Eyring Science Center (ESC) and proceed to room S288.
*Note: If you would like to shorten the duration of this visit to approximately 60 minutes, you
can complete the food frequency questionnaire at home by visiting our website at
www.byuppiproject.com and clicking on “Food Frequency Questionnaire”. If you choose to
complete the questionnaire online, please do so prior to scheduling your lab visit. Your
user ID for the food frequency questionnaire is your participant ID (located at the top right of
your consent form) and your password is also your participant ID. If you have any questions or
concerns, please call 1.877.4.BYU.PPI (1.877.429.8774).
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This is a sample form. Do not use for scanning.
NATIONAL INSTITUTES OF HEALTH

Diet History Questionnaire

GENERAL INSTRUCTIONS
•

Answer each question as best you can. Estimate if you are not sure. A guess is
better than leaving a blank.

•

Use only a black ball-point pen. Do not use a pencil or felt-tip pen. Do not fold,
staple, or tear the pages.

•

Put an X in the box next to your answer.

•

If you make any changes, cross out the incorrect answer and put an X in the box
next to the correct answer. Also draw a circle around the correct answer.

•

If you mark NEVER, NO, or DON’T KNOW for a question, please follow any
arrows or instructions that direct you to the next question.

BEFORE TURNING THE PAGE, PLEASE COMPLETE THE FOLLOWING QUESTIONS.
In what month were
you born?

Today's date:
MONTH
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec

DAY

YEAR

|___|___|

2007
2008
2009
2010
2011

0
1
2
3

0
1
2
3
4
5
6
7
8
9

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec

In what year were
you born?

19 |___|___|
0
1
2
3
4
5
6
7
8
9

0
1
2
3
4
5
6
7
8
9

Are you male or
female?
Male
Female

BAR CODE LABEL OR SUBJECT ID
HERE

|___|___|___|___|___|___|___|___|
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This is a sample form. Do not use for scanning.
1. Over the past 12 months, how often did you drink
tomato juice or vegetable juice?

Over the past 12 months…

NEVER (GO TO QUESTION 2)
1 time per month or less
2–3 times per month
1–2 times per week
3–4 times per week
5–6 times per week

1a.

1 time per day
2–3 times per day
4–5 times per day
6 or more times per day

4. How often did you drink other fruit drinks (such
as cranberry cocktail, Hi-C, lemonade, or KoolAid, diet or regular)?
NEVER (GO TO QUESTION 5)
1 time per month or less
2–3 times per month
1–2 times per week
3–4 times per week
5–6 times per week

Each time you drank tomato juice or
vegetable juice, how much did you usually
drink?
4a.

Less than ¾ cup (6 ounces)
¾ to 1¼ cups (6 to 10 ounces)
More than 1¼ cups (10 ounces)

4b.

NEVER (GO TO QUESTION 3)

2a.

1 time per day
2–3 times per day
4–5 times per day
6 or more times per day

Each time you drank orange juice or
grapefruit juice, how much did you usually
drink?

5. How often did you drink milk as a beverage
(NOT in coffee, NOT in cereal)? (Please include
chocolate milk and hot chocolate.)
NEVER (GO TO QUESTION 6)
1 time per month or less
2–3 times per month
1–2 times per week
3–4 times per week
5–6 times per week

3. Over the past 12 months, how often did you drink
other 100% fruit juice or 100% fruit juice
mixtures (such as apple, grape, pineapple, or
others)?
5a.

NEVER (GO TO QUESTION 4)

3a.

1 time per day
2–3 times per day
4–5 times per day
6 or more times per day

1 time per day
2–3 times per day
4–5 times per day
6 or more times per day

Each time you drank milk as a beverage,
how much did you usually drink?
Less than 1 cup (8 ounces)
1 to 1½ cups (8 to 12 ounces)
More than 1½ cups (12 ounces)

5b.

Each time you drank other fruit juice or fruit
juice mixtures, how much did you usually
drink?

What kind of milk did you usually drink?
Whole milk
2% fat milk
1 % fat milk
Skim, nonfat, or ½% fat milk
Soy milk
Rice milk
Other

Less than ¾ cup (6 ounces)
¾ to 1½ cups (6 to 12 ounces)
More than 1½ cups (12 ounces)

Question 4 appears in the next column

How often were your fruit drinks diet or
sugar-free drinks?
Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

Less than ¾ cup (6 ounces)
¾ to 1¼ cups (6 to 10 ounces)
More than 1¼ cups (10 ounces)

1 time per month or less
2–3 times per month
1–2 times per week
3–4 times per week
5–6 times per week

Each time you drank fruit drinks, how much
did you usually drink?
Less than 1 cup (8 ounces)
1 to 2 cups (8 to 16 ounces)
More than 2 cups (16 ounces)

2. Over the past 12 months, how often did you drink
orange juice or grapefruit juice?

1 time per month or less
2–3 times per month
1–2 times per week
3–4 times per week
5–6 times per week

1 time per day
2–3 times per day
4–5 times per day
6 or more times per day

2

Question 6 appears on the next page
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7d.

Over the past 12 months…
6. How often did you drink meal replacement,
energy, or high-protein beverages such as
Instant Breakfast, Ensure, Slimfast, Sustacal or
others?

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

NEVER (GO TO QUESTION 7)
1 time per month or less
2–3 times per month
1–2 times per week
3–4 times per week
5–6 times per week

6a.

1 time per day
2–3 times per day
4–5 times per day
6 or more times per day

7e.

8. Over the past 12 months, did you drink beer?
NO (GO TO QUESTION 9)
YES

7. Over the past 12 months, did you drink soft
drinks, soda, or pop?
8a.

NO (GO TO QUESTION 8)
YES

1 time per month or less
2–3 times per month
1–2 times per week
3–4 times per week
5–6 times per week

NEVER

7b.

1 time per day
2–3 times per day
4–5 times per day
6 or more times
per day

8b.

How often did you drink beer DURING THE
REST OF THE YEAR?

1 time per month or less
2–3 times per month
1–2 times per week
3–4 times per week
5–6 times per week

NEVER

7c.

1 time per day
2–3 times per day
4–5 times per day
6 or more times
per day

NEVER

How often did you drink soft drinks, soda,
or pop DURING THE REST OF THE YEAR?

1 time per month or less
2–3 times per month
1–2 times per week
3–4 times per week
5–6 times per week

How often did you drink beer IN THE
SUMMER?
NEVER

How often did you drink soft drinks, soda,
or pop IN THE SUMMER?

1 time per month or less
2–3 times per month
1–2 times per week
3–4 times per week
5–6 times per week

How often were these soft drinks, soda, or
pop caffeine-free?
Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

Each time you drank meal replacement
beverages, how much did you usually drink?
Less than 1 cup (8 ounces)
1 to 1½ cups (8 to 12 ounces)
More than 1½ cups (12 ounces)

7a.

How often were these soft drinks, soda, or
pop diet or sugar-free?

1 time per day
2–3 times per day
4–5 times per day
6 or more times
per day

8c.

1 time per day
2–3 times per day
4–5 times per day
6 or more times
per day

Each time you drank beer, how much did you
usually drink?
Less than a 12-ounce can or bottle
1 to 3 12-ounce cans or bottles
More than 3 12-ounce cans or bottles

Each time you drank soft drinks, soda, or
pop, how much did you usually drink?
Less than 12 ounces or less than 1 can or bottle
12 to 16 ounces or 1 can or bottle
More than 16 ounces or more than 1 can or bottle

Question 8 appears in the next column

3

Question 9 appears on the next page
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11b. How often did you eat oatmeal, grits, or
other cooked cereal DURING THE REST
OF THE YEAR?

Over the past 12 months…
9. How often did you drink wine or wine coolers?

9a.

NEVER (GO TO QUESTION 10)

NEVER

1 time per month or less
2–3 times per month
1–2 times per week
3–4 times per week
5–6 times per week

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

1 time per day
2–3 times per day
4–5 times per day
6 or more times per day

Each time you drank wine or wine coolers,
how much did you usually drink?

11c. Each time you ate oatmeal, grits, or other
cooked cereal, how much did you usually
eat?

Less than 5 ounces or less than 1 glass
5 to 12 ounces or 1 to 2 glasses
More than 12 ounces or more than 2 glasses

Less than ¾ cup
¾ to 1¼ cups
More than 1¼ cups

10. How often did you drink liquor or mixed drinks?

12. How often did you eat cold cereal?

NEVER (GO TO QUESTION 11)
1 time per month or less
2–3 times per month
1–2 times per week
3–4 times per week
5–6 times per week

1 time per day
2–3 times per day
4–5 times per day
6 or more times per day

10a. Each time you drank liquor or mixed drinks,
how much did you usually drink?

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

Less than 1 cup
1 to 2½ cups
More than 2½ cups

11. Over the past 12 months, did you eat oatmeal,
grits, or other cooked cereal?

12b. How often was the cold cereal you ate Total,
Product 19, or Right Start?

NO (GO TO QUESTION 12)

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

YES

11a. How often did you eat oatmeal, grits, or
other cooked cereal IN THE WINTER?

12c. How often was the cold cereal you ate All
Bran, Fiber One, 100% Bran, or Bran
Buds?

NEVER

Question 12 appears in the next column

NEVER (GO TO QUESTION 13)

12a. Each time you ate cold cereal, how much
did you usually eat?

Less than 1 shot of liquor
1 to 3 shots of liquor
More than 3 shots of liquor

1–6 times per winter
7–11 times per winter
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times
per day

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times
per day

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

4

Question 13 appears on the next page
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13a. Each time you ate applesauce, how much
did you usually eat?

Over the past 12 months…
12d. How often was the cold cereal you ate some
other bran or fiber cereal (such as
Cheerios, Shredded Wheat, Raisin Bran,
Bran Flakes, Grape-Nuts, Granola,
Wheaties, or Healthy Choice)?

Less than ½ cup
½ to 1 cup
More than 1 cup

14. How often did you eat apples?

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

NEVER (GO TO QUESTION 15)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

12e. How often was the cold cereal you ate any
other type of cold cereal (such as Corn
Flakes, Rice Krispies, Frosted Flakes,
Special K, Froot Loops, Cap'n Crunch, or
others)?

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

14a. Each time you ate apples, how many did you
usually eat?
Less than 1 apple
1 apple
More than 1 apple

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

15. How often did you eat pears (fresh, canned, or
frozen)?

12f. Was milk added to your cold cereal?

NEVER (GO TO QUESTION 16)

NO (GO TO QUESTION 13)

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

YES

12g. What kind of milk was usually added?
Whole milk
2% fat milk
1% fat milk
Skim, nonfat, or ½% fat milk
Soy milk
Rice milk
Other

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

15a. Each time you ate pears, how many did you
usually eat?
Less than 1 pear
1 pear
More than 1 pear

16. How often did you eat bananas?

12h. Each time milk was added to your cold
cereal, how much was usually added?

NEVER (GO TO QUESTION 17)

Less than ½ cup
½ to 1 cup
More than 1 cup

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

13. How often did you eat applesauce?

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

NEVER (GO TO QUESTION 14)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

Question 14 appears in the next column

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

5

Question 17 appears on the next page
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18c. Each time you ate peaches, nectarines, or
plums, how much did you usually eat?

Over the past 12 months…
16a. Each time you ate bananas, how many did
you usually eat?

Less than 1 fruit or less than ½ cup
1 to 2 fruits or ½ to ¾ cup
More than 2 fruits or more than ¾ cup

Less than 1 banana
1 banana
More than 1 banana

19. How often did you eat grapes?
NEVER (GO TO QUESTION 20)

17. How often did you eat dried fruit, such as prunes
or raisins (not including dried apricots)?

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

NEVER (GO TO QUESTION 18)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

19a. Each time you ate grapes, how much did
you usually eat?
Less than ½ cup or less than 10 grapes
½ to 1 cup or 10 to 30 grapes
More than 1 cup or more than 30 grapes

17a. Each time you ate dried fruit, how much did
you usually eat (not including dried apricots)?
Less than 2 tablespoons
2 to 5 tablespoons
More than 5 tablespoons

20. Over the past 12 months, did you eat
cantaloupe?
NO (GO TO QUESTION 21)

18. Over the past 12 months, did you eat peaches,
nectarines, or plums?

YES

NO (GO TO QUESTION 19)

20a. How often did you eat fresh cantaloupe
WHEN IN SEASON?

YES

NEVER

18a. How often did you eat fresh peaches,
nectarines, or plums WHEN IN SEASON?

1–6 times per season
7–11 times per season
1 time per month
2–3 times per month
1 time per week

NEVER
1–6 times per season
7–11 times per season
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times
per day

20b. How often did you eat fresh or frozen cantaloupe
DURING THE REST OF THE YEAR?
NEVER

18b. How often did you eat peaches, nectarines,
or plums (fresh, canned, or frozen) DURING
THE REST OF THE YEAR?

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

NEVER
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

Question 19 appears in the next column

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times
per day

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times
per day

6

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times
per day

Question 21 appears on the next page
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22. Over the past 12 months, did you eat
strawberries?

Over the past 12 months…
20c. Each time you ate cantaloupe, how much
did you usually eat?

NO (GO TO QUESTION 23)
YES

Less than ¼ melon or less than ½ cup
¼ melon or ½ to 1 cup
More than ¼ melon or more than 1 cup

22a. How often did you eat fresh strawberries
WHEN IN SEASON?

21. Over the past 12 months, did you eat melon,
other than cantaloupe (such as watermelon or
honeydew)?

NEVER
1–6 times per season
7–11 times per season
1 time per month
2–3 times per month
1 time per week

NO (GO TO QUESTION 22)
YES

21a. How often did you eat fresh melon, other
than cantaloupe (such as watermelon or
honeydew) WHEN IN SEASON?

22b. How often did you eat fresh or frozen
strawberries DURING THE REST OF THE YEAR?

NEVER
1–6 times per season
7–11 times per season
1 time per month
2–3 times per month
1 time per week

NEVER
2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times
per day

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

21b. How often did you eat fresh or frozen
melon, other than cantaloupe (such as
watermelon or honeydew) DURING THE
REST OF THE YEAR?

Less than ¼ cup or less than 3 berries
¼ to ¾ cup or 3 to 8 berries
More than ¾ cup or more than 8 berries

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times
per day

23. Over the past 12 months, did you eat oranges,
tangerines, or tangelos?
NO (GO TO QUESTION 24)
YES

21c. Each time you ate melon other than
cantaloupe, how much did you usually eat?

23a. How often did you eat fresh oranges, tangerines,
or tangelos WHEN IN SEASON?

Less than ½ cup or 1 small wedge
½ to 2 cups or 1 medium wedge
More than 2 cups or 1 large wedge

NEVER
1–6 times per season
7–11 times per season
1 time per month
2–3 times per month
1 time per week

Question 22 appears in the next column

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times
per day

22c. Each time you ate strawberries, how much
did you usually eat?

NEVER
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times
per day

7

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times
per day

Question 24 appears on the next page
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25. How often did you eat other kinds of fruit?

Over the past 12 months…
23b. How often did you eat oranges, tangerines,
or tangelos (fresh or canned) DURING THE
REST OF THE YEAR?

NEVER (GO TO QUESTION 26)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

NEVER
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times
per day

25a. Each time you ate other kinds of fruit, how
much did you usually eat?
Less than ¼ cup
¼ to ¾ cup
More than ¾ cup

23c. Each time you ate oranges, tangerines, or
tangelos, how many did you usually eat?

26. How often did you eat COOKED greens (such as
spinach, turnip, collard, mustard, chard, or kale)?

Less than 1 fruit
1 fruit
More than 1 fruit

NEVER (GO TO QUESTION 27)

24. Over the past 12 months, did you eat grapefruit?

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

NO (GO TO QUESTION 25)
YES

Less than ½ cup
½ to 1 cup
More than 1 cup

NEVER
2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times
per day

27. How often did you eat RAW greens (such as
spinach, turnip, collard, mustard, chard, or kale)?
(We will ask about lettuce later.)
NEVER (GO TO QUESTION 28)

24b. How often did you eat grapefruit (fresh or
canned) DURING THE REST OF THE YEAR?

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

NEVER
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

26a. Each time you ate COOKED greens, how
much did you usually eat?

24a. How often did you eat fresh grapefruit
WHEN IN SEASON?

1–6 times per season
7–11 times per season
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times
per day

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

27a. Each time you ate RAW greens, how much
did you usually eat?
Less than ½ cup
½ to 1 cup
More than 1 cup

24c. Each time you ate grapefruit, how much did
you usually eat?
Less than ½ grapefruit
½ grapefruit
More than ½ grapefruit

Question 25 appears in the next column

8

Question 28 appears on the next page
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31. How often did you eat string beans or green
beans (fresh, canned, or frozen)?

Over the past 12 months…
28. How often did you eat coleslaw?

NEVER (GO TO QUESTION 32)

NEVER (GO TO QUESTION 29)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

31a. Each time you ate string beans or green
beans, how much did you usually eat?

28a. Each time you ate coleslaw, how much did
you usually eat?

Less than ½ cup
½ to 1 cup
More than 1 cup

Less than ¼ cup
¼ to ¾ cup
More than ¾ cup

32. How often did you eat peas (fresh, canned, or
frozen)?

29. How often did you eat sauerkraut or cabbage
(other than coleslaw)?

NEVER (GO TO QUESTION 33)

NEVER (GO TO QUESTION 30)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

Less than ¼ cup
¼ to ¾ cup
More than ¾ cup

Less than ¼ cup
¼ to 1 cup
More than 1 cup

33. Over the past 12 months, did you eat corn?

30. How often did you eat carrots (fresh, canned, or
frozen)?

NO (GO TO QUESTION 34)
YES

NEVER (GO TO QUESTION 31)
2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

33a. How often did you eat fresh corn WHEN IN
SEASON?
NEVER
1–6 times per season
7–11 times per season
1 time per month
2–3 times per month
1 time per week

30a. Each time you ate carrots, how much did
you usually eat?
Less than ¼ cup or less than 2 baby carrots
¼ to ½ cup or 2 to 5 baby carrots
More than ½ cup or more than 5 baby carrots

Question 31 appears in the next column

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

32a. Each time you ate peas, how much did you
usually eat?

29a. Each time you ate sauerkraut or cabbage,
how much did you usually eat?

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

9

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times
per day

Question 34 appears on the next page
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36. How often did you eat mixed vegetables?

Over the past 12 months…
33b. How often did you eat corn (fresh, canned, or
frozen) DURING THE REST OF THE YEAR?

NEVER (GO TO QUESTION 37)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

NEVER
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times
per day

36a. Each time you ate mixed vegetables, how
much did you usually eat?
Less than ½ cup
½ to 1 cup
More than 1 cup

33c. Each time you ate corn, how much did you
usually eat?

37. How often did you eat onions?

Less than 1 ear or less than ½ cup
1 ear or ½ to 1 cup
More than 1 ear or more than 1 cup

NEVER (GO TO QUESTION 38)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

34. Over the past 12 months, how often did you eat
broccoli (fresh or frozen)?
NEVER (GO TO QUESTION 35)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

37a. Each time you ate onions, how much did
you usually eat?

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

Less than 1 slice or less than 1 tablespoon
1 slice or 1 to 4 tablespoons
More than 1 slice or more than 4 tablespoons

34a. Each time you ate broccoli, how much did
you usually eat?

38. Now think about all the cooked vegetables you
ate in the past 12 months and how they were
prepared. How often were your vegetables
COOKED WITH some sort of fat, including oil
spray? (Please do not include potatoes.)

Less than ¼ cup
¼ to 1 cup
More than 1 cup

35. How often did you eat cauliflower or Brussels
sprouts (fresh or frozen)?

NEVER (GO TO QUESTION 39)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

NEVER (GO TO QUESTION 36)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

35a. Each time you ate cauliflower or Brussels
sprouts, how much did you usually eat?
Less than ¼ cup
¼ to ½ cup
More than ½ cup

Question 36 appears in the next column

10

Question 39 appears on the next page
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40. Over the past 12 months, how often did you eat
sweet peppers (green, red, or yellow)?

Over the past 12 months…
38a. Which fats were usually added to your
vegetables DURING COOKING? (Please do
not include potatoes. Mark all that apply.)
Margarine
(including low-fat)
Butter (including
low-fat)
Lard, fatback, or
bacon fat
Olive oil

NEVER (GO TO QUESTION 41)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

Corn oil
Canola or rapeseed oil
Oil spray, such as Pam
or others
Other kinds of oils
None of the above

40a. Each time you ate sweet peppers, how
much did you usually eat?

39. Now, thinking again about all the cooked
vegetables you ate in the past 12 months, how
often was some sort of fat, sauce, or dressing
added AFTER COOKING OR AT THE TABLE?
(Please do not include potatoes.)

Less than ⅛ pepper
⅛ to ¼ pepper
More than ¼ pepper

41. Over the past 12 months, did you eat fresh
tomatoes (including those in salads)?

NEVER (GO TO QUESTION 40)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1–2 times per week

NO (GO TO QUESTION 42)

3–4 times per week
5–6 times per week
1 time per day
2 times per day
3 or more times per day

YES

41a. How often did you eat fresh tomatoes
(including those in salads) WHEN IN
SEASON?

39a. Which fats, sauces, or dressings were
usually added AFTER COOKING OR AT
THE TABLE? (Please do not include
potatoes. Mark all that apply.)
Margarine
(including low-fat)
Butter (including
low-fat)
Lard, fatback, or
bacon fat

NEVER
1–6 times per season
7–11 times per season
1 time per month
2–3 times per month
1 time per week

Salad dressing
Cheese sauce
White sauce
Other

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times
per day

41b. How often did you eat fresh tomatoes
(including those in salads) DURING THE
REST OF THE YEAR?

39b. If margarine, butter, lard, fatback, or bacon
fat was added to your cooked vegetables
AFTER COOKING OR AT THE TABLE, how
much did you usually add?

NEVER
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

Did not usually add these
Less than 1 teaspoon
1 to 3 teaspoons
More than 3 teaspoons

39c. If salad dressing, cheese sauce, or white
sauce was added to your cooked vegetables
AFTER COOKING OR AT THE TABLE, how
much did you usually add?

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times
per day

41c. Each time you ate fresh tomatoes, how
much did you usually eat?
Less than ¼ tomato
¼ to ½ tomato
More than ½ tomato

Did not usually add these
Less than 1 tablespoon
1 to 3 tablespoons
More than 3 tablespoons

Question 40 appears in the next column

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

11

Question 42 appears on the next page
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45. How often did you eat French fries, home fries,
hash browned potatoes, or tater tots?

Over the past 12 months…
42. How often did you eat lettuce salads (with or
without other vegetables)?

NEVER (GO TO QUESTION 46)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

NEVER (GO TO QUESTION 43)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

45a. Each time you ate French fries, home fries,
hash browned potatoes, or tater tots how
much did you usually eat?

42a. Each time you ate lettuce salads, how much
did you usually eat?

Less than 10 fries or less than ½ cup
10 to 25 fries or ½ to 1 cup
More than 25 fries or more than 1 cup

Less than ¼ cup
¼ to 1¼ cups
More than 1¼ cups

46. How often did you eat potato salad?

43. How often did you eat salad dressing (including
low-fat) on salads?

NEVER (GO TO QUESTION 47)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

NEVER (GO TO QUESTION 44)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

46a. Each time you ate potato salad, how much
did you usually eat?

43a. Each time you ate salad dressing on salads,
how much did you usually eat?

Less than ½ cup
½ to 1 cup
More than 1 cup

Less than 2 tablespoons
2 to 4 tablespoons
More than 4 tablespoons

47. How often did you eat baked, boiled, or mashed
potatoes?

44. How often did you eat sweet potatoes or yams?
NEVER (GO TO QUESTION 48)
NEVER (GO TO QUESTION 45)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

47a. Each time you ate baked, boiled, or
mashed potatoes, how much did you
usually eat?

44a. Each time you ate sweet potatoes or yams,
how much did you usually eat?
1 small potato or less than ¼ cup
1 medium potato or ¼ to ¾ cup
1 large potato or more than ¾ cup

Question 45 appears in the next column

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

1 small potato or less than ½ cup
1 medium potato or ½ to 1 cup
1 large potato or more than 1 cup

12

Question 48 appears on the next page
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47h. Each time cheese or cheese sauce was
added to your potatoes, how much was
usually added?

Over the past 12 months…
47b. How often was sour cream (including lowfat) added to your potatoes, EITHER IN
COOKING OR AT THE TABLE?

Less than 1 tablespoon
1 to 3 tablespoons
More than 3 tablespoons

Almost never or never (GO TO QUESTION 47d)
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

48. How often did you eat salsa?
NEVER (GO TO QUESTION 49)

47c. Each time sour cream was added to your
potatoes, how much was usually added?

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

Less than 1 tablespoon
1 to 3 tablespoons
More than 3 tablespoons

48a. Each time you ate salsa, how much did you
usually eat?

47d. How often was margarine (including low-fat)
added to your potatoes, EITHER IN
COOKING OR AT THE TABLE?

Less than 1 tablespoon
1 to 5 tablespoons
More than 5 tablespoons

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

49. How often did you eat catsup?
NEVER (GO TO QUESTION 50)

47e. How often was butter (including low-fat)
added to your potatoes, EITHER IN
COOKING OR AT THE TABLE?

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

49a. Each time you ate catsup, how much did you
usually eat?
Less than 1 teaspoon
1 to 6 teaspoons
More than 6 teaspoons

47f. Each time margarine or butter was added to
your potatoes, how much was usually
added?

50. How often did you eat stuffing, dressing, or
dumplings?

Never added
Less than 1 teaspoon
1 to 3 teaspoons
More than 3 teaspoons

NEVER (GO TO QUESTION 51)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

47g. How often was cheese or cheese sauce
added to your potatoes, EITHER IN
COOKING OR AT THE TABLE?
Almost never or never (GO TO QUESTION 48)
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

Question 48 appears in the next column

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

50a. Each time you ate stuffing, dressing, or
dumplings, how much did you usually eat?
Less than ½ cup
½ to 1 cup
More than 1 cup

13

Question 51 appears on the next page
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53b. How often were the beans you ate refried
beans, beans prepared with any type of
fat, or with meat added?

Over the past 12 months…
51. How often did you eat chili?
NEVER (GO TO QUESTION 52)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

54. How often did you eat other kinds of
vegetables?

51a. Each time you ate chili, how much did you
usually eat?

NEVER (GO TO QUESTION 55)

Less than ½ cup
½ to 1¾ cups
More than 1¾ cups

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

52. How often did you eat Mexican foods (such as
tacos, tostados, burritos, tamales, fajitas,
enchiladas, quesadillas, and chimichangas)?

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

54a. Each time you ate other kinds of
vegetables, how much did you usually eat?

NEVER (GO TO QUESTION 53)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

Less than ¼ cup
¼ to ½ cup
More than ½ cup

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

55. How often did you eat rice or other cooked
grains (such as bulgur, cracked wheat, or
millet)?

52a. Each time you ate Mexican foods, how
much did you usually eat?

NEVER (GO TO QUESTION 56)

Less than 1 taco, burrito, etc.
1 to 2 tacos, burritos, etc.
More than 2 tacos, burritos, etc.

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

53. How often did you eat cooked dried beans
(such as baked beans, pintos, kidney, blackeyed
peas, lima, lentils, soybeans, or refried beans)?
(Please don't include bean soups or chili.)

55a. Each time you ate rice or other cooked
grains, how much did you usually eat?
Less than ½ cup
½ to 1½ cups
More than 1½ cups

NEVER (GO TO QUESTION 54)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

55b. How often was butter, margarine, or oil
added to your rice IN COOKING OR AT THE
TABLE?

53a. Each time you ate beans, how much did you
usually eat?

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

Less than ½ cup
½ to 1 cup
More than 1 cup

Question 54 appears in the next column

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

14

Question 56 appears on the next page
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56f. Each time syrup was added to your
pancakes, waffles, or French toast, how
much was usually added?

Over the past 12 months…
56. How often did you eat pancakes, waffles, or
French toast?

Less than 1 tablespoon
1 to 4 tablespoons
More than 4 tablespoons

NEVER (GO TO QUESTION 57)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

57. How often did you eat lasagna, stuffed shells,
stuffed manicotti, ravioli, or tortellini? (Please
do not include spaghetti or other pasta.)
NEVER (GO TO QUESTION 58)

56a. Each time you ate pancakes, waffles, or
French toast, how much did you usually
eat?

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

Less than 1 medium piece
1 to 3 medium pieces
More than 3 medium pieces

57a. Each time you ate lasagna, stuffed shells,
stuffed manicotti, ravioli, or tortellini, how
much did you usually eat?

56b. How often was margarine (including low-fat)
added to your pancakes, waffles, or French
toast AFTER COOKING OR AT THE
TABLE?

Less than 1 cup
1 to 2 cups
More than 2 cups

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

58. How often did you eat macaroni and cheese?
NEVER (GO TO QUESTION 59)

56c. How often was butter (including low-fat)
added to your pancakes, waffles, or French
toast AFTER COOKING OR AT THE
TABLE?

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

58a. Each time you ate macaroni and cheese,
how much did you usually eat?
Less than 1 cup
1 to 1½ cups
More than 1½ cups

56d. Each time margarine or butter was added to
your pancakes, waffles, or French toast, how
much was usually added?

59. How often did you eat pasta salad or macaroni
salad?

Never added
Less than 1 teaspoon
1 to 3 teaspoons
More than 3 teaspoons

NEVER (GO TO QUESTION 60)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

56e. How often was syrup added to your
pancakes, waffles, or French toast?
Almost never or never (GO TO QUESTION 57)
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always
Question 57 appears in the next column

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

15

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

Question 57
60 appears in
onthe
thenext
nextcolumn
page
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61. How often did you eat bagels or English
muffins?

Over the past 12 months…
59a. Each time you ate pasta salad or macaroni
salad, how much did you usually eat?

NEVER (GO TO INTRODUCTION TO QUESTION 62)

Less than ½ cup
½ to 1 cup
More than 1 cup

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

60. Other than the pastas listed in Questions 57, 58,
and 59, how often did you eat pasta, spaghetti,
or other noodles?

61a. Each time you ate bagels or English
muffins, how many did you usually eat?

NEVER (GO TO QUESTION 61)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

Less than 1 bagel or English muffin
1 bagel or English muffin
More than 1 bagel or English muffin

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

61b. How often was margarine (including low-fat)
added to your bagels or English muffins?

60a. Each time you ate pasta, spaghetti, or
other noodles, how much did you usually
eat?

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

Less than 1 cup
1 to 3 cups
More than 3 cups

61c. How often was butter (including low-fat)
added to your bagels or English muffins?

60b. How often did you eat your pasta, spaghetti,
or other noodles with tomato sauce or
spaghetti sauce made WITH meat?

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

61d. Each time margarine or butter was added to
your bagels or English muffins, how much
was usually added?

60c. How often did you eat your pasta, spaghetti,
or other noodles with tomato sauce or
spaghetti sauce made WITHOUT meat?

Never added
Less than 1 teaspoon
1 to 2 teaspoons
More than 2 teaspoons

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

61e. How often was cream cheese (including lowfat) spread on your bagels or English
muffins?

60d. How often did you eat your pasta, spaghetti,
or other noodles with margarine, butter, oil,
or cream sauce?

Almost never or never (GO TO INTRODUCTION
TO QUESTION 62)
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

Question 61 appears in the next column

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

16

Introduction to Question 62 appears on the next page
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62d. Each time mayonnaise or mayonnaise-type
dressing was added to your sandwich
breads or rolls, how much was usually
added?

Over the past 12 months…
61f. Each time cream cheese was added to your
bagels or English muffins, how much was
usually added?

Less than 1 teaspoon
1 to 3 teaspoons
More than 3 teaspoons

Less than 1 tablespoon
1 to 2 tablespoons
More than 2 tablespoons

62e. How often was margarine (including low-fat)
added to your sandwich bread or rolls?
The next questions ask about your intake of
breads other than bagels or English muffins. First,
we will ask about bread you ate as part of
sandwiches only. Then we will ask about all other
bread you ate.

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

62. How often did you eat breads or rolls AS PART
OF SANDWICHES (including burger and hot dog
rolls)?

62f. How often was butter (including low-fat)
added to your sandwich bread or rolls?
Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

NEVER (GO TO QUESTION 63)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

62g. Each time margarine or butter was added to
your sandwich breads or rolls, how much
was usually added?

62a. Each time you ate breads or rolls AS PART
OF SANDWICHES, how many did you
usually eat?

Never added
Less than 1 teaspoon
1 to 2 teaspoons
More than 2 teaspoons

1 slice or ½ roll
2 slices or 1 roll
More than 2 slices or more than 1 roll

63. How often did you eat breads or dinner rolls,
NOT AS PART OF SANDWICHES?

62b. How often were the breads or rolls that you
used for your sandwiches white bread
(including burger and hot dog rolls)?

NEVER (GO TO QUESTION 64)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

63a. Each time you ate breads or dinner rolls,
NOT AS PART OF SANDWICHES, how
much did you usually eat?

62c. How often was mayonnaise or
mayonnaise-type dressing (including lowfat) added to your sandwich bread or rolls?

1 slice or 1 dinner roll
2 slices or 2 dinner rolls
More than 2 slices or 2 dinner rolls

Almost never or never (GO TO QUESTION 62e)
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

Question 62e appears in the next column
Question 63 appears in the next column

17

Question 64 appears on the next page

89

This is a sample form. Do not use for scanning.
64. How often did you eat jam, jelly, or honey on
bagels, muffins, bread, rolls, or crackers?

Over the past 12 months…
63b. How often were the breads or rolls you ate
white bread?

NEVER (GO TO QUESTION 65)

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

63c. How often was margarine (including low-fat)
added to your breads or rolls?

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

64a. Each time you ate jam, jelly, or honey, how
much did you usually eat?

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

Less than 1 teaspoon
1 to 3 teaspoons
More than 3 teaspoons

65. How often did you eat peanut butter or other
nut butter?

63d. How often was butter (including low-fat)
added to your breads or rolls?

NEVER (GO TO QUESTION 66)

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

63e. Each time margarine or butter was added to
your breads or rolls, how much was usually
added?

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

65a. Each time you ate peanut butter or other
nut butter, how much did you usually eat?

Never added
Less than 1 teaspoon
1 to 2 teaspoons
More than 2 teaspoons

Less than 1 tablespoon
1 to 2 tablespoons
More than 2 tablespoons

63f. How often was cream cheese (including lowfat) added to your breads or rolls?

66. How often did you eat roast beef or steak IN
SANDWICHES?

Almost never or never (GO TO QUESTION 64)
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

NEVER (GO TO QUESTION 67)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

63g. Each time cream cheese was added to your
breads or rolls, how much was usually
added?

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

66a. Each time you ate roast beef or steak IN
SANDWICHES, how much did you usually
eat?

Less than 1 tablespoon
1 to 2 tablespoons
More than 2 tablespoons

Less than 1 slice or less than 2 ounces
1 to 2 slices or 2 to 4 ounces
More than 2 slices or more than 4 ounces

Question 64 appears in the next column

18
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69. How often did you eat other cold cuts or
luncheon meats (such as bologna, salami,
corned beef, pastrami, or others, including lowfat)? (Please do not include ham, turkey, or
chicken cold cuts.)

Over the past 12 months…
67. How often did you eat turkey or chicken COLD
CUTS (such as loaf, luncheon meat, turkey ham,
turkey salami, or turkey pastrami)? (We will ask
about other turkey or chicken later.)

NEVER (GO TO QUESTION 70)

NEVER (GO TO QUESTION 68)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

69a. Each time you ate other cold cuts or
luncheon meats, how much did you usually
eat?

67a. Each time you ate turkey or chicken COLD
CUTS, how much did you usually eat?

Less than 1 slice
1 to 3 slices
More than 3 slices

Less than 1 slice
1 to 3 slices
More than 3 slices

69b. How often were the other cold cuts or
luncheon meats you ate light, low-fat, or fatfree cold cuts or luncheon meats? (Please
do not include ham, turkey, or chicken cold
cuts.)

68. How often did you eat luncheon or deli-style
ham? (We will ask about other ham later.)
NEVER (GO TO QUESTION 69)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

70. How often did you eat canned tuna (including in
salads, sandwiches, or casseroles)?

68a. Each time you ate luncheon or deli-style
ham, how much did you usually eat?

NEVER (GO TO QUESTION 71)

Less than 1 slice
1 to 3 slices
More than 3 slices

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

68b. How often was the luncheon or deli-style
ham you ate light, low-fat, or fat-free?
Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

70a. Each time you ate canned tuna, how much
did you usually eat?
Less than ¼ cup or less than 2 ounces
¼ to ½ cup or 2 to 3 ounces
More than ½ cup or more than 3 ounces

70b. How often was the canned tuna you ate
water-packed tuna?
Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always
Question 69 appears in the next column
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73. How often did you eat ground beef in mixtures
(such as meatballs, casseroles, chili, or
meatloaf)?

Over the past 12 months…
70c. How often was the canned tuna you ate
prepared with mayonnaise or other
dressing (including low-fat)?

NEVER (GO TO QUESTION 74)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

71. How often did you eat GROUND chicken or
turkey? (We will ask about other chicken and
turkey later.)

73a. Each time you ate ground beef in mixtures,
how much did you usually eat?
Less than 3 ounces or less than ½ cup
3 to 8 ounces or ½ to 1 cup
More than 8 ounces or more than 1 cup

NEVER (GO TO QUESTION 72)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

74. How often did you eat hot dogs or frankfurters?
(Please do not include sausages or vegetarian
hot dogs.)
NEVER (GO TO QUESTION 75)

71a. Each time you ate GROUND chicken or
turkey, how much did you usually eat?

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

Less than 2 ounces or less than ½ cup
2 to 4 ounces or ½ to 1 cup
More than 4 ounces or more than 1 cup

74a. Each time you ate hot dogs or frankfurters,
how many did you usually eat?

72. How often did you eat beef hamburgers or
cheeseburgers?

Less than 1 hot dog
1 to 2 hot dogs
More than 2 hot dogs

NEVER (GO TO QUESTION 73)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

74b. How often were the hot dogs or frankfurters
you ate light or low-fat hot dogs?
Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

72a. Each time you ate beef hamburgers or
cheeseburgers, how much did you usually
eat?
Less than 1 patty or less than 2 ounces
1 patty or 2 to 4 ounces
More than 1 patty or more than 4 ounces

72b. How often were the beef hamburgers or
cheeseburgers you ate made with lean
ground beef?
Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always
Question 73 appears in the next column
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Question 75 appears on the next page
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This is a sample form. Do not use for scanning.
77b. How often was the steak you ate lean steak?

Over the past 12 months…
75. How often did you eat beef mixtures such as
beef stew, beef pot pie, beef and noodles, or
beef and vegetables?

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

NEVER (GO TO QUESTION 76)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

78. How often did you eat pork or beef spareribs?

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

NEVER (GO TO QUESTION 79)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

75a. Each time you ate beef stew, beef pot pie,
beef and noodles, or beef and vegetables,
how much did you usually eat?

78a. Each time you ate pork or beef spareribs,
how much did you usually eat?

Less than 1 cup
1 to 2 cups
More than 2 cups

Less than 4 ribs
4 to 12 ribs
More than 12 ribs

76. How often did you eat roast beef or pot roast?
(Please do not include roast beef or pot roast in
sandwiches.)

79. How often did you eat roast turkey, turkey
cutlets, or turkey nuggets (including in
sandwiches)?

NEVER (GO TO QUESTION 77)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

NEVER (GO TO QUESTION 80)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

76a. Each time you ate roast beef or pot roast
(including in mixtures), how much did you
usually eat?

Less than 2 ounces
2 to 4 ounces
More than 4 ounces

77. How often did you eat steak (beef)? (Do not
include steak in sandwiches)
NEVER (GO TO QUESTION 78)

80. How often did you eat chicken as part of salads,
sandwiches, casseroles, stews, or other
mixtures?

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

NEVER (GO TO QUESTION 81)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

77a. Each time you ate steak (beef), how much
did you usually eat?
Less than 3 ounces
3 to 7 ounces
More than 7 ounces
Question 78 appears in the next column

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

79a. Each time you ate roast turkey, turkey
cutlets, or turkey nuggets, how much did
you usually eat? (Please note: 4 to 8 turkey
nuggets = 3 ounces.)

Less than 2 ounces
2 to 5 ounces
More than 5 ounces

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day
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2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

Question 81 appears on the next page
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This is a sample form. Do not use for scanning.
82. How often did you eat baked ham or ham
steak?

Over the past 12 months…
80a. Each time you ate chicken as part of salads,
sandwiches, casseroles, stews, or other
mixtures, how much did you usually eat?

NEVER (GO TO QUESTION 83)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

Less than ½ cup
½ to 1½ cups
More than 1½ cups

81. How often did you eat baked, broiled, roasted,
stewed, or fried chicken (including nuggets)?
(Please do not include chicken in mixtures.)

82a. Each time you ate baked ham or ham steak,
how much did you usually eat?

NEVER (GO TO QUESTION 82)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

Less than 1 ounce
1 to 3 ounces
More than 3 ounces

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

83. How often did you eat pork (including chops,
roasts, and in mixed dishes)? (Please do not
include ham, ham steak, or sausage.)

81a. Each time you ate baked, broiled, roasted,
stewed, or fried chicken (including
nuggets), how much did you usually eat?

NEVER (GO TO QUESTION 84)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

Less than 2 drumsticks or wings, less than
1 breast or thigh, or less than 4 nuggets
2 drumsticks or wings, 1 breast or thigh, or 4 to
8 nuggets
More than 2 drumsticks or wings, more than
1 breast or thigh, or more than 8 nuggets

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

83a. Each time you ate pork, how much did you
usually eat?
Less than 2 ounces or less than 1 chop
2 to 5 ounces or 1 chop
More than 5 ounces or more than 1 chop

81b. How often was the chicken you ate fried
chicken (including deep fried) or chicken
nuggets?

84. How often did you eat gravy on meat, chicken,
potatoes, rice, etc.?

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

NEVER (GO TO QUESTION 85)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

81c. How often was the chicken you ate WHITE
meat?
Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

84a. Each time you ate gravy on meat, chicken,
potatoes, rice, etc., how much did you
usually eat?
Less than ⅛ cup
⅛ to ½ cup
More than ½ cup

81d. How often did you eat chicken WITH skin?
Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always
Question 82 appears in the next column

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day
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Question 85 appears on the next page
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This is a sample form. Do not use for scanning.
87a. Each time you ate sausage, how much did
you usually eat?

Over the past 12 months…
85. How often did you eat liver (all kinds) or
liverwurst?

Less than 1 patty or 2 links
1 to 3 patties or 2 to 5 links
More than 3 patties or 5 links

NEVER (GO TO QUESTION 86)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

87b. How often was the sausage you ate light,
low-fat, or lean sausage?

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

85a. Each time you ate liver or liverwurst, how
much did you usually eat?

88. How often did you eat fish sticks or fried fish
(including fried seafood or shellfish)?

Less than 1 ounce
1 to 4 ounces
More than 4 ounces

NEVER (GO TO QUESTION 89)

86. How often did you eat bacon (including low-fat)?
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

NEVER (GO TO QUESTION 87)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

88a. Each time you ate fish sticks or fried fish,
how much did you usually eat?

86a. Each time you ate bacon, how much did you
usually eat?

Less than 2 ounces or less than 1 fillet
2 to 7 ounces or 1 fillet
More than 7 ounces or more than 1 fillet

Fewer than 2 slices
2 to 3 slices
More than 3 slices

89. How often did you eat fish or seafood that was
NOT FRIED (including shellfish)?

86b. How often was the bacon you ate light, lowfat, or lean bacon?

NEVER (GO TO INTRODUCTION TO QUESTION 90)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

NEVER (GO TO QUESTION 88)

Question 88 appears in the next column

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

89a. Each time you ate eat fish or seafood that
was NOT FRIED, how much did you usually
eat?

87. How often did you eat sausage (including lowfat)?

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

Less than 2 ounces or less than 1 fillet
2 to 5 ounces or 1 fillet
More than 5 ounces or more than 1 fillet

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day
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Introduction to Question 90 appears on the next page
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92. Over the past 12 months, did you eat soups?

Over the past 12 months…

NO (GO TO QUESTION 93)

Now think about all the meat, poultry, and fish
you ate in the past 12 months and how they were
prepared.

YES

90. How often was oil, butter, margarine, or other
fat used to FRY, SAUTE, BASTE, OR
MARINATE any meat, poultry, or fish you ate?
(Please do not include deep frying.)

92a. How often did you eat soup DURING THE
WINTER?
NEVER

NEVER (GO TO QUESTION 91)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

1–6 times per winter
7–11 times per winter
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

92b. How often did you eat soup DURING THE
REST OF THE YEAR?

90a. Which of the following fats were regularly
used to prepare your meat, poultry, or fish?
(Mark all that apply.)
Margarine (including
low-fat)
Butter (including
low-fat)
Lard, fatback, or
bacon fat
Olive oil

NEVER
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

Corn oil
Canola or rapeseed oil
Oil spray, such as Pam
or others
Other kinds of oils
None of the above

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times
per day

92c. Each time you ate soup, how much did you
usually eat?

91. How often did you eat tofu, soy burgers, or soy
meat-substitutes?

Less than 1 cup
1 to 2 cups
More than 2 cups

NEVER (GO TO QUESTION 92)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times
per day

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

92d. How often were the soups you ate bean
soups?
Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

91a. Each time you ate tofu, soy burgers, or soy
meat-substitutes, how much did you usually
eat?

92e. How often were the soups you ate cream
soups (including chowders)?

Less than ¼ cup or less than 2 ounces
¼ to ½ cup or 2 to 4 ounces
More than ½ cup or more than 4 ounces

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

Question 92 appears in the next column

24

Question 93 appears on the next page
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94a. Each time you ate crackers, how many did
you usually eat?

Over the past 12 months…
92f. How often were the soups you ate tomato or
vegetable soups?

Fewer than 4 crackers
4 to 10 crackers
More than 10 crackers

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

95. How often did you eat corn bread or corn
muffins?
NEVER (GO TO QUESTION 96)

92g. How often were the soups you ate broth
soups (including chicken) with or without
noodles or rice?

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

95a. Each time you ate corn bread or corn
muffins, how much did you usually eat?

93. How often did you eat pizza?

Less than 1 piece or muffin
1 to 2 pieces or muffins
More than 2 pieces or muffins

NEVER (GO TO QUESTION 94)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

96. How often did you eat biscuits?

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

NEVER (GO TO QUESTION 97)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

93a. Each time you ate pizza, how much did you
usually eat?
Less than 1 slice or less than 1 mini pizza
1 to 3 slices or 1 mini pizza
More than 3 slices or more than 1 mini pizza

Fewer than 1 biscuit
1 to 2 biscuits
More than 2 biscuits

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

97. How often did you eat potato chips, tortilla
chips, or corn chips (including low-fat, fat-free,
or low-salt)?
NEVER (GO TO QUESTION 98)

94. How often did you eat crackers?

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

NEVER (GO TO QUESTION 95)

Question 95 appears in the next column

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

96a. Each time you ate biscuits, how many did
you usually eat?

93b. How often did you eat pizza with pepperoni,
sausage, or other meat?

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day
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2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

Question 98 appears on the next page
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This is a sample form. Do not use for scanning.
99a. Each time you ate pretzels, how many did
you usually eat?

Over the past 12 months…
97a. Each time you ate potato chips, tortilla
chips, or corn chips, how much did you
usually eat?

Fewer than 5 average twists
5 to 20 average twists
More than 20 average twists

Fewer than 10 chips or less than 1 cup
10 to 25 chips or 1 to 2 cups
More than 25 chips or more than 2 cups

100. How often did you eat peanuts, walnuts,
seeds, or other nuts?
NEVER (GO TO QUESTION 101)

97b. How often were the chips you ate Wow
chips or other chips made with fat
substitute (Olean or Olestra)?

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

100a. Each time you ate peanuts, walnuts, seeds,
or other nuts, how much did you usually eat?

97c. How often were the chips you ate other lowfat or fat-free chips?

Less than ¼ cup
¼ to ½ cup
More than ½ cup

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

101. How often did you eat energy, high-protein, or
breakfast bars such as Power Bars, Balance,
Clif, or others?
NEVER (GO TO QUESTION 102)

98. How often did you eat popcorn (including lowfat)?

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

NEVER (GO TO QUESTION 99)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

Less than 1 bar
1 bar
More than 1 bar

Less than 2 cups, popped
2 to 5 cups, popped
More than 5 cups, popped

102. How often did you eat yogurt (NOT including
frozen yogurt)?

99. How often did you eat pretzels?

NEVER (GO TO QUESTION 103)

NEVER (GO TO QUESTION 100)

Question 100 appears in the next column

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

101a. Each time you ate energy, high-protein, or
breakfast bars, how much did you usually
eat?

98a. Each time you ate popcorn, how much did
you usually eat?

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day
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2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

Question 103 appears on the next page
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104c. How often was the cheese you ate fat-free
cheese?

Over the past 12 months…
102a. Each time you ate yogurt, how much did
you usually eat?

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

Less than ½ cup or less than 1 container
½ to 1 cup or 1 container
More than 1 cup or more than 1 container

103. How often did you eat cottage cheese
(including low-fat)?

105. How often did you eat frozen yogurt, sorbet, or
ices (including low-fat or fat-free)?

NEVER (GO TO QUESTION 104)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

NEVER (GO TO QUESTION 106)

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

103a. Each time you ate cottage cheese, how
much did you usually eat?

105a. Each time you ate frozen yogurt, sorbet, or
ices, how much did you usually eat?

Less than ¼ cup
¼ to 1 cup
More than 1 cup

Less than ½ cup or less than 1 scoop
½ to 1 cup or 1 to 2 scoops
More than 1 cup or more than 2 scoops

104. How often did you eat cheese (including low-fat;
including on cheeseburgers or in sandwiches or
subs)?

106. How often did you eat ice cream, ice cream
bars, or sherbet (including low-fat or fat-free)?

NEVER (GO TO QUESTION 105)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

NEVER (GO TO QUESTION 107)

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

104a. Each time you ate cheese, how much did
you usually eat?

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

106a. Each time you ate ice cream, ice cream
bars, or sherbet, how much did you usually
eat?

Less than ½ ounce or less than 1 slice
½ to 1½ ounces or 1 slice
More than 1½ ounces or more than 1 slice

Less than ½ cup or less than 1 scoop
½ to 1½ cups or 1 to 2 scoops
More than 1½ cups or more than 2 scoops

104b. How often was the cheese you ate light or
low-fat cheese?

106b. How often was the ice cream you ate light,
low-fat, or fat-free ice cream or sherbet?

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

Question 105 appears in the next column

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always
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109. How often did you eat doughnuts, sweet rolls,
Danish, or pop-tarts?

Over the past 12 months…
107. How often did you eat cake (including low-fat or
fat-free)?

NEVER (GO TO QUESTION 110)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

NEVER (GO TO QUESTION 108)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

109a. Each time you ate doughnuts, sweet rolls,
Danish, or pop-tarts, how much did you
usually eat?

107a. Each time you ate cake, how much did you
usually eat?

Less than 1 piece
1 to 2 pieces
More than 2 pieces

Less than 1 medium piece
1 medium piece
More than 1 medium piece

110. How often did you eat sweet muffins or
dessert breads (including low-fat or fat-free)?

107b. How often was the cake you ate light, lowfat, or fat-free cake?

NEVER (GO TO QUESTION 111)
Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

108. How often did you eat cookies or brownies
(including low-fat or fat-free)?

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

110a. Each time you ate sweet muffins or dessert
breads, how much did you usually eat?

NEVER (GO TO QUESTION 109)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

Less than 1 medium piece
1 medium piece
More than 1 medium piece

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

110b. How often were the sweet muffins or
dessert breads you ate light, low-fat, or fatfree sweet muffins or dessert breads?

108a. Each time you ate cookies or brownies,
how much did you usually eat?

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

Less than 2 cookies or 1 small brownie
2 to 4 cookies or 1 medium brownie
More than 4 cookies or 1 large brownie

111. How often did you eat fruit crisp, cobbler, or
strudel?

108b. How often were the cookies or brownies you
ate light, low-fat, or fat-free cookies or
brownies?

NEVER (GO TO QUESTION 112)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

Question 109 appears in the next column
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2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

Question 112 appears on the next page
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112e. How often were the pies you ate pecan pie?

Over the past 12 months…
111a. Each time you ate fruit crisp, cobbler, or
strudel, how much did you usually eat?

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

Less than ½ cup
½ to 1 cup
More than 1 cup

113. How often did you eat chocolate candy?

112. How often did you eat pie?

NEVER (GO TO QUESTION 114)

NEVER (GO TO QUESTION 113)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

113a. Each time you ate chocolate candy, how
much did you usually eat?

112a. Each time you ate pie, how much did you
usually eat?

Less than 1 average bar or less than 1 ounce
1 average bar or 1 to 2 ounces
More than 1 average bar or more than 2 ounces

Less than ⅛ of a pie
About ⅛ of a pie
More than ⅛ of a pie

114. How often did you eat other candy?

The next four questions ask about the kinds of
pie you ate. Please read all four questions
before answering.

NEVER (GO TO QUESTION 115)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

112b. How often were the pies you ate fruit pie
(such as apple, blueberry, others)?
Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

114a. Each time you ate other candy, how much
did you usually eat?
Fewer than 2 pieces
2 to 9 pieces
More than 9 pieces

112c. How often were the pies you ate cream,
pudding, custard, or meringue pie?

115. How often did you eat eggs, egg whites, or egg
substitutes (NOT counting eggs in baked
goods and desserts)? (Please include eggs in
salads, quiche, and soufflés.)

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

NEVER (GO TO QUESTION 116)

112d. How often were the pies you ate pumpkin or
sweet potato pie?

1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

Question 113 appears in the next column

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day
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2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times per day

Question 116 appears on the next page
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This is a sample form. Do not use for scanning.
116. How many cups of coffee, caffeinated or
decaffeinated, did you drink?

Over the past 12 months…
115a. Each time you ate eggs, how many did you
usually eat?

NEVER (GO TO QUESTION 117)
Less than 1 cup per
month
1–3 cups per month
1 cup per week
2–4 cups per week

1 egg
2 eggs
3 or more eggs

115b. How often were the eggs you ate egg
substitutes?

116a. How often was the coffee you drank
decaffeinated?

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

115c. How often were the eggs you ate egg
whites only?

117. How many glasses of ICED tea, caffeinated or
decaffeinated, did you drink?

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

NEVER (GO TO QUESTION 118)
Less than 1 cup per
month
1–3 cups per month
1 cup per week
2–4 cups per week

115d. How often were the eggs you ate regular
whole eggs?
Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

5–6 cups per week
1 cup per day
2–3 cups per day
4–5 cups per day
6 or more cups per day

117a. How often was the iced tea you drank
decaffeinated or herbal tea?
Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

115e. How often were the eggs you ate cooked in
oil, butter, or margarine?

118. How many cups of HOT tea, caffeinated or
decaffeinated, did you drink?

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

NEVER (GO TO QUESTION 119)
Less than 1 cup per
month
1–3 cups per month
1 cup per week
2–4 cups per week

115f. How often were the eggs you ate part of
egg salad?
Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

Question 116 appears in the next column

5–6 cups per week
1 cup per day
2–3 cups per day
4–5 cups per day
6 or more cups per day

5–6 cups per week
1 cup per day
2–3 cups per day
4–5 cups per day
6 or more cups per day

118a. How often was the hot tea you drank
decaffeinated or herbal tea?
Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always
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Question 119 appears on the next page
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This is a sample form. Do not use for scanning.
121b. What kind of non-dairy creamer did you
usually use?

Over the past 12 months…
119. How often did you add sugar or honey to your
coffee or tea?

Regular powdered
Low-fat or fat-free powdered
Regular liquid
Low-fat or fat-free liquid

NEVER (GO TO QUESTION 120)
Less than 1 time per
month
1–3 times per month
1 time per week
2–4 times per week

5–6 times per week
1 time per day
2–3 times per day
4–5 times per day
6 or more times per day

122. How often was cream or half and half added to
your coffee or tea?
NEVER (GO TO QUESTION 123)

119a. Each time sugar or honey was added to
your coffee or tea, how much was usually
added?

Less than 1 time per
month
1–3 times per month
1 time per week
2–4 times per week

Less than 1 teaspoon
1 to 3 teaspoons
More than 3 teaspoons

122a. Each time cream or half and half was
added to your coffee or tea, how much was
usually added?

120. How often did you add artificial sweetener to
your coffee or tea?

Less than 1 tablespoon
1 to 2 tablespoons
More than 2 tablespoons

NEVER (GO TO QUESTION 121)
Less than 1 time per
month
1–3 times per month
1 time per week
2–4 times per week

5–6 times per week
1 time per day
2–3 times per day
4–5 times per day
6 or more times per day

123. How often was milk added to your coffee or
tea?
NEVER (GO TO QUESTION 124)

120a. What kind of artificial sweetener did you
usually use?

Less than 1 time per
month
1–3 times per month
1 time per week
2–4 times per week

Equal or aspartame
Sweet N Low or saccharin

Less than 1 tablespoon
1 to 3 tablespoons
More than 3 tablespoons

NEVER (GO TO QUESTION 122)
5–6 times per week
1 time per day
2–3 times per day
4–5 times per day
6 or more times per day

123b. What kind of milk was usually added to your
coffee or tea?
Whole milk
2% milk
1% milk
Skim, nonfat, or ½% milk
Evaporated or condensed (canned) milk
Soy milk
Rice milk
Other

121a. Each time non-dairy creamer was added to
your coffee or tea, how much was usually
used?
Less than 1 teaspoon
1 to 3 teaspoons
More than 3 teaspoons

Question 122 appears in the next column

5–6 times per week
1 time per day
2–3 times per day
4–5 times per day
6 or more times per day

123a. Each time milk was added to your coffee or
tea, how much was usually added?

121. How often was non-dairy creamer added to
your coffee or tea?

Less than 1 time per
month
1–3 times per month
1 time per week
2–4 times per week

5–6 times per week
1 time per day
2–3 times per day
4–5 times per day
6 or more times per day
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Question 124 appears on the next page
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This is a sample form. Do not use for scanning.
125c. How often was the margarine you ate fatfree margarine?

Over the past 12 months…
124. How often was sugar or honey added to foods
you ate? (Please do not include sugar in coffee,
tea, other beverages, or baked goods.)

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

NEVER (GO TO INTRODUCTION TO
QUESTION 125)
1–6 times per year
7–11 times per year
1 time per month
2–3 times per month
1 time per week

126. Over the past 12 months, did you eat butter?

2 times per week
3–4 times per week
5–6 times per week
1 time per day
2 or more times
per day

NO (GO TO QUESTION 127)
YES

126a. How often was the butter you ate light or
low-fat butter?

124a. Each time sugar or honey was added to
foods you ate, how much was usually
added?

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

Less than 1 teaspoon
1 to 3 teaspoons
More than 3 teaspoons

The following questions are about the kinds of
margarine, mayonnaise, sour cream, cream
cheese, and salad dressing that you eat. If
possible, please check the labels of these foods
to help you answer.

127. Over the past 12 months, did you eat
mayonnaise or mayonnaise-type dressing?
NO (GO TO QUESTION 128)
YES

125. Over the past 12 months, did you eat
margarine?

127a. How often was the mayonnaise you ate
regular-fat mayonnaise?

NO (GO TO QUESTION 126)
YES

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

125a. How often was the margarine you ate
regular-fat margarine (stick or tub)?

127b. How often was the mayonnaise you ate light
or low-fat mayonnaise?

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

125b. How often was the margarine you ate light
or low-fat margarine (stick or tub)?
Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

Question 126 appears in the next column
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Question 128 appears on the next page
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This is a sample form. Do not use for scanning.
129b. How often was the cream cheese you ate
light, low-fat, or fat-free cream cheese?

Over the past 12 months…
127c. How often was the mayonnaise you ate fatfree mayonnaise?

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

130. Over the past 12 months, did you eat salad
dressing?

128. Over the past 12 months, did you eat sour
cream?

NO (GO TO INTRODUCTION TO QUESTION 131)
YES

NO (GO TO QUESTION 129)
YES

130a. How often was the salad dressing you ate
regular-fat salad dressing (including oil
and vinegar dressing)?

128a. How often was the sour cream you ate
regular-fat sour cream?

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

130b. How often was the salad dressing you ate
light or low-fat salad dressing?

128b. How often was the sour cream you ate light,
low-fat, or fat-free sour cream?

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

130c. How often was the salad dressing you ate
fat-free salad dressing?

129. Over the past 12 months, did you eat cream
cheese?

Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

NO (GO TO QUESTION 130)
YES

The following two questions ask you to
summarize your usual intake of vegetables and
fruits. Please do not include salads, potatoes, or
juices.

129a. How often was the cream cheese you ate
regular-fat cream cheese?
Almost never or never
About ¼ of the time
About ½ of the time
About ¾ of the time
Almost always or always

131. Over the past 12 months, how many servings of
vegetables (not including salad or potatoes) did
you eat per week or per day?
Less than 1 per week
1–2 per week
3–4 per week
5–6 per week
1 per day

Question 130 appears in the next column
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2 per day
3 per day
4 per day
5 or more per day
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This is a sample form. Do not use for scanning.
Over the past 12 months…

The next questions are about your use of fiber
supplements or vitamin pills.

132. Over the past 12 months, how many servings of
fruit (not including juices) did you eat per week
or per day?
Less than 1 per week
1–2 per week
3–4 per week
5–6 per week
1 per day

135. Over the past 12 months, did you take any of the
following types of fiber or fiber supplements
on a regular basis (more than once per week for
at least 6 of the last 12 months)?
(Mark all that apply.)

2 per day
3 per day
4 per day
5 or more per day

NO, didn't take any fiber supplements on a regular
basis (GO TO QUESTION 136)
YES, psyllium products (such as Metamucil,
Fiberall, Serutan, Perdiem, Correctol)
YES, methylcellulose/cellulose products (such as
Citrucel, Unifiber)
YES, Fibercon
YES, Bran (such as wheat bran, oat bran, or bran
wafers)

133. Over the past month, which of the following
foods did you eat AT LEAST THREE TIMES?
(Mark all that apply.)
Avocado, guacamole
Cheesecake
Chocolate, fudge, or
butterscotch toppings
or syrups
Chow mein noodles
Croissants
Dried apricots
Egg rolls
Granola bars
Hot peppers
Jello, gelatin
Milkshakes or
ice-cream sodas

Olives
Oysters
Pickles or pickled
vegetables or fruit
Plantains
Pork neckbones, hock,
head, feet
Pudding or custard
Veal, venison, lamb
Whipped cream, regular
Whipped cream,
substitute

136. Over the past 12 months, did you take any
multivitamins, such as One-a-Day-, Theragran-,
or Centrum-type multivitamins (as pills, liquids, or
packets)?
NO (GO TO INTRODUCTION TO QUESTION 138)
YES

NONE

137. How often did you take One-a-day-, Theragran-,
or Centrum-type multivitamins?

134. For ALL of the past 12 months, have you
followed any type of vegetarian diet?

Less than 1 day per month
1–3 days per month
1–3 days per week
4–6 days per week
Every day

NO (GO TO INTRODUCTION TO QUESTION 135)
YES

137a. Does your multivitamin usually contain
minerals (such as iron, zinc, etc.)?

134a. Which of the following foods did you
TOTALLY EXCLUDE from your diet?
(Mark all that apply.)

NO
YES
Don't know

Meat (beef, pork, lamb, etc.)
Poultry (chicken, turkey, duck)
Fish and seafood
Eggs
Dairy products (milk, cheese, etc.)

137b. For how many years have you taken
multivitamins?
Less than 1 year
1–4 years
5–9 years
10 or more years

Introduction to Question 135 appears in the next column

Introduction to Question 138 appears on the next page
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139. How often did you take Vitamin A (NOT as part
of a multivitamin in Question 137)?

Over the past 12 months…
137c. Over the past 12 months, did you take any
vitamins, minerals, or other herbal
supplements other than your multivitamin?

NEVER (GO TO QUESTION 140)
Less than 1 day per month
1–3 days per month
1–3 days per week
4–6 days per week
Every day

NO

Thank you very much for completing this
questionnaire! Because we want to be able to
use all the information you have provided, we
would greatly appreciate it if you would please
take a moment to review each page making sure
that you:

139a. When you took Vitamin A, about how much
did you take in one day?
Less than 8,000 IU
8,000–9,999 IU
10,000–14,999 IU
15,000–24,999 IU
25,000 IU or more
Don't know

• Did not skip any pages and
• Crossed out the incorrect answer and circled
the correct answer if you made any changes.

139b. For how many years have you taken
Vitamin A?

YES (GO TO INTRODUCTION TO
QUESTION 138)

Less than 1 year
1–4 years
5–9 years
10 or more years

These last questions are about the vitamins,
minerals, or herbal supplements you took that are
NOT part of a One-a-day-, Theragran-, or
Centrum-type of multivitamin.

140. How often did you take Vitamin C (NOT as part
of a multivitamin in Question 137)?

Please include vitamins taken as part of an
antioxidant supplement.

NEVER (GO TO QUESTION 141)

138. How often did you take Beta-carotene (NOT as
part of a multivitamin in Question 137)?

Less than 1 day per month
1–3 days per month
1–3 days per week
4–6 days per week
Every day

NEVER (GO TO QUESTION 139)
Less than 1 day per month
1–3 days per month
1–3 days per week
4–6 days per week
Every day

140a. When you took Vitamin C, about how much
did you take in one day?
Less than 500 mg
500–999 mg
1,000–1,499 mg
1,500–1,999 mg
2,000 mg or more
Don't know

138a. When you took Beta-carotene, about how
much did you take in one day?
Less than 10,000 IU
10,000–14,999 IU
15,000–19,999 IU
20,000–24,999 IU
25,000 IU or more
Don't know

140b. For how many years have you taken
Vitamin C?
Less than 1 year
1–4 years
5–9 years
10 or more years

138b. For how many years have you taken Betacarotene?
Less than 1 year
1–4 years
5–9 years
10 or more years
Question 139 appears in the next column
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Question 141 appears on the next page
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This is a sample form. Do not use for scanning.
142b. For how many years have you taken
Calcium or Calcium-containing antacids?

Over the past 12 months…
141. How often did you take Vitamin E (NOT as part
of a multivitamin in Question 137)?

Less than 1 year
1–4 years
5–9 years
10 or more years

NEVER (GO TO QUESTION 142)
Less than 1 day per month
1–3 days per month
1–3 days per week
4–6 days per week
Every day

The last two questions ask you about other
supplements you took more than once per week.
143. Please mark any of the following single
supplements you took more than once per
week (NOT as part of a multivitamin in Question
137):

141a. When you took Vitamin E, about how much
did you take in one day?
Less than 400 IU
400–799 IU
800–999 IU
1,000 IU or more
Don't know

B-6
B-complex
Brewer's yeast
Cod liver oil
Coenzyme Q
Fish oil
(Omega-3 fatty acids)

141b. For how many years have you taken
Vitamin E?

144. Please mark any of the following herbal or
botanical supplements you took more than
once per week.

Less than 1 year
1–4 years
5–9 years
10 or more years

Aloe Vera
Astragalus
Bilberry
Cascara sagrada
Cat's claw
Cayenne
Cranberry
Dong Kuai (Tangkwei)
Echinacea
Evening primrose oil
Feverfew
Garlic

142. How often did you take Calcium or Calciumcontaining antacids (NOT as part of a
multivitamin in Question 137)?
NEVER (GO TO QUESTION 143)
Less than 1 day per month
1–3 days per month
1–3 days per week
4–6 days per week
Every day

142a. When you took Calcium or Calciumcontaining antacids, about how much
elemental calcium did you take in one day?
(If possible, please check the label for
elemental calcium.)

Ginger
Ginkgo biloba
Ginseng (American or
Asian)
Goldenseal
Grapeseed extract
Kava, kava
Milk thistle
Saw palmetto
Siberian ginseng
St. John's wort
Valerian
Other

Thank you very much for completing this
questionnaire! Because we want to be able to use
all the information you have provided, we would
greatly appreciate it if you would please take a
moment to review each page making sure that you:

Less than 500 mg
500–599 mg
600–999 mg
1,000 mg or more
Don't know

Question 143 appears in the next column

Folic acid/folate
Glucosamine
Hydroxytryptophan (HTP)
Iron
Niacin
Selenium
Zinc

•
•

36

Did not skip any pages and
Crossed out the incorrect answer and circled the
correct answer if you made any changes.
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Supplemental Physical Activity Questions
The following questions are to determine your level of physical activity, as bone density is affected by
physical activity.
1. Are you currently involved in a regular exercise program?
YES
2. If yes, what exercise activities are you involved in? (Check all that apply)
□ Biking
□ Karate
□ Kickboxing
□ Walking
□ Yoga
□ Jogging

□ Pilates

□ Swimming

□ Weight Training

NO

□ Other ___________

3. Over the last 20 years, have you participated in any of the following exercise activities? (Check
all that apply)
□ Biking

□ Karate

□ Kickboxing

□ Walking

□ Yoga

□ Jogging

□ Pilates

□ Swimming

□ Weight Training

□ Other ___________

If yes, please list the months and years of participation
__________________________________
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APPENDIX C
RAW DATA

1. EXPLANATION OF RAW DATA
2. RAW DATA TABLES
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EXPLANATION OF RAW DATA

PARTICIPANT ID:

Arbitrary identification number assigned for tracking purposes only

GENDER:

Identifies participant gender (M = Male, F = Female)

PPI USE:

Identifies participant as a “0” if they are NOT a PPI user and as a “1” if
they are a PPI user

TREATMENT:

Identifies participant as a “control” if they are NOT a PPI user and as a
“case” if they are a PPI user

PPI DOSE:

Dosage of PPI in milligrams

PPI DURATION:

Duration of PPI therapy in months

BIRTHDATE:

Participant birthdate in MM/DD/YY format

AGE:

Identifies participant age at time of data collection

HEIGHT:

Participant height in inches

WAIST:

Participant waist circumference in inches

HIP:

Participant hip circumference in inches

W:H RATIO:

Ratio of WAIST:HIP categories as listed above (no units)

THYROID:

Identifies participant as a “0” if they do NOT currently use prescription
thyroid medication and as a “1” if they currently use prescription thyroid
medication

H2RA:

Identifies participant as a “0” if they do NOT currently use Histamine-2
Receptor Antagonist (H2RA) medication and as a “1” if they currently
use H2RA’s

CALCIUM (SUPPL):

Identifies participants as a “0” if they do NOT currently use calcium
supplements and as a “1” if they currently use calcium supplements

VIT D (SUPPL):

Identifies participants as a “0” if they do NOT currently use vitamin D
supplements and as a “1” if they currently use vitamin D supplements

MVI:

Identifies participants as a “0” if they do NOT currently use a
multivitamin and as a “1” if they currently use a multivitamin

MAGNESIUM (SUPPL):

Identifies participants as a “0” if they do NOT currently use magnesium
supplements and as a “1” if they currently use magnesium supplements
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VIT A (SUPPL):

Identifies participants as a “0” if they do NOT currently use vitamin A
supplements and as a “1” if they currently use vitamin A supplements

VIT C (SUPPL):

Identifies participants as a “0” if they do NOT currently use vitamin C
supplements and as a “1” if they currently use vitamin C supplements

POTASSIUM (SUPPL):

Identifies participants as a “0” if they do NOT currently use potassium
supplements and as a “1” if they currently use potassium supplements

DPX:

Lab value for urinary deoxypyridinoline in nmol

CREATININE:

Lab value for urinary creatinine in mg/dl

DPX:CREATININE RATIO:

Ratio of DPX:CREATININE categories as listed above (no units)

MG, URINE:

Lab value for urinary magnesium in mg/dl

DAY 1 – 24 HOUR URINE VOLUME:
Total volume of 24 hour urine collections in ml
24 HOUR MAGNESIUM, URINE:
Calculation of (MG, URINE)* (DAY 1 – 24 HOUR URINE
VOLUME)/100 = mg magnesium per 24 hours
CA, URINE:

Lab value for urinary calcium in mg/dl

24 HOUR CALCIUM, URINE:
Calculation of (CA, URINE)* (DAY 1 – 24 HOUR URINE
VOLUME)/100 = mg calcium per 24 hours
OSTEOCALCIN, SERUM:

Lab value for serum osteocalcin in ng/ml

25-HYDROXY VIT D:

Lab value for 25 hydroxy vitamin D in ng/ml

MG, SERUM:

Lab value for serum magnesium in mg/dl

PTH:

Lab value for parathyroid hormone in pg/ml

L1-L4 BMD:

Bone mineral density score for L1-L4 in grams/cm2

LEFT HIP BMD:

Bone mineral density score for left hip in grams/cm2

RIGHT HIP BMD:

Bone mineral density score for right hip in grams/cm2

MEAN HIP BMD:

Mean bone mineral density score averaging LEFT HIP BMD and
RIGHT HIP BMD in grams/cm2

TISSUE:

Grams of tissue as reported from DXA full body scan reports
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FAT:

Grams of fat as reported from DXA full body scan reports

LEAN:

Grams of lean as reported from DXA full body scan reports

BMC:

Grams of bone mineral content as reported from DXA full body scan
reports

FAT FREE:

Grams of fat free mass as reported from DXA full body scan reports

ANDROID:

Percent android fat as reported from DXA full body scan reports

GYNOID:

Percent gynoid fat as reported from DXA full body scan reports

TOTAL BODY FAT:

Percent total fat as reported from DXA full body scan reports

A/G RATIO:

Ratio of ANDROID:GYNOID categories as listed above (no units)

BMI:

Body mass index (BMI) as reported from DXA full body scan reports

TOTAL MASS:

Total body mass in kilograms as reported from DXA full body scan
reports

FOOD ENERGY:

Output from DHQ for daily energy intake in calories

PROTEIN:

Output from DHQ for daily protein intake in grams

TOTAL FAT:

Output from DHQ for daily fat intake in grams

CARBOHYDRATE:

Output from DHQ for daily carbohydrate intake in grams

VITAMIN A IU:

Output from DHQ for daily vitamin A intake in international units

VITAMIN A RE:

Output from DHQ for daily vitamin A intake in retinol equivalents

TOTAL VITAMIN A ACTIVITY:
Output from DHQ for daily vitamin A intake in retinol activity
equivalents
VITAMIN C:

Output from DHQ for daily vitamin C intake in milligrams

CALCIUM:

Output from DHQ for daily calcium intake in milligrams

PHOSPHORUS:

Output from DHQ for daily phosphorus intake in milligrams

MAGNESIUM:

Output from DHQ for daily magnesium intake in milligrams

SODIUM:

Output from DHQ for daily sodium intake in milligrams

POTASSIUM:

Output from DHQ for daily potassium intake in milligrams

CAFFEINE:

Output from DHQ for daily caffeine intake in milligrams
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VITAMIN D (CALCIFEROL):
Output from DHQ for daily vitamin D intake in micrograms
VITAMIN D (IU):

Output from DHQ for daily vitamin D intake in international units

SUPP VITAMIN A:

Output from DHQ for daily supplemental vitamin A intake in retinol
activity equivalents

SUPP VITAMIN C:

Output from DHQ for daily supplemental vitamin C intake in milligrams

SUPP CALCIUM:

Output from DHQ for daily supplemental calcium intake in milligrams

SUPP MAGNESIUM:

Output from DHQ for daily supplemental magnesium intake in
milligrams

SUPP VITAMIN D:

Output from DHQ for daily supplemental vitamin D intake in
international units

AEROBIC CURRENT:

Identifies participants as a “0” if they are NOT currently participating in
an aerobic exercise program for a minimum of 30 minutes per day, 3
days per week and as “1” if they are currently participating in an aerobic
exercise program for a minimum of 30 minutes per day, 3 days per week.

RESISTANCE CURRENT:

Identifies participants as a “0” if they are NOT currently participating in
a resistance training program for a minimum of 2 days per week and as
“1” if they are currently participating in a resistance training program for
a minimum of 2 days per week.

AEROBIC PAST:

Identifies participants as a “0” if they have NOT participated in any
aerobic exercise programs consistently over the last 20 years and as “1”
if they have participated in any aerobic exercise programs consistently
over the last 20 years.

RESISTANCE PAST:

Identifies participants as a “0” if they have NOT participated in any
resistance training programs consistently over the last 20 years and as
“1” if they have participated in any resistance training programs
consistently over the last 20 years.

TOTAL VITAMIN A:

Calculated total vitamin A intake in retinol activity equivalents (TOTAL
VITAMIN A ACTIVITY + SUPP VITAMIN A)

TOTAL VITAMIN C:

Calculated total vitamin C intake in milligrams (VITAMIN C + SUPP
VITAMIN C)

TOTAL CALCIUM:

Calculated total calcium intake in milligrams (CALCIUM + SUPP
CALCIUM)
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TOTAL MAGNESIUM:

Calculated total magnesium intake in milligrams (MAGNESIUM +
SUPP MAGNESIUM)

TOTAL VITAMIN D:

Calculated total vitamin D intake in international units (VITAMIN D
CALCIFEROL + SUPP VITAMIN D)

SPINE:

Category of T-score from lumbar spine DXA scans (Normal, Osteopenia,
Osteoporosis)

HIP:

Category of T-score from hip DXA scans (Normal, Osteopenia,
Osteoporosis)

SPINE HIP:

Worst category from SPINE and HIP above (Osteoporosis < Osteopenia
< Normal)
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PPI Project Raw Data
Participant ID Gender PPI Use treatment PPI Dose PPI Duration Birthdate age Height Waist
mg
months
MM/DD/YY years inches inches
143778 F
0 control
0
0
05/05/33 76.00
64.5
34
156191 F
0 control
0
0
10/19/38 70.00
64 31.25
186859 F
0 control
0
0
06/24/27 82.00
62.5 39.25
194554 F
0 control
0
0
03/26/28 81.00 60.75 33.75
200004 M
1 case
20
12
06/01/44 65.00 70.75 52.25
216549 M
1 case
20
120
11/20/52 56.00
72
45
230453 F
0 control
0
0
02/05/48 61.00 67.25 31.75
230499 M
1 case
40
30
09/13/57 52.00 68.75
42
255516 M
1 case
20
180
05/15/47 62.00 68.25
38.5
312030 F
0 control
0
0
09/02/53 56.00 60.75 35.75
339596 F
0 control
0
0
10/10/51 58.00
61
26.5
352370 F
0 control
0
0
10/01/48 61.00
61 34.75
358284 F
0 control
0
0
03/07/43 66.00
62.5 31.75
376015 F
0 control
0
0
04/09/37 72.00 62.25
29.5
398933 F
0 control
0
0
03/15/50 59.00 66.25
47
432753 M
0 control
0
0
02/11/47 62.00 71.25 41.75
464561 M
1 case
20
144
12/21/45 63.00
68.5 45.25
509383 M
0 control
0
0
01/01/47 62.00
69 36.75
569482 M
1 case
20
120
08/02/60 49.00
74
42.5
587755 F
0 control
0
0
02/24/47 62.00 61.25 33.25
609593 M
1 case
20
4
08/19/62 47.00
70.5
34
640807 M
1 case
30
96
09/11/37 72.00
65.5
43
646395 M
0 control
0
0
02/01/62 47.00
66.5
31
647641 M
1 case
20
60
11/07/54 54.00
76.5 42.75
698799 F
0 control
0
0
03/23/52 57.00 63.25 39.75
708771 F
0 control
0
0
02/09/57 52.00 62.25
28.5
712709 F
0 control
0
0
04/10/54 55.00
63
33.5
717551 M
0 control
0
0
02/20/52 57.00
66.5
40
720105 F
1 case
40
48
02/27/52 57.00
64.5
44.5
747737 F
1 case
20
60
05/14/38 71.00 62.25
38.5
758002 M
0 control
0
0
05/08/53 56.00
68.5 42.25
760342 F
0 control
0
0
06/11/35 74.00
60.5
34
765918 M
1 case
40
156
06/15/38 71.00
65.5
39.5
775008 M
1 case
20
180
01/03/66 43.00 75.25 42
777907 M
1 case
20
72
03/29/44 65.00
69.5 43.75
784819 M
1 case
30
18
05/24/35 74.00
71.5 33.25
788789 M
1 case
30
120
03/21/52 57.00 68.25
46
806492 M
1 case
20
120
11/25/34 74.00 64.75 40.25
812964 M
1 case
20
84
02/26/37 72.00 72.75
44
833746 M
1 case
20
60
12/07/21 87.00 66.75 42.75
835846 M
1 case
40
2
10/13/53 56.00
72.5
37
836130 M
1 case
40
60
11/17/48 60.00
71
36.5
839855 F
1 case
20
24
10/12/30 79.00
64.5
42
853838 M
1 case
20
72
06/19/39 70.00
66
42.5
865646 F
1 case
40
84
12/08/49 59.00
64
31.5
875236 F
0 control
0
0
10/03/50 59.00
63 35.25
875636 M
1 case
40
36
09/01/59 50.00
72 52.25
920971 M
1 case
40
36
02/22/39 70.00
68
43.5
925821 M
0 control
0
0
06/08/68 41.00 70.75 31.75

116

PPI Project Raw Data
Participant ID Gender PPI Use treatment PPI Dose PPI Duration Birthdate age Height Waist
mg
months
MM/DD/YY years inches inches
950103 M
1 case
40
60
12/06/44 64.00
76 48.75
980834 F
1 case
20
120
08/24/47 62.00 60.25
44
985282 M
1 case
10
60
03/18/44 65.00
65 43.75
992966 M
1 case
30
300
03/25/45 64.00 70.25 41.25
998751 F
1 case
40
240
06/20/36 73.00
64
35.5
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PPI Project Raw Data
Participant ID
143778
156191
186859
194554
200004
216549
230453
230499
255516
312030
339596
352370
358284
376015
398933
432753
464561
509383
569482
587755
609593
640807
646395
647641
698799
708771
712709
717551
720105
747737
758002
760342
765918
775008
777907
784819
788789
806492
812964
833746
835846
836130
839855
853838
865646
875236
875636
920971
925821

Hips
inches
42.5
39
39.25
40.5
51
46.25
40.25
42.5
43.75
41.5
37.5
45.75
42.5
38.25
56.5
44
45.25
38
45.5
41.75
40.25
42
37.25
44.5
43
36.5
42
44
48.5
45.5
41.5
38.5
41.25
44
42.25
39.5
44.25
38.25
46
43.25
42
41
48.5
42.75
45.25
41.5
52
46.5
37.25

W:H Thyroid H2RA Calcium Vit D MVI Magnesium Vit A
(Rx)
(Suppl) (Suppl)
(Suppl)
(Suppl)
0.80
0
0
0
0
0
0
0
0.80
0
0
0
0
0
0
0
1.00
0
0
0
0
0
0
0
0.83
1
0
0
0
0
0
0
1.02
0
0
0
0
1
0
0
0.97
0
0
0
0
0
0
0
0.79
0
0
1
0
1
1
0
0.99
0
0
0
0
0
0
0
0.88
0
0
0
0
1
0
0
0.86
1
1
0
0
1
0
0
0.71
0
0
1
0
1
1
1
0.76
0
0
0
0
1
0
0
0.75
0
0
0
0
0
0
0
0.77
0
0
0
0
1
0
0
0.83
0
0
0
0
1
0
0
0.95
0
0
0
0
1
0
0
1.00
0
0
0
0
1
0
0
0.97
0
0
0
0
0
0
0
0.93
0
0
0
0
0
0
0
0.80
1
0
1
0
1
0
0
0.84
0
0
0
0
0
0
0
1.02
0
0
1
0
0
0
0
0.83
0
0
1
1
1
0
0
0.96
0
0
0
0
1
0
0
0.92
0
0
0
0
0
0
0
0.78
0
0
0
1
0
1
0
0.80
0
0
0
0
0
0
0
0.91
0
1
0
0
1
0
0
0.92
0
0
0
0
0
0
0
0.85
1
0
0
0
1
0
0
1.02
0
0
0
0
0
0
0
0.88
0
0
1
0
1
0
0
0.96
0
0
0
0
0
0
0
0.95
0
0
0
0
0
0
0
1.04
0
0
0
0
0
0
0
0.84
0
0
1
1
0
0
0
c
0
0
0
1
1
0
0
1.05
1
0
0
0
0
0
0
0.96
0
1
0
0
1
0
0
0.99
0
0
0
0
0
0
0
0.88
0
0
0
0
0
0
0
0.89
0
0
0
0
1
0
0
0.87
0
0
0
0
1
0
0
0.99
0
0
0
0
0
0
0
0.70
0
0
1
0
1
0
0
0.85
0
0
1
0
0
0
0
1.00
0
0
0
0
1
0
0
0.94
0
0
0
0
1
0
0
0.85
0
0
0
0
0
0
0
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PPI Project Raw Data
Participant ID
950103
980834
985282
992966
998751

Hips
inches
47.75
51
44.25
45.5
42

W:H Thyroid H2RA Calcium Vit D MVI Magnesium Vit A
(Rx)
(Suppl) (Suppl)
(Suppl)
(Suppl)
1.02
0
0
0
0
1
0
0
0.86
0
0
0
0
0
0
0
0.99
0
0
1
0
1
0
0
0.91
0
0
0
0
1
0
0
0.85
0
0
0
0
1
0
0
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PPI Project Raw Data
Participant ID
143778
156191
186859
194554
200004
216549
230453
230499
255516
312030
339596
352370
358284
376015
398933
432753
464561
509383
569482
587755
609593
640807
646395
647641
698799
708771
712709
717551
720105
747737
758002
760342
765918
775008
777907
784819
788789
806492
812964
833746
835846
836130
839855
853838
865646
875236
875636
920971
925821

Vit C Potassium DPX Creatinine DPX/Creatinine Ratio Mg, urine
(Suppl) (Suppl) (nmol)
(mg/dl)
(0mol DPX/mmol Cr)
(mg/dl)
0
0
143
44.9
36
2.7
0
0
121
111.4
12.3
8.3
0
0 23.1
22
11.9
1.1
0
0 14.3
31.5
5.1
5.5
0
0 80.7
127.2
7.2
8.6
0
0 60.2
127.8
5.3
7.6
1
0
22
74.4
3.3
10.1
0
0 36.7
129.3
3.2
6.6
0
0
103
105.1
11.1
8.6
0
0 42.1
28.4
16.8
6.7
0
0 65.1
73.3
10
8.7
0
0 22.1
58.5
4.3
5.3
0
0 38.5
47.3
9.2
2.8
0
0
121
32
42.7
3.7
0
0
46
62.8
8.3
7.8
0
0 59.8
171.1
3.9
6.7
0
0
114
162.5
7.9
8.9
0
0 40.7
107.2
4.3
6.6
0
0 61.3
175
4
10.3
0
0 13.5
35.3
4.3
6.7
0
0
38.5
91.3
4.8
5.5
0
0
41.9
95.2
5
5.7
0
0
50.4
85.1
6.7
13.2
0
0
118
273.3
4.9
6.3
0
0
35.5
65.2
6.2
4.1
0
0 32.3
73.4
5
14.2
0
0
124
90.5
15.5
3.6
1
0 41.2
79.7
5.8
9
0
0 73.3
161
5.1
5.5
0
0
28
69
4.6
8.7
0
0 83.2
183.5
5.1
17
1
0 37.4
39.3
10.8
7.4
0
0
130
96.6
15.2
4.2
0
0 42.9
136.2
3.6
6.6
0
0
33.6
94.1
4
2.8
0
0
70.1
93.3
8.5
14
0
0
63.1
123
5.8
9.5
0
0
87.8
158.9
6.2
11.2
0
0
23.7
73.2
3.7
3.4
0
0
86.5
59.9
16.3
3.3
0
0
143
186.6
8.7
10
1
0
87.8
164.4
6
10.1
0
0
82.5
55.1
16.9
1.9
0
0
99.8
118.8
9.5
2.9
0
0
95.8
62.7
17.3
6.1
0
0
26
38.1
7.7
2.6
1
0
118
118.3
11.3
3.1
0
0 66.6
146.1
5.2
9.4
0
0 34.3
56
6.9
4.5
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PPI Project Raw Data
Participant ID
950103
980834
985282
992966
998751

Vit C Potassium DPX Creatinine DPX/Creatinine Ratio Mg, urine
(Suppl) (Suppl) (nmol)
(mg/dl)
(0mol DPX/mmol Cr)
(mg/dl)
0
0
123
135.1
10.3
5.9
0
0 62.4
112.1
6.3
8.9
0
1 23.5
128
2.1
6.1
0
0 65.3
82.2
9
7.1
0
0 94.5
83.8
12.7
8.1
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PPI Project Raw Data
Participant ID
143778
156191
186859
194554
200004
216549
230453
230499
255516
312030
339596
352370
358284
376015
398933
432753
464561
509383
569482
587755
609593
640807
646395
647641
698799
708771
712709
717551
720105
747737
758002
760342
765918
775008
777907
784819
788789
806492
812964
833746
835846
836130
839855
853838
865646
875236
875636
920971
925821

Day 1 – 24 hr urine volume 24 hr Mg, urine Ca, urine 24 hr Ca, urine
(ml)
(mg/24 hr)
(mg/dl)
(mg/24 hr)
2200
59.4
7.5
165
640
53.12
16.8
107.52
1.6
1750
96.25
2.7
47.25
1575
135.45
9
141.75
1800
136.8
16.4
295.2
1200
121.2
18.8
225.6
1450
95.7
22.5
326.25
1575
135.45
7.5
118.125
1600
107.2
7.9
126.4
1000
87
20.3
203
1500
79.5
14.3
214.5
0.9
2150
79.55
3.7
79.55
2500
195
25.7
642.5
1250
83.75
15
187.5
1325
117.925
30.9
409.425
1100
72.6
12.1
133.1
1250
128.75
17
212.5
13.5
1875
103.125
17.9
335.625
1500
85.5
3.3
49.5
1500
198
21.1
316.5
1000
63
7.1
71
1575
64.575
7.3
114.975
575
81.65
18.8
108.1
1175
42.3
17.9
210.325
1525
137.25
6.9
105.225
1050
57.75
13.6
142.8
1625
141.375
7.3
118.625
1100
187
19
209
2100
155.4
7.7
161.7
1350
56.7
12.7
171.45
1150
75.9
9.3
106.95
1825
51.1
4.9
89.425
1375
192.5
4.9
67.375
1325
125.875
33.6
445.2
725
81.2
11.5
83.375
800
27.2
9.5
76
1400
46.2
0.7
9.8
32
925
93.425
16.3
150.775
1375
26.125
10.6
145.75
1075
31.175
14.5
155.875
1500
91.5
13
195
2525
65.65
3.7
93.425
15.7
1450
136.3
20.5
297.25
2925
131.625
12.9
377.325
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PPI Project Raw Data
Participant ID
950103
980834
985282
992966
998751

Day 1 – 24 hr urine volume 24 hr Mg, urine Ca, urine 24 hr Ca, urine
(ml)
(mg/24 hr)
(mg/dl)
(mg/24 hr)
1575
92.925
11.9
187.425
700
62.3
22.4
156.8
1150
70.15
7.5
86.25
2250
159.75
12.4
279
725
58.725
4.8
34.8
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PPI Project Raw Data
Participant ID
143778
156191
186859
194554
200004
216549
230453
230499
255516
312030
339596
352370
358284
376015
398933
432753
464561
509383
569482
587755
609593
640807
646395
647641
698799
708771
712709
717551
720105
747737
758002
760342
765918
775008
777907
784819
788789
806492
812964
833746
835846
836130
839855
853838
865646
875236
875636
920971
925821

Osteocalcin, serum 25-hydroxy Vit D Mg, serum PTH
(ng/ml)
(ng/ml)
(mg/dl)
(pg/ml)
18.6
22.8
2.2
36
19.1
12.3
1.9
81
27.9
18.1
2.1
37
20.7
18.4
2.2
39
23.9
26
1.9
94
37.4
40.7
2.1
33
36.6
28
2.2
56
32.6
17.7
2.2
43
32.6
21
1.8
29
24.2
31.4
2
23
36.1
42.7
2.3
34
27.9
10
2
40
19.5
22.9
2
45
44.1
24.6
2
86
15.4
16.5
2
95
23
17.9
2.1
36
22
13.3
1.9
31
19.5
16.6
2
62
16.6
15.4
2.1
27
31.5
34.5
2.1
41
21.4
24.2
2.2
42
18.7
25.2
2.1
47
19.4
49.7
2.1
25
28.1
43.9
2.1
24
26.9
14
2.2
48
30.5
44
1.9
27
24.1
30.6
2.2
40
20.9
2.1
50
24.1
1.9
45
31.2
34.7
1.9
55
30.9
16.9
1.9
41
11.7
27.2
2.2
21
13.1
14.6
2
36
30
22.1
2
20
13.8
10.9
2.1
31
60.9
58
2.1
49
24.2
24.6
1.9
18
23.2
61.8
2
19
34.2
35.7
2.4
129
12
34
2.1
69
22
32
2.1
20
24.4
22.1
2.1
37
42.5
23.1
1.9
54
23
21.5
2.2
28
16.7
32.4
2.3
48
28.1
20.2
2
37
18.8
19.6
1.8
37
45.5
2.1
49
13.2
31.1
2.1
41

L1-L4_BMD
g/cm2
1.381
0.931
0.969
0.901
1.514
1.266
0.979
1.016
1.223
1.111
1.051
1.046
0.959
0.769
1.117
1.359
1.220
1.088
1.218
1.059
1.015
0.898
0.981
1.228
1.094
1.075
1.102
1.071
1.317
1.280
1.265
1.292
1.255
1.460
1.575
1.116
1.392
1.610
1.169
1.376
1.436
1.191
1.609
1.455
1.093
1.037
0.931
1.338
1.249
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PPI Project Raw Data
Participant ID
950103
980834
985282
992966
998751

Osteocalcin, serum 25-hydroxy Vit D Mg, serum PTH
(ng/ml)
(ng/ml)
(mg/dl)
(pg/ml)
31.6
28.6
1.8
39
20.8
11.2
2.2
75
8
25.6
2.1
17
12.1
19.4
2.5
45
34.7
25.9
1.8
40

L1-L4_BMD
g/cm2
1.156
1.000
1.226
1.363
1.335

125

PPI Project Raw Data
Participant ID Left_Hip_BMD Right_Hip_BMD Mean_Hip_BMD Tissue
Fat
Lean BMC
2
2
2
g/cm
g/cm
g/cm
g
g
g
g
143778
1.207
0.459
68,480 29,396 39,084 2,902
156191
0.598
0.059
0.593 53,997 18,606 35,391 1,781
186859
0.745
0.727
0.736 62,581 25,888 36,693 2,052
194554
0.687
2.413
55,499 22,148 33,351 1,710
200004
1.115
1.088
1.102 129,649 54,878 74,771 4,289
216549
1.201
1.240
1.220 116,746 47,746 69,001 4,114
230453
0.753
0.763
0.758 64,014 25,086 38,928 2,151
230499
0.819
0.826
0.822 91,251 29,554 61,697 3,106
255516
1.035
1.002
1.019 81,850 26,758 55,092 3,195
312030
0.857
0.918
0.888 62,977 31,549 31,428 2,412
339596
0.884
0.901
0.892 46,514 15,279 31,235 1,951
352370
0.859
0.861
0.860 67,537 33,120 34,417 2,343
358284
0.866
0.882
0.874 65,604 27,381 38,223 2,086
376015
0.646
0.600
0.623 52,476 14,743 37,732 1,758
398933
0.873
0.864
0.868 121,512 57,599 63,913 2,548
432753
1.120
1.046
1.083 91,129 33,526 57,603 4,002
464561
0.830
0.949
0.889 95,677 32,497 63,181 3,074
509383
0.855
0.888
0.871 68,609 18,383 50,226 2,684
569482
0.991
0.975
0.983 93,938 31,517 62,422 3,409
587755
0.732
0.690
0.711 60,229 21,199 39,030 2,035
609593
0.942
0.947
0.944 69,355 12,679 56,677 2,927
640807
0.823
0.794
0.809 80,451 24,916 55,535 2,416
646395
0.938
0.919
0.928 60,460 14,051 46,409 2,438
647641
1.259
1.259
1.259 102,404 30,275 72,130 4,017
698799
1.000
0.942
0.971 79,340 34,250 45,090 2,522
708771
0.852
0.846
0.858 51,305 14,454 36,851 2,234
712709
0.928
0.887
0.908 62,976 24,097 38,879 2,306
717551
0.986
0.920
0.953 77,191 22,308 54,883 2,619
720105
1.044
1.034
1.039 88,258 39,852 48,406 2,542
747737
0.940
0.954
0.947 75,875 37,851 38,025 2,936
758002
1.232
1.259
1.245 90,342 22,970 67,372 3,701
760342
1.068
1.056
1.062 59,133 25,403 33,731 2,372
765918
0.955
0.947
0.951 74,498 22,865 51,633 2,959
775008
1.177
1.132
1.155 97,570 28,115 69,454 4,217
777907
1.137
1.095
1.116 91,350 29,222 62,128 3,600
784819
0.803
0.804
0.822 65,868 10,818 55,050 3,105
788789
1.046
1.005
1.025 94,176 35,358 58,818 3,523
806492
1.059
1.013
1.036 68,936 19,519 49,417 2,905
812964
1.044
1.071
1.058 92,653 35,786 56,867 3,257
833746
75,217 28,329 46,887 2,664
835846
1.224
1.152
1.188 81,195 20,143 61,052 3,851
836130
0.948
0.874
0.911 73,844 21,120 52,724 2,991
839855
1.284
1.320
1.302 87,375 42,344 45,031 3,386
853838
0.787
0.794
0.791 83,339 27,723 55,617 2,829
865646
0.951
0.894
0.922 65,885 28,314 37,571 2,399
875236
0.879
0.875
0.877 65,729 27,608 38,120 2,433
875636
0.896
0.933
0.914 132,138 52,530 79,608 3,088
920971
0.825
0.802
0.814 95,544 31,578 63,966 2,991
925821
1.117
1.089
1.103 71,743 10,598 61,146 3,276
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PPI Project Raw Data
Participant ID Left_Hip_BMD Right_Hip_BMD Mean_Hip_BMD Tissue
Fat
Lean BMC
2
2
2
g/cm
g/cm
g/cm
g
g
g
g
950103
0.847
0.906
0.877 117,602 41,884 75,717 4,302
980834
0.792
0.836
0.814 79,885 43,030 36,855 1,952
985282
0.998
0.968
0.983 75,513 21,960 53,553 2,764
992966
1.236
1.138
1.187 102,783 34,627 68,156 3,823
998751
1.176
1.188
1.182 65,442 30,681 34,761 2,801
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PPI Project Raw Data
Participant ID Fat_Free Android Gynoid Total_Body_Fat A/G_Ratio BMI Total_Mass
g
%
%
%
kg
143778
41,985
44.00
49.20
42.90
0.89 27.20
71.40
156191
37,172
41.50
43.60
34.50
0.95 21.60
55.80
186859
38,745
49.10
45.60
41.40
1.08 26.00
64.60
194554
35,060
38.40
50.60
39.90
0.76 25.00
57.20
200004
79,060
54.40
43.50
42.30
1.25 41.70
133.90
216549
73,115
56.00
39.30
40.90
1.43 36.30
120.90
230453
41,079
37.00
49.30
39.20
0.75 23.20
66.20
230499
64,803
44.20
36.20
32.40
1.22 31.00
94.40
255516
58,287
39.10
39.30
32.70
1.00 28.30
85.00
312030
33,840
56.30
55.40
50.10
1.02 28.00
65.40
339596
33,186
35.20
43.80
32.80
0.80 20.40
48.50
352370
36,760
54.70
57.90
49.00
0.94 29.50
69.90
358284
40,309
44.90
51.40
41.70
0.87 27.30
67.70
376015
39,490
21.30
41.60
28.10
0.51 21.90
54.20
398933
66,460
50.10
56.50
47.40
0.89 45.60
124.10
432753
61,605
45.20
38.10
36.80
1.18 29.30
95.10
464561
66,254
45.90
34.50
34.00
1.33 33.00
98.80
509383
52,910
34.40
33.30
26.80
1.03 23.30
71.30
569482
65,831
46.10
37.20
33.60
1.24 27.70
97.30
587755
41,065
33.80
44.30
35.20
0.76 26.30
62.30
609593
59,604
22.60
26.50
18.30
0.85 22.60
72.30
640807
57,951
44.70
28.30
30.00
1.58 30.00
82.90
646395
48,847
32.40
30.30
23.20
1.07 22.00
62.90
647641
76,146
39.10
31.90
29.60
1.23 28.20
106.40
698799
47,612
53.00
42.50
43.20
1.25 31.60
81.90
708771
39,085
24.70
38.40
28.20
0.64 21.60
53.50
712709
41,185
45.20
43.10
38.30
1.05 25.80
65.30
717551
57,502
40.70
29.50
28.90
1.38 28.10
79.80
720105
50,949
55.40
43.10
45.20
1.28 34.50
90.80
747737
40,961
53.20
55.40
49.90
0.96 32.30
78.80
758002
71,073
37.50
26.20
25.40
1.43 31.00
94.00
760342
36,103
49.00
47.00
43.00
1.04 26.20
61.50
765918
54,591
41.60
31.20
30.70
1.33 28.20
77.50
775008
73,672
38.20
31.50
28.80
1.21 27.80
101.80
777907
65,727
42.80
29.90
32.00
1.43 30.50
94.90
784819
58,156
19.50
22.70
16.40
0.86 20.90
69.00
788789
62,341
49.30
40.40
37.50
1.22 33.00
97.70
806492
52,321
36.30
32.70
28.30
1.11 26.70
71.80
812964
60,124
49.60
38.40
38.60
1.29 28.30
95.90
833746
49,551
49.00
38.00
37.70
1.29 28.10
77.90
835846
64,903
34.10
25.30
24.80
1.35 25.20
85.00
836130
55,715
42.40
29.50
28.60
1.44 23.60
76.80
839855
48,418
54.70
54.50
48.50
1.00 34.10
90.80
853838
58,446
48.30
34.10
33.30
1.41 30.70
86.20
865646
39,970
45.80
52.10
43.00
0.88 26.20
68.30
875236
40,553
39.80
53.40
42.00
0.74 26.90
68.20
875636
82,696
50.60
42.50
39.80
1.19 40.60
135.20
920971
66,958
43.20
35.40
33.10
1.22 33.10
98.50
925821
64,421
21.70
18.40
14.80
1.18 22.90
75.00

128

PPI Project Raw Data
Participant ID Fat_Free Android Gynoid Total_Body_Fat A/G_Ratio BMI Total_Mass
g
%
%
%
kg
950103
80,019
46.00
38.00
35.60
1.21 33.00
121.90
980834
38,807
61.30
56.00
53.90
1.09 35.80
81.80
985282
56,317
39.70
29.90
29.10
1.33 28.80
78.30
992966
71,979
45.20
37.60
33.70
1.20 33.40
106.60
998751
37,563
49.30
55.10
46.90
0.89 26.20
68.20
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PPI Project Raw Data
Participant ID Food energy Protein Total fat Carbohydrate Vitamin A IU Vitamin A RE
kcal
g
g
g
IU (CSFII)
mcg RE (CSFII)
143778
2341.25 105.79
96.38
276.58
27787.19
2971.95
156191
1063.82
43.23
35.1
153.25
8062.3
929.05
186859
1871.02
85.38
72.4
231.71
12251.46
1725.67
194554
1048.37
33.04
37.46
156.34
21785.77
2450.67
200004
2743.37 100.78
114.41
345.83
5405.1
1016.68
216549
2142.09
90.61
71.22
292.96
7341.36
1370.2
230453
937.25
32.29
42.6
120.73
4926.06
521.36
230499
2369.35
83.64
93.09
312.96
7104.28
1121.84
255516
1888.75
59.24
59.07
295.04
5999.8
1164.76
312030
1610.36
75.54
48.52
226.12
11488.02
1922.38
339596
1213.16
48.02
41.77
170.45
4077.66
870.97
352370
1081.36
58.34
33.72
138.1
3265.86
792.05
358284
566.91
22.92
18.58
81.99
5790.52
677.32
376015
918.97
33.44
31.75
131.88
7151.94
820.67
398933
2075.07
77.99
83.69
261.58
7106.06
1280.81
432753
1755.52
75.54
76.51
206.48
12575.81
1701.56
464561
3187.45 118.11
105.7
457.46
11982.44
2066.82
509383
1954.82
88.13
65.47
267.89
26069.99
3073.22
569482
2630.53
92.32
117.78
316.2
9695.95
1403.61
587755
2008.57 106.27
54.01
291.35
23404.87
2711.32
609593
2328.08
91.41
89.25
305.29
19192.2
2311.79
640807
1449.4
53.52
58.1
186.79
4703.18
727.77
646395
1959.96
73.29
72.39
262.51
10414.75
1411.36
647641
3139.05 124.24
127.81
392.97
24318.38
3471.3
698799
1258.4
38.16
43.59
190.77
9514.65
1081.23
708771
1047.83
19.66
45.66
148.47
33025.95
3355.05
712709
2450.61 130.64
91.18
289.53
23994.52
2836.1
717551
3288.18 124.98
114.9
460.16
23617.29
2855.09
720105
707.43
33.06
22.38
98.47
4859.99
616.04
747737
1755.49
74.27
46.62
277.99
7112.67
1188.22
758002
1771.6
49.43
50.15
294.89
13893.47
1644.1
760342
778.05
32.43
35.74
90.28
7735.92
850.94
765918
1504.19
39.55
38.88
257.26
3803.94
506.31
775008
2828.67
107.3
100.12
387.61
11257.99
1790.63
777907
2334.54
131.8
119.69
187.72
4366.21
647.01
784819
2588.15 102.24
88.61
365.47
10972.28
1764.63
788789
2419.38
92.46
93.08
320.86
6140.04
1253.65
806492
1310.09
46.15
43.55
193.85
3975
670.87
812964
1859.25
63.64
64.34
270.51
10665.01
1333.98
833746
1966.49
64.87
86.79
246.93
5529.5
894.82
835846
2163.16
69.75
87.26
287.69
8377.97
1190.28
836130
1290.48
52.88
41.61
184.03
9115.87
1250.61
839855
1226.56
45.68
46.06
170.4
4141.49
738.03
853838
1625.41
63.22
74.37
181.07
5933.99
815.96
865646
2627.17 108.52
87.09
368.72
15915.91
1986.51
875236
2183.89
97.01
63.56
324.14
14395.44
1850.04
875636
700.03
35.93
29.07
77.23
4432.91
720.39
920971
1571.78
66.87
61.27
195.83
6297.61
1033.18
925821
2187.74
88.3
87.79
274.12
9075.38
1612.68
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PPI Project Raw Data
Participant ID Food energy Protein Total fat Carbohydrate Vitamin A IU Vitamin A RE
kcal
g
g
g
IU (CSFII)
mcg RE (CSFII)
950103
4555.5 169.17
191.41
558.58
11723.57
2431.29
980834
2021.37
92.85
64.97
279.36
12752.26
1766.18
985282
2165.38
85.65
94.15
256.64
11862.56
1617.69
992966
2336.11
97.06
94.43
293.53
11819.38
1632.5
998751
1995.61
71.78
77.13
272.22
12128.23
1556.95
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PPI Project Raw Data
Participant ID
143778
156191
186859
194554
200004
216549
230453
230499
255516
312030
339596
352370
358284
376015
398933
432753
464561
509383
569482
587755
609593
640807
646395
647641
698799
708771
712709
717551
720105
747737
758002
760342
765918
775008
777907
784819
788789
806492
812964
833746
835846
836130
839855
853838
865646
875236
875636
920971
925821

Total Vitamin A Activity Vitamin C Calcium Phosphorus Magnesium
mcg RAE (NDS-R)
mg
mg
mg
mg
1449.26
217.42
822.92
1434
360.79
485.13
167.22
517.33
735.16
181.32
1208.78
255.48 1392.51
1579.64
321.35
1096.97
108.3
447.37
658.91
259.17
868.98
81 1111.21
1800.85
446.75
1119.45
132.69 1815.48
1977.12
307.31
252.28
117.27
288.13
663.14
249.13
797.69
127.45
877.01
1382.84
310.12
894.7
226.27
797.25
1172.37
363.13
1403.39
144
1634.6
1594.23
444.09
655.93
34.89
976.92
1141.76
235.76
657.6
47.7
942.18
1063.18
233.85
358.58
37.53
322.74
421.26
92.43
427.25
101.69
409.81
588.75
152.89
1065.08
79.64 1370.78
1526.01
349.19
1028.7
101.14
762.45
1354.04
389.48
1659.36
157.81 2519.51
2540.19
500.97
1500.97
122.71 1093.24
1604.8
372.13
1011.72
122.56 1021.97
1574
353.85
1339.04
321.87 1155.06
1744.72
531.01
1213.92
142.39 1018.95
1518.47
364.98
526.59
56.27
491.28
899.75
225.01
811.69
116.78
756.15
1245.71
265.93
2163.6
260.65 1801.99
2321.88
568.78
535.68
152.35
368
760.46
274.45
1425.6
50.41
266.49
378.24
160.65
1489.25
177.63
1095.7
1861.55
392.71
1589.61
312.53 1479.03
2381.37
592.03
321.2
56.37
283.43
514.36
120.58
919.38
86.85 1706.27
1833.38
383
815.73
133.49
565.54
961.57
281.78
435.55
159.93
364.23
529.59
149.24
342.41
69.07
463.24
807.07
161.44
1320.38
104.34 1760.61
2113.28
378.75
511.67
178.37
946.77
1702.27
291.27
1168.92
104.79 1597.13
2077.7
479.39
952.51
153.74 1192.41
1645.86
411.17
517.62
75.04
956.12
1042.46
226.71
753.53
109.95
779.62
1138.23
282.75
608.28
86.15
688.63
1224.58
337.55
803.09
70.63
822.96
1272.56
266.2
802.64
83.97
980.94
1126.73
233.78
567.39
100.59
865.15
1036.07
228.13
572.17
60
530.39
928.2
185.29
1196.56
220.78 1115.79
1729.51
436.89
1051.48
169.92 1283.92
1804.99
428.29
557.33
71.85
426.3
599.9
113.1
787.17
134.59 1278.53
1429.77
229.52
1252.75
102.81 1804.08
1951.95
402.95
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PPI Project Raw Data
Participant ID
950103
980834
985282
992966
998751

Total Vitamin A Activity Vitamin C Calcium Phosphorus Magnesium
mcg RAE (NDS-R)
mg
mg
mg
mg
2102.88
168.16 2842.46
3209.53
593.03
1196.35
155.12 1101.07
1498.67
379.67
954.58
92.25
875.76
1442.26
321.08
1062.84
198.47 1132.29
1833.1
472.77
842.94
206.82
807.37
1357.96
379.43
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PPI Project Raw Data
Participant ID Sodium Potassium Caffeine
mg
mg
mg
143778 4193.58
4239.38
1.38
156191 1588.41
2205.5
1.62
186859 2960.23
4048.53
3.55
194554 1180.58
2186.55
6.11
200004 4499.03
3159.69
4.81
216549 3340.47
3523.21
7.47
230453 1072.89
1829.53
0.13
230499 3661.41
3074.3
3.8
255516 2208.81
3087.95
14.31
312030 2514.05
3738.73
12.04
339596 1743.44
1939.63
1.44
352370 1637.96
1865.37
6.78
358284 876.26
1068.51
9.22
376015 1441.54
1806.46
0.04
398933 2758.25
3182.37
34.46
432753 2559.34
2774.02
4.26
464561 4414.64
5110.46
23.29
509383 3345.71
3361.07
1.3
569482 3562.14
3778.58
2.7
587755 4251.09
5533.15
107.02
609593 3349.51
3557.15
6.26
640807 2289.35
1821.67
3.38
646395 3346.26
2742.25
2.13
647641 5220.3
4764.27
14.39
698799 1895.34
2159.69
0.3
708771 1270.94
1681.22
3.41
712709 5072.67
4067.62
1.58
717551 5478.18
5665.64
6.36
720105 1293.98
1318.42
0.51
747737 2334.14
3775.85
8.66
758002 2675.78
2425.65
4.22
760342 2533.85
1913.45
1.6
765918 1696.99
1604.05
207.37
775008 4601.74
3936.02
8.91
777907 4897.74
3400.02
31.41
784819 3470.88
4256.01
9.68
788789 3110.08
3621.93
13.83
806492 1691.75
2206.98
6.62
812964 2839.7
2734.31
4.62
833746 2811.47
2456.53
15.29
835846 3278.28
2352.12
22.54
836130 2256.11
2522.31
5.5
839855 1545.94
2192.11
5.22
853838 2458.22
1793.83
82.68
865646 4255.18
4572.34
3.78
875236 3482.7
4525.45
4.61
875636 1660.27
1332.58
0.74
920971 2439.19
2811.26
5.58
925821 3322.28
3455.64
15.32

Vitamin D (calciferol)
mcg (NDS-R)
3.74
3.31
7.72
3.29
8
12.59
0.2
6.48
4.46
13.56
6.3
7
1.27
1.1
11.13
6.72
15.85
5.07
4.58
11.01
6.06
2.61
4.45
13.04
0.74
0.76
5.07
7.94
1.58
9.35
2.01
0.9
1.76
9.08
5.32
8.6
8.63
4.61
3.57
2.73
4.04
6.04
4.06
3.2
4.53
6.96
2.56
7.11
10.06

Vitamin D (IU)
IU
149.6
132.4
308.8
131.6
320
503.6
8
259.2
178.4
542.4
252
280
50.8
44
445.2
268.8
634
202.8
183.2
440.4
242.4
104.4
178
521.6
29.6
30.4
202.8
317.6
63.2
374
80.4
36
70.4
363.2
212.8
344
345.2
184.4
142.8
109.2
161.6
241.6
162.4
128
181.2
278.4
102.4
284.4
402.4
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PPI Project Raw Data
Participant ID Sodium Potassium Caffeine
mg
mg
mg
950103 6566.66
6124.53
65.42
980834 3584.97
3942.02
7.7
985282 3711.28
2954.08
3.26
992966 4472.7
3656.39
8.22
998751 2797.46
3323.46
7.38

Vitamin D (calciferol)
mcg (NDS-R)
22.34
8.19
4.24
4.62
3.29

Vitamin D (IU)
IU
893.6
327.6
169.6
184.8
131.6
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PPI Project Raw Data
Participant ID
143778
156191
186859
194554
200004
216549
230453
230499
255516
312030
339596
352370
358284
376015
398933
432753
464561
509383
569482
587755
609593
640807
646395
647641
698799
708771
712709
717551
720105
747737
758002
760342
765918
775008
777907
784819
788789
806492
812964
833746
835846
836130
839855
853838
865646
875236
875636
920971
925821

Supp – Vitamin A Supp – Vitamin C Supp - Calcium Supp – Magnesium
mcg RAE
mg
mg
mg
496.1
80.02
33.18
0
0
0
0
0
0
0
0
0
3571.43
42.86
428.57
71.43
3571.43
42.86
0
71.43
0
0
0
0
0
757.14
428.57
0
0
0
16.43
0
3571.43
42.86
8.21
71.43
3571.43
42.86
0
71.43
1428.57
160
142.86
28.57
1428.57
17.14
0
28.57
0
0
0
0
0
0
0
0
331.83
3.98
0
6.64
3571.43
42.86
0
0
82.14
17.41
4.11
1.64
0
0
0
0
0
0
0
0
3571.43
42.86
0
71.43
0
109.22
66.37
0
3571.43
51.07
171.43
71.43
3571.43
109.22
714.29
71.43
3571.43
59.28
0
71.43
0
0
0
0
0
0
0
0
0
0
0
0
3571.43
42.86
0
71.43
0
0
714.29
0
3571.43
42.86
0
71.43
0
0
0
0
3571.43
1114.29
714.29
71.43
0
0
0
0
82.14
0.99
0
0
3571.43
42.86
0
71.43
3571.43
42.86
714.29
71.43
3571.43
42.86
0
71.43
7142.86
757.14
357.14
71.43
3571.43
42.86
0
71.43
3571.43
42.86
285.71
71.43
0
16.43
8.21
0
331.83
37.16
0
6.64
3571.43
221.43
0
71.43
0
0
0
0
3571.43
85.71
714.29
71.43
0
0
142.86
0
9285.71
757.14
357.14
71.43
82.14
0.99
0
1.64
1428.57
50
0
28.57
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PPI Project Raw Data
Participant ID
950103
980834
985282
992966
998751

Supp – Vitamin A Supp – Vitamin C Supp - Calcium Supp – Magnesium
mcg RAE
mg
mg
mg
3571.43
51.07
8.21
71.43
0
0
4.11
0
3571.43
42.86
71.43
71.43
3571.43
42.86
0
71.43
3571.43
42.86
0
71.43
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PPI Project Raw Data
Participant ID
143778
156191
186859
194554
200004
216549
230453
230499
255516
312030
339596
352370
358284
376015
398933
432753
464561
509383
569482
587755
609593
640807
646395
647641
698799
708771
712709
717551
720105
747737
758002
760342
765918
775008
777907
784819
788789
806492
812964
833746
835846
836130
839855
853838
865646
875236
875636
920971
925821

Supp – Vitamin D Aerobic_current Resistance_current Aerobic_past
IU
26.55
0
0
0
0
0
0
0
0
1
0
1
285.71
1
0
1
285.71
1
1
1
0
0
0
0
0
1
0
1
0
0
0
1
285.71
1
0
1
285.71
0
0
1
114.29
1
0
1
114.29
1
0
1
0
1
1
1
0
1
1
0
26.55
0
0
0
285.71
1
1
1
6.57
0
0
0
0
1
0
1
0
0
0
0
285.71
1
0
1
0
1
0
1
285.71
0
0
0
285.71
1
0
0
285.71
1
1
1
0
1
0
0
0
0
0
1
0
1
1
1
285.71
1
0
1
0
1
0
1
285.71
1
0
1
0
0
0
0
285.71
1
0
1
0
1
0
1
6.57
0
0
1
285.71
1
0
1
285.71
1
1
1
285.71
0
0
0
285.71
1
0
1
285.71
0
0
1
285.71
1
0
1
0
0
0
0
26.55
1
0
1
285.71
1
1
1
0
0
0
0
285.71
1
0
1
0
1
0
1
285.71
0
0
0
6.57
1
0
0
114.29
1
0
1
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PPI Project Raw Data
Participant ID
950103
980834
985282
992966
998751

Supp – Vitamin D Aerobic_current Resistance_current Aerobic_past
IU
285.71
0
0
0
0
0
0
1
285.71
1
0
0
285.71
1
1
1
285.71
0
0
1
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PPI Project Raw Data
Participant ID Resistance_past Total Vitamin A Total Vitamin C Total Calcium Total Magnesium
(RAE)
mg
mg
mg
143778
0
1945.36
297.44
856.1
360.79
156191
0
485.13
167.22
517.33
181.32
186859
0
1208.78
255.48
1392.51
321.35
194554
0
4668.4
151.16
875.94
330.6
200004
1
4440.41
123.86
1111.21
518.18
216549
0
1119.45
132.69
1815.48
307.31
230453
0
252.28
874.41
716.7
249.13
230499
0
797.69
127.45
893.44
310.12
255516
1
4466.13
269.13
805.46
434.56
312030
0
4974.82
186.86
1634.6
515.52
339596
0
2084.5
194.89
1119.78
264.33
352370
0
2086.17
64.84
942.18
262.42
358284
0
358.58
37.53
322.74
92.43
376015
0
427.25
101.69
409.81
152.89
398933
0
1396.91
83.62
1370.78
355.83
432753
1
4600.13
144
762.45
389.48
464561
0
1741.5
175.22
2523.62
502.61
509383
0
1500.97
122.71
1093.24
372.13
569482
0
1011.72
122.56
1021.97
353.85
587755
0
4910.47
364.73
1155.06
602.44
609593
0
1213.92
251.61
1085.32
364.98
640807
0
4098.02
107.34
662.71
296.44
646395
0
4383.12
226
1470.44
337.36
647641
1
5735.03
319.93
1801.99
640.21
698799
0
535.68
152.35
368
274.45
708771
0
1425.6
50.41
266.49
160.65
712709
1
1489.25
177.63
1095.7
392.71
717551
0
5161.04
355.39
1479.03
663.46
720105
0
321.2
56.37
997.72
120.58
747737
0
4490.81
129.71
1706.27
454.43
758002
0
815.73
133.49
565.54
281.78
760342
0
4006.98
1274.22
1078.52
220.67
765918
0
342.41
69.07
463.24
161.44
775008
0
1402.52
105.33
1760.61
378.75
777907
0
4083.1
221.23
946.77
362.7
784819
1
4740.35
147.65
2311.42
550.82
788789
0
4523.94
196.6
1192.41
482.6
806492
0
7660.48
832.18
1313.26
298.14
812964
0
4324.96
152.81
779.62
354.18
833746
0
4179.71
129.01
974.34
408.98
835846
0
803.09
87.06
831.17
266.2
836130
0
1134.47
121.13
980.94
240.42
839855
0
4138.82
322.02
865.15
299.56
853838
0
572.17
60
530.39
185.29
865646
0
4767.99
306.49
1830.08
508.32
875236
0
1051.48
169.92
1426.78
428.29
875636
0
9843.04
828.99
783.44
184.53
920971
0
869.31
135.58
1278.53
231.16
925821
1
2681.32
152.81
1804.08
431.52
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PPI Project Raw Data
Participant ID Resistance_past Total Vitamin A Total Vitamin C Total Calcium Total Magnesium
(RAE)
mg
mg
mg
950103
0
5674.31
219.23
2850.67
664.46
980834
0
1196.35
155.12
1105.18
379.67
985282
0
4526.01
135.11
947.19
392.51
992966
1
4634.27
241.33
1132.29
544.2
998751
0
4414.37
249.68
807.37
450.86

141

PPI Project Raw Data
Participant ID
143778
156191
186859
194554
200004
216549
230453
230499
255516
312030
339596
352370
358284
376015
398933
432753
464561
509383
569482
587755
609593
640807
646395
647641
698799
708771
712709
717551
720105
747737
758002
760342
765918
775008
777907
784819
788789
806492
812964
833746
835846
836130
839855
853838
865646
875236
875636
920971
925821

Total Vitamin D
IU
176.15
132.4
308.8
417.31
605.71
503.6
8
259.2
464.11
828.11
366.29
394.29
50.8
44
471.75
554.51
640.57
202.8
183.2
726.11
242.4
390.11
463.71
807.31
29.6
30.4
202.8
603.31
63.2
659.71
80.4
321.71
70.4
369.77
498.51
629.71
630.91
470.11
428.51
394.91
161.6
268.15
448.11
128
466.91
278.4
388.11
290.97
516.69

Spine

Hip

Normal
Osteopenia
Osteopenia
Osteopenia
Normal
Normal
Osteopenia
Osteopenia
Normal
Normal
Osteopenia
Osteopenia
Osteopenia
Osteoporosis
Normal
Normal
Normal
Osteopenia
Normal
Osteopenia
Osteopenia
Osteoporosis
Osteopenia
Normal
Normal
Normal
Normal
Osteopenia
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Osteopenia
Osteoporosis
Normal
Normal

Osteoporosis
Osteoporosis
Osteopenia
Normal
Normal
Normal
Osteopenia
Osteopenia
Normal
Osteopenia
Normal
Osteopenia
Osteopenia
Osteoporosis
Osteopenia
Normal
Osteopenia
Osteopenia
Normal
Osteoporosis
Osteopenia
Osteopenia
Osteopenia
Normal
Normal
Osteopenia
Normal
Osteopenia
Normal
Normal
Normal
Normal
Osteopenia
Normal
Normal
Osteopenia
Normal
Normal
Normal
NA
Normal
Osteopenia
Normal
Osteopenia
Normal
Osteopenia
Osteopenia
Osteopenia
Normal

spine_hip
Osteoporosis
Osteoporosis
Osteopenia
Osteopenia
Normal
Normal
Osteopenia
Osteopenia
Normal
Osteopenia
Osteopenia
Osteopenia
Osteopenia
Osteoporosis
Osteopenia
Normal
Osteopenia
Osteopenia
Normal
Osteoporosis
Osteopenia
Osteoporosis
Osteopenia
Normal
Normal
Osteopenia
Normal
Osteopenia
Normal
Normal
Normal
Normal
Osteopenia
Normal
Normal
Osteopenia
Normal
Normal
Normal
Normal
Normal
Osteopenia
Normal
Osteopenia
Normal
Osteopenia
Osteoporosis
Osteopenia
Normal
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PPI Project Raw Data
Participant ID
950103
980834
985282
992966
998751

Total Vitamin D
IU
1179.31
327.6
455.31
470.51
417.31

Spine

Hip

Normal
Osteopenia
Normal
Normal
Normal

Osteopenia
Osteopenia
Normal
Normal
Normal

spine_hip
Osteopenia
Osteopenia
Normal
Normal
Normal
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